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ABSTRACT 
Fish and shellfish allergy is a leading cause of anaphylaxis. There is limited data providing 
accurate information on the prevalence, clinical characteristics and management guidelines 
for this type of food allergy. Furthermore, it is recognised that food hypersensitivity 
negatively impacts on the health-related quality of life (HRQL) of sufferers when 
compared to healthy controls, as well as those suffering from other chronic diseases. 
However, little is known about the HRQL of adults with a fish and or shellfish allergy and 
how this may differ compared with other allergies. As this is a food allergy with an often 
later onset and one which is persistent throughout an individual’s life, it is of interest to 
examine the associated effect on HRQL in order to build upon the existing knowledge of 
this type of food allergy. 
 
The programme of research set out to first determine the prevalence as this underpins the 
knowledge base for food allergy. Next, in order to diagnose food allergy appropriately, an 
in-depth knowledge of the mechanisms and clinical presentations is needed. Once 
diagnosis is made, the best ways of managing the food allergy, taking into account the 
health-related quality of life of an individual, need to be known. 
 
This research was guided by a quantitative methodology and consisted of a systematic 
review of the prevalence of fish and shellfish allergy worldwide and a cross-sectional study 
of adult patients (≥ 16 years of age) with a record of fish and or shellfish allergy, from 
three NHS allergy outpatient clinics, as well as members of a patient support group 
(Anaphylaxis Campaign), which sought to describe the clinical characteristics and measure 
the HRQL of this sample.  
 
III 
The main findings of this research were that very few studies have established the 
prevalence of fish and shellfish allergy using the gold standard, double-blind, placebo-
controlled challenge criteria, with the majority instead relying on self-reported 
questionnaire-based methods. Where food challenges were used, the prevalence for fish 
allergy was found to be 0-0.3% and for shellfish allergy was 0-0.9%. It was shown that fish 
and shellfish allergy often co-exist, fish and shellfish allergic individuals frequently have 
other atopic conditions, and the clinical phenotype with regards to reactivity to vapours 
and tolerance of tinned fish varies between individuals. In addition, the associated HRQL 
of fish and shellfish allergic adults was found to be negatively impaired.  
 
This research has identified some novel findings, which have both clinical and research 
implications. There is a need for the development of clinical guidelines for the diagnosis of 
fish and shellfish allergy, to ensure consistent dietary and avoidance advice as well as 
provide management strategies to reduce the associated effects on the individual’s HRQL. 
A promising new treatment for food allergy, oral immunotherapy, needs to be investigated 
further for its effectiveness in treating fish and shellfish allergy as this would improve 
HRQL further.   
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CHAPTER 1 
GENERAL INTRODUCTION 
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1.1 Background 
The consumption of fish and shellfish has increased in recent years and it is believed that 
the incidence of fish and shellfish allergy has also increased (Lopata, O'hehir, & Lehrer, 
2010). Fish and shellfish allergy is a long lasting, life-threatening, chronic condition which 
is common in both children and adults, although it is believed to be more prevalent in 
adults (Lopata, O'hehir, & Lehrer, 2010). The actual prevalence is difficult to determine 
due to the different diagnostic methods that are used but a widely reported study carried 
out in the United States indicates the self-reported prevalence of shellfish allergy is 2% and 
for fish allergy is 0.4% (Sicherer, Munoz-Furlong, & Sampson, 2004). The prevalence is 
believed to be higher in countries where the consumption of fish and shellfish is high 
(Turner, Ng, Kemp, & Campbell, 2011).  
 
Literature to date has identified the allergenic proteins believed to be most implicated in 
fish and shellfish allergy. These are: tropomyosin, arginine kinase, myosin light chain, and 
sarcoplasmic calcium-binding protein in shellfish, and parvalbumins, aldolase and enolase 
in fish. Furthermore the cross reactivity between different types of crustacean shellfish is 
well documented, however the situation with fish species and molluscan shellfish is less 
understood and there is limited information available on the clinical characteristics and 
management of fish and shellfish allergy. No published data has looked at the effect of fish 
and shellfish allergy on health-related quality of life, leaving the question of whether the 
burden of disease is heterogeneous unanswered. There is also a disparity of food 
hypersensitivity literature describing the clinical characteristics, diagnosis and therapy in 
adults (Crespo & Rodriguez, 2003).  
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The term clinical characteristic in this thesis refers to the typical presentation of individuals 
with regards to their fish and or shellfish allergy. The term cross sensitisation will be used 
where members of the same protein family share IgE and T cell epitopes, causing allergic 
reactions, for example between fish species. Where there is a clinical history of this 
triggering an allergic reaction in the patient, the term clinical cross reactivity will be used. 
The term co sensitisation refers to the sensitisation to multiple, unrelated allergens.   
 
As relatively little is currently known about fish and shellfish allergy, this thesis will seek 
to explore the epidemiology to understand how prevalent this type of food allergy is in the 
population. It will describe the clinical characteristics of allergic patients and it will 
investigate from a patients’ perspective how this type of allergy impacts on their everyday 
by means of measuring health-related quality of life. By doing this, this thesis aims to add 
to the current body of literature and expand the understanding of fish and shellfish allergy.  
 
1.2 Aim and research questions 
The overall aim of this research is to characterise and describe fish and shellfish allergy so 
that the research and clinical community can better understand it and thus manage it more 
effectively. To address this aim, three studies were undertaken using a quantitative 
methodology approach.  
 
The following research aims and objectives will be addressed in this thesis: 
 To carry out a systematic review of published and unpublished data related to the 
prevalence of fish, crustacean and mollusc allergy in order to understand the true 
prevalence of fish and shellfish allergy. 
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 To describe the clinical characteristics of fish and or shellfish allergic adults in a 
UK sample. This will be achieved by addressing the following objectives: to 
describe the atopic status, history of allergic disease and characteristics of allergic 
participants; to describe the prevalence of fish, crustacean and mollusc allergy and 
the common symptoms experienced in this sample; to examine co-existing and 
cross sensitivity within fish and shellfish allergy; to examine other co-existing food 
and aeroallergen sensitivities; to examine the level of tolerance to tinned fish and 
shellfish and the reactivity to airborne traces; and to describe the dietary advice and 
medical management strategies adopted by this sample.  
 To investigate how fish and shellfish allergy affects the health-related quality of 
life of adult sufferers in the UK. This will be achieved by addressing the following 
objectives: to assess the health-related quality of life of adults with a fish and or 
shellfish allergy; to compare the health-related quality of life of adults with an early 
onset diagnosis with those with a late onset diagnosis; to compare the health-related 
quality of life of adults recruited through an allergy outpatient clinic with those 
recruited through an allergy support charity. 
 
1.3 Possible clinical implications 
The results of this thesis are expected to inform clinical practice further about fish and 
shellfish allergy, in particular with regards to the phenotype of patients and the effect on 
health-related quality of life to help to optimise the diagnosis and long-term management 
of these patients.  
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1.4 Thesis layout 
Following on from this introductory chapter, chapter two reviews the current literature 
relevant to fish and shellfish allergy in order to establish a context for the research 
objectives. It introduces the topic of food hypersensitivity generally, the impact of food 
hypersensitivity on health-related quality of life, and fish and shellfish allergy specifically. 
However, the literature specific to the individual studies of this thesis is further presented 
in the respective chapters. The literature review search strategy is detailed in Appendix 1. 
 
Chapter three presents a quantitative systematic review of the prevalence of fish and 
shellfish allergy, according to age, region of the world, and method of diagnosis. A 
systematic review methodology allows for accurate information on the prevalence of food 
allergy. The findings are discussed in relation to existing literature on prevalence. 
 
Chapter four presents a quantitative cross-sectional questionnaire survey, which 
investigated the clinical characteristics of adults with a fish and or shellfish allergy in the 
UK. Data was analysed and the findings are discussed in relation to existing literature on 
the clinical characteristics of fish and shellfish allergy.  
 
Chapter five investigates the health-related quality of life of fish and or shellfish allergic 
adults in the UK using the same methodology as the previous chapter, as well as a 
validated disease-specific health-related quality of life measure. Data was analysed and the 
findings are discussed in relation to existing literature on the effect of food hypersensitivity 
on health-related quality of life and clinical characteristics of fish and shellfish allergy.   
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In conclusion, chapter six summarises the overall findings of the programme of research 
by collating the results of the three studies together. The findings are discussed in the 
context of previous literature. It re-addresses the principle aim of this research, which was 
to characterise and describe fish and shellfish allergy. To address this broad aim, three 
studies were undertaken using a quantitative methodology approach. The implications for 
the clinical management of fish and shellfish allergy are discussed and the strengths and 
limitations of the research, as well as directions for future research are outlined.  
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CHAPTER 2 
LITERATURE REVIEW 
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2.1 Overview 
This chapter will review the current literature relevant to food hypersensitivity, health-
related quality of life, and fish and shellfish allergy. The first section introduces the field of 
food hypersensitivity generally by examining the epidemiology, symptoms, diagnosis, and 
management and treatment. The second section introduces the topics of quality of life and 
health-related quality of life, and a review of the current literature on the impact of food 
hypersensitivity on health-related quality of life is provided. The third section of this 
review gives a detailed overview of what is known to date about fish and shellfish allergy. 
Literature relevant to the identification of specific allergic proteins, the diagnosis and 
management related to this type of food allergy is discussed. The final section provides a 
rationale for this programme of research and details the aims and objectives. 
 
2.2 Food Hypersensitivity 
2.2.1 Definition and epidemiology 
The World Allergy Organisation proposes the overall term of food hypersensitivity (FHS), 
and that the term food allergy should only be used when immunologic mechanisms have 
been demonstrated (Johansson et al., 2004). Food allergy is commonly mediated by an IgE 
antibody to specific food proteins (IgE-mediated food allergy) but other immunological 
pathways can also be implicated (non-IgE-mediated food allergy). All other adverse 
reactions to food should be referred to as non-allergic food hypersensitivity. Often in 
prevalence studies it is unclear which different phenotypes of FHS is being studied, further 
making comparisons and understanding of the accurate prevalence rate difficult. 
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FHS affects all ages and can result in severe reactions including anaphylaxis. There is 
currently no cure and therefore FHS is managed by allergen avoidance and the 
management of symptoms due to accidental exposure. The exact prevalence of food 
allergy is unknown but is believed to affect more than 1-2% but less than 10% of the 
population (Chafen et al., 2010). It has been suggested that the prevalence of FHS has 
increased in recent years (Allen & Koplin, 2012; Sicherer, 2011), representing a substantial 
burden to healthcare systems and society (Gupta, Sheikh, Strachan, & Anderson, 2004). A 
review by Miles, Fordham, Mills, Valovirta, & Mugford (2005) describes the cost of FHS 
under three categories: direct costs, including the use of emergency services, appointment 
with medical professionals, medication, hospitalisation, diagnostic testing, therapy and 
allergen avoidance measures, for example purchasing exclusive and expensive ‘free from’ 
product; indirect costs arising due to the presence of an allergy, for example days off sick 
or loss of employment or education opportunities; and intangible costs, including 
detrimental effects on the individuals’ quality of life. In the UK, National Health Service 
(NHS) costs due to allergic disease are thought to be over one billion pounds per annum 
(Gupta, Sheikh, Strachan, & Anderson, 2004). In the Unites States estimates of the direct 
health care cost of food allergic reaction are close to $300 million (Patel, Holdford, 
Edwards, & Carroll, 2011), it is therefore clear that FHS represents a significant health 
care problem.   
 
Any food can trigger an allergic reaction but the majority of reactions are caused by one of 
the major food allergens: peanut, tree nut, egg, milk, fish, crustacean shellfish, wheat and 
soy. Furthermore, celery, mustard, sesame, lupine and molluscan shellfish are major 
allergens in Europe (Boyce et al., 2010; Burks et al., 2012). The food allergens, commonly 
proteins, are recognised by allergen-specific immune cells and cause specific 
LITERATURE REVIEW 
10 
immunological reactions, this can be the case not only after ingestion but also if the 
allergen is inhaled. Cross reactivity occurs when an allergen is homologous with a 
different allergen, although clinical cross reactivity is variable, with cross reactivity 
between crustacean species being the most common (Burks et al., 2012).  
 
The most cited FHS prevalence study (Bock, 1987) recruited a birth cohort from a private 
practice clinic in Colorado in 1980. A total of 480 children (from an initial 501) took part 
in the three-year study. This study used many methods which are crucial in the diagnosis 
of food allergy, including questionnaires completed by parents to identify possible food 
hypersensitivity, followed by open food challenges or double-blind placebo-controlled 
food challenges. Adverse reactions to foods, other than fruit juices, were reported in 28% 
of children but in only 8% were these reactions reproducible by method of food challenge. 
It is not known though how many of these reactions were IgE-mediated, as information is 
not provided on the length of time after feeding and the onset of symptoms. In addition, the 
children may not have yet been exposed to some foods and thus these figures may not 
include undiagnosed food allergies.  
 
A cohort study carried out on the Isle of Wight was able to compare UK food allergy 
prevalence rates for children based on open food challenges and a good clinical history 
with those identified by Bock (1987), showing no significant difference in food allergy 
prevalence over a 20 year period (Venter et al., 2008). However, hospital admission due to 
systemic allergic reactions had increased between 1990 and 2001 (Gupta, Sheikh, 
Strachan, & Anderson, 2007) with a 7-fold increase from 1992 to 2012 in England and 
Wales for admission due to anaphylaxis (Turner et al., 2014). This observed increase may 
be due to a true increase in FHS or a change in health care provider and patient behaviours 
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(Turner et al., 2014). Prevalence data from developing countries and emerging economies 
is far more limited compared to Western countries but the assumption is that prevalence is 
lower (Boye, 2012). It is vital that the management of FHS is considered at a global level 
and particular consideration is needed in the developing world where malnutrition already 
poses a significant challenge and food aid provided is frequently made up of common 
allergens (peanut, milk, eggs, soya, fish, wheat). 
 
Accurate national and international data on the prevalence of FHS is a useful measure of 
the burden of the disease in a community, which is valuable for the provision and planning 
of allergy services and informing policy, such as European labelling laws and allergy 
prevention guidelines (Skypala & Venter, 2009). We see similarities in the major allergens 
that are associated with FHS however the clinical spectrum and characteristics of food 
allergies often depend on the geographical region, pattern of consumption, and 
environmental exposures (Dalal et al., 2002; Hill et al., 1997) and so it is important when 
trying to comprehend prevalence to include data from all countries. Two types of studies 
can be utilised when obtaining prevalence data. First, cohort studies, which involve the 
selection of exposed and non exposed individuals, or a defined population before 
individuals become exposed, and follow up both to compare the incidence of disease as 
well as to establish temporal relationships. Secondly, cross-sectional studies, which take a 
snapshot of a defined population at a certain time point and determine exposure and 
disease outcomes simultaneously; this is the most common design for obtaining prevalence 
data, however they give no indication of duration of disease nor represents the general 
population due to selection bias (Gordis, 2008). It is important that population studies 
represent the wider population, as enriched samples (for example, using asthmatic 
individuals or individuals attending an allergy outpatient clinic) may be misleading and 
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overestimate the true prevalence of FHS in the general population. In order to accurately 
and meaningfully collate all of the existing available prevalence data a systematic review 
methodology is the best approach. 
2.2.2 Symptoms 
IgE-mediated reactions are characterised by the acute onset of symptoms (generally within 
two hours after ingestion or exposure) and can involve the skin, gastrointestinal and 
respiratory tracts. Symptoms affecting the skin include urticaria, angioedema, erythema 
and puritus, gastrointestinal tract symptoms include vomiting, diarrhoea and abdominal 
pain, and respiratory tract symptoms include cough, hoarse voice, wheeze, stridor, 
respiratory distress and nasal congestion. The circulatory system can also be implicated 
causing hypotension and collapse (Burks et al., 2012). Severe generalised reactions are 
called anaphylaxis. The factors most commonly associated with fatal food-induced 
anaphylaxis are: a reaction to peanuts or tree nuts, delayed treatment with epinephrine, 
teenagers and young adults with a history of asthma, and multiple food allergies (Bock, 
Munoz-Furlong, & Sampson, 2001; Pumphrey & Gowland, 2007). There are a wide range 
of non-IgE mediated food allergy symptoms which can affect the gastrointestinal tract, 
skin and respiratory tract, including but not limited to diarrhoea, constipation, abdominal 
discomfort, vomiting, pruritus, erythema, atopic eczema and ‘catarrhal’ airway symptoms, 
but the main characteristic is the delay in symptoms (usually several hours) following 
ingestion of the allergen (Venter, Brown, Shah, Walsh, & Fox, 2013). 
2.2.3 Diagnosis 
Taking an allergy-focused history forms the basis of diagnosis for all types of adverse 
reactions to foods, and an accurate history can indicate to the clinician further diagnostic 
tests to be carried out, whether a food and symptom diary would be useful, which foods 
should be avoided in the diet, and whether a food challenge or a gradual introduction of the 
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food is required (Skypala & Venter, 2009; Skypala et al., 2015). For IgE-mediated food 
allergies additional testing for the presence of specific IgE (SIgE) is required. Skin prick 
tests (SPT), which measure SIgE attached to mast cells in the skin, and serum SIgE tests, 
which measure levels of circulating SIgE to allergens in the blood, are both useful in the 
diagnosis of IgE-mediated food allergy. However, caution should be applied to the results 
as the presence of IgE in the skin or blood give only an indication that an individual is 
sensitised to an allergen, not necessarily indicating a clinical allergy (Burks et al., 2012). In 
addition both tests, although scientifically valid, lack standardisation. It has been suggested 
that a positive SPT indicates with 50% positive predictive accuracy a true IgE-mediated 
allergy to the food, however, a SPT result below the cut-off point combined with a good 
clinical history does not rule out allergy altogether and further diagnostic tests would be 
needed (Skypala & Venter, 2009). As a general rule, the higher the level of SIgE in the 
blood the more likely the presence of an allergy, however, as with SPT, cut off points used 
in serum SIgE tests should be used only as a guideline for diagnosis. Diagnosis of non-IgE 
mediated food allergies is reliant on elimination and reintroduction of the suspected food 
as there are no validated laboratory tests at present. Atopy patch testing is not 
recommended for the diagnosis of an IgE-mediated allergy, but it may be a usefully 
diagnostic tool for testing for T-cell mediated immune responses (non-IgE-mediated) 
(Boyce et al., 2010).  
 
The accepted gold standard in objectively diagnosing food hypersensitivity is the oral food 
challenge and in particular the double-blind placebo-controlled food challenge (DBPCFC). 
The open food challenge (OFC) is often the challenge of choice in most cases in a clinical 
setting, and is useful when refuting the diagnosis of a food allergy where the food is not 
likely to cause allergic reactions. But research has shown that OFC yields 27% more 
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positive challenges than DBPCFC (Venter et al., 2007). Venter et al. (2007) suggest the 
OFC is suitable for diagnosing immediate objective symptoms, but that the DBPCFC may 
be needed for the diagnosis of delayed subjective symptoms. DBPCFC is regarded 
universally as the gold standard for diagnosing food allergy because bias is minimised 
(Bindslev-Jensen et al., 2004), but due to its labour-intensive nature, lack of available 
blinding recipes and uniform protocols it is sparsely used. A systematic review of 
diagnostic methods for FHS recommends that SPT, serum SIgE and food challenges all 
play an important role with no one test having sufficient ease of use, sensitivity or 
specificity to be recommended for sole use (Chafen et al., 2010). 
 
Many people consider themselves to be allergic or intolerant to a food but in the majority 
of cases this will not be confirmed by appropriate tests. Some of these individuals will 
experience life-threatening adverse reactions causing a huge impact on their quality of life, 
as avoidance is crucial to preventing severe symptoms. For others such strict avoidance 
strategies may not be clinically necessary but nonetheless impairment on quality of life 
may exist. False negative diagnosis can lead to ongoing symptoms and the risk of further 
severe reactions whereas false positive diagnosis can lead to unnecessary restrictions on 
lifestyle and the avoidance of nutrients. Explanations for the misreporting of FHS through 
self-reports include the inability to distinguish between a food intolerance and allergy, 
incorrectly associating symptoms of allergic reactions to a food, and not being able to 
report allergic status to foods not yet introduced into the diet, as with infants (Allen & 
Koplin, 2012).  
2.2.4 Management and treatment 
At present there is no cure available for FHS and so management of this disease is based 
solely on the avoidance of allergens from the individuals diet and the prompt 
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administration of medications in the case of a reaction; antihistamines and epinephrine in 
the case of anaphylaxis. There are some novel treatments for the treatment of FHS which, 
although are not routine practice, do yield promising results and are worthy of further 
study (de Silva et al., 2014). These include, but are not limited to, immunotherapy, 
monoclonal anti-IgE antibodies, traditional Chinese medicine and probiotics (Nowak-
Wegrzyn, 2003). A suspected IgE-mediated allergy should be managed by the elimination 
of the suspected allergen from the diet, followed by SPT and serum SIgE tests and where 
possible food challenges, carried out in a clinical setting and in the case of a suspected 
non-IgE-mediated allergy, there should be a trial elimination period of 2-4 weeks followed 
by a planned reintroduction (Venter, Brown, Shah, Walsh, & Fox, 2013). The diagnosis, 
prognosis and knowledge of allergy resolution are all key components in the management 
of FHS, with the ultimate goal to reduce the number of foods being excluded from the 
individual’s diet to the least amount necessary (Savage, Sicherer, & Wood, 2016). 
 
2.3 Health-related quality of life  
Health is a dynamic, multifactor phenomena which influences physical, psychological and 
social functioning and it is now recognised that outcome measures that reflect patient 
perspectives, such as quality of life (QOL), are important for evidence-based decision 
making in clinical practice (DunnGalvin, Dubois, Flokstra-de Blok, & Hourihane, 2015). 
Furthermore, because of improved treatments and prevention, healthcare is now focused 
more on chronic as opposed to acute disease and therefore the management of chronic 
disease is a major concern. Health is more than physical well-being and interestingly 
disease severity is not always correlated with individuals’ reports of their quality of life 
(Bowling, 2001). Similarly, physiological measures have been shown to be poor predictors 
of QOL, with many people with serious and persistent disabilities reporting a good or 
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excellent quality of life; this is known as the disability paradox (Albrecht & Devlieger, 
1999). The ever growing importance of how patients feel, how satisfied they are with 
healthcare treatment and of disease outcomes can be seen in the increased use of QOL 
measures of disease in assessment of the quality of services, healthcare need, effectiveness 
and cost utility; funded trials are now frequently required to include QOL as an outcome 
measure (Ogden, 2012).  
 
The term health-related quality of life (HRQL) refers to the individuals QOL related to 
their health or treatment. While there is some disagreement on a single definition, there is 
consensus that the multidimensional nature of HRQL includes emotional wellbeing, 
psychological wellbeing, social wellbeing and roles, and physical health and functioning 
(Bowling, 2003). The measurement of HRQL provides a subjective dimension to health 
status assessment however QOL often means different things to different people as 
individuals value different areas of their life greater than others. In addition, it is a dynamic 
construct and therefore a patient’s attitude towards a particular domain of HRQL may 
change through psychological phenomena such as adaptation, coping or expectations 
(Allison, Locker, & Feine, 1997). There are an infinite number of factors which could 
contribute to an individual’s HRQL, however authors commonly agree on three core 
domains; physical (self-rated health status, disability or ability to perform daily activities), 
emotional (anxiety, depressions and cognitive indicators), and social (personal and wider 
social capital, social support and social activities) (Bowling, 2001; De Geest & Moons, 
2000; Mandzuk & McMillan, 2005; Testa & Simonson, 1996).  
 
HRQL can be measured by a number of different instruments. Generic HRQL instruments 
are interested in the way illnesses and treatments affect general QOL and are not specific 
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to any one disease. This type of measure is useful when looking to make comparisons 
between the HRQL of individuals with different health conditions however this 
generalisability means that they are not sensitive to particular ways in which specific 
diseases affect HRQL (Bowling, 2001). Alternatively disease-specific HRQL instruments 
focus on the ways in which a particular disease may affect HRQL by measuring domains 
that are particularly important for a certain patient group. These measures are able to 
capture small changes in HRQL as a result of clinical and therapeutic treatments and are 
more clinically relevant (Bowling, 2001). One argument which exists in HRQL literature is 
that the domains of a HRQL instrument should not be determined by a researcher, but by 
the patients themselves; this is known as a individualised measure and it allows the 
individual to choose and rate domains of importance to their own HRQL (Hickey et al., 
1996). This type of measure yields high validity and is useful for clinical decision making, 
but this measure is not appropriate for use in a research setting as patients rate their HRQL 
on different domains which prevents comparisons between individuals (Wood-Dauphinee, 
1999). 
2.3.1 Impact of FHS on health-related quality of life 
Due to the current lack of cure or treatment for FHS it can be considered a chronic 
condition. Indeed, Higginson & Carr (2001) comment that HRQL is of particular 
importance as an outcome measure for chronic and progressive illnesses, where the 
management of the disease and associated symptoms are the priority. Furthermore, 
physiological measures of FHS, such as the frequency of reactions, do not successfully 
measure how well the condition is managed due to the possibility of accidental ingestion 
(Bock & Atkins, 1989; Ewan & Clark, 2001) and symptoms have been shown to be a poor 
measure of HRQL (Salvilla et al., 2014). Stressors associated with FHS which have been 
shown to affect HRQL include allergen labeling, auto-injector use, diagnosis, transition 
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periods, and lack of awareness in social settings (DunnGalvin, Dubois, Flokstra-de Blok, 
& Hourihane, 2015). In addition, the strict avoidance and vigilance which is essential in 
managing FHS often has a negative impact on an individual’s HRQL (Mills et al., 2007). 
There is also further anxiety related to the burden of managing severe reactions, such as 
the administration of adrenaline (Monks et al., 2010). 
 
To identify the current gaps in the literature it is important to first review what we do know 
with regards to the effect of FHS on HRQL. Several studies have examined the HRQL of 
children with FHS in comparison with other groups of children. These studies have used 
two generic HRQL measures; the Child Health Questionnaire- Parent Form is a 50 item 
and 28 item consisting of 13 scales measuring different aspects of HRQL (Raat, 
Botterweck, Landgraf, Hoogeveen, & Essink-Bot, 2005) and the Impact on Family 
Questionnaire (completed by parents) measures the impact of an illness on the family and 
consists of four domains (familial/social, personal strain, financial burden, and mastery) 
(Stein & Riessman, 1980).  
 
Using the Child Health Questionnaire as a measure, parents of children with FHS rated 
their children as having significantly worse general health compared to other children from 
the US. In addition the parents experienced significantly more anxiety about their child’s 
health and perceived more interruption to family activities (Sicherer, Noone, & Munoz-
Furlong, 2001). In another study which used the same measure, parents of children with 
FHS felt their children were significantly more limited in physical activities, there was a 
significantly greater impact of emotional, behavioural and physical problems on 
schoolwork and peer relationships, experienced significantly more bodily pain, and 
significantly poorer mental health, compared with parents of children with no allergic 
LITERATURE REVIEW 
19 
disease. Compared with parents of children with allergic disease (but no FHS) the parents 
rated their children as significantly more limited in physical activities, significantly greater 
impact of emotional, behavioural and physical problems on schoolwork and peer 
relationships, and having significantly worse general health (Ostblom, Egmar, Gardulf, 
Lilja, & Wickman, 2008). Similarly compared to parents of children with allergic disease 
(but no FHS), parents reported their children’s HRQL lower on physical dimension 
(physical functioning, role-social limitations, bodily pain, general health), significantly 
greater impact on the parents own emotional well-being and demands on their time, and 
significantly greater restrictions on family activities (Marklund, Ahlstedt, & Nordstrom, 
2006). Using the Impact on Family Questionnaire, parents of children with a peanut allergy 
reported significantly more disruption to child’s activities and a negative effect on the 
family social life compared with parents of children with rheumatological disease. 
However the financial burden was lesser for those with peanut allergy and there was no 
difference seen in personal strain and coping strategies (Primeau et al., 2000). Caution 
should be applied to the findings of the above studies for two main reasons. Firstly the 
evaluation of HRQL has been made by the parent and evidence suggests that parents are 
often poor raters of their child’s HRQL (Eiser & Morse, 2001). Secondly the use of the 
generic measures may not be valid as they are primarily concerned with the impact the 
disease has on the family, and where this may play some role it is not a direct measure of 
HRQL. 
 
Using a disease-specific measure, the HRQL of peanut allergic children was found to be 
significantly impaired when compared to diabetic children with peanut allergic children 
scoring lower on QOL, having higher levels of anxiety, being more afraid of accidental 
ingestion than a diabetic of a hypoglycemic episode, felt they had a higher risk of reaction, 
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felt more strongly that they had to be careful about what they ate and higher anxiety 
around holidays and birthdays (Avery, King, Knight, & Hourihane, 2003). A limitation of 
this study is that the use of a disease-specific measure may not be comparable for two 
distinct diseases, food allergy and diabetes.  
 
With regards to teenagers, females with FHS experience more bodily pain, worse level of 
general health and are less able to take part in social activities than females with allergic 
conditions (no FHS). Males with FHS scored lower on social functioning than males with 
allergic conditions (no FHS), which suggests a differing experience according to gender 
(Marklund, Ahlstedt, & Nordstrom, 2004). This study reports self-reported FHS 
prevalence at 19%, which is much higher than prevalence studies would suggest for a 
similar population (2.3% (Pereira et al., 2005)), however, of note no significant difference 
was found in the scores between those individuals with and without a clinician diagnosis 
and so it appears that there is no impact on FHS from a diagnosis of FHS. When 
comparing the HRQL of individuals with FHS with the general population it was found 
that children and adolescents with FHS report fewer limitations in school work or activities 
with friends due to behavioral problems than children and adolescents from the general 
population, however adolescents and adults report more limitations due to pain, a more 
impaired perception of overall health, more limitations in social activities and a lower 
degree of vitality and liveliness than adolescents and adults of the general population 
(DunnGalvin, Dubois, Flokstra-de Blok, & Hourihane, 2015). Furthermore food allergic 
children score significantly higher on role-functioning-behaviour than children from the 
general population suggesting a better HRQL, teenagers with FHS scored significantly 
higher on role-functioning-behaviour but lower on bodily pain and general health than 
adolescents from the general population, and adults with FHS had lower scores on social 
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functioning, vitality and general health than the general population suggesting a poorer 
HRQL (B.M. Flokstra-de Blok et al., 2010). 
 
In summary, the HRQL of children and teenagers with FHS has been widely studied and 
shown to have a negative affect on overall HRQL as well as sub group domains. Despite 
the large body of research in children and adolescents, only a few studies in adults have so 
far been published, and even fewer of these use disease-specific measures to assess HRQL.  
 
It has been researched how FHS compares with other chronic diseases with regards to 
HRQL. Primeau et al. (2000) examined the impact of FHS (specifically peanut allergy) on 
the HRQL of adults compared with those with rheumatological disease, using the Impact 
on Family Questionnaire (IFQ) measure. They found that peanut allergic adults 
experienced less familial/social disruption, less personal strain, and less financial burden 
than adults with rheumatological disease. Peanut allergic adults also scored higher on the 
mastery subscale which suggests that they developed less effective coping skills to manage 
their FHS. As previously mentioned, a limitation of this study however is that the Impact 
on Family Questionnaire is not a reliable measure of HRQL as it is primarily concerned 
with the impact of an illness on the family rather than the individual. In addition this study 
focused on peanut allergy only and so it is not known to what extent the results are 
generalisable to other types of FHS. A more recent study compared the impact of FHS on 
HRQL of adults, with the impact of other chronic conditions using a generic HRQL 
measure (RAND-36). The findings suggest that adults with FHS indicated: poorer HRQL 
compared to diabetic adults on role-functioning-physical, vitality, bodily pain and general 
health; better HRQL than asthma on all scales except mental health; better HRQL than 
rheumatoid arthritis on 6 scales; and better HRQL than irritable bowel syndrome on all 
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scales (B.M. Flokstra-de Blok et al., 2010). These findings suggest that HRQL is more 
impaired in individuals with FHS than diabetes, but less so than other chronic conditions 
such as asthma, rheumatoid arthritis and irritable bowel syndrome.  
 
Some research has also looked at specific factors affecting HRQL of individuals with FHS. 
One study used a validated disease-specific measure of HRQL (Food Allergy Quality of 
Life Questionnaire- Adult Form) to investigate Swedish adults who were allergic to so 
called ‘staple foods’ (cow’s milk, egg or wheat). They found that the restrictions imposed 
due to following a restriction/elimination diet, the presence of other allergic diseases 
(especially if asthma was present), and the severity of allergy (defined by prescription of 
epinephrine auto injectors) were all important factors which had a negative effect on 
HRQL (Jansson et al., 2013). The mean HRQL score was 4.85 which indicates poor 
HRQL (based on a 7-point scale where 1 is the highest HRQL and 7 is the lowest HRQL), 
and no significant difference was seen between males and females. A qualitative study 
carried out in adults in New Zealand sought to use qualitative methods to gain an in-depth 
understanding of the issues impacting on the HRQL of this age group (Peniamina, Bremer, 
Conner, & Mirosa, 2014). There were three key themes which emerged from the focus 
groups: issues related to living with a food allergy (allergen-free eating issues, health care 
system issues, costs of having a food allergy, and effects on well-being), external 
influences (others lack of awareness, and others attitudes), and internal influences 
(personal growth and adaptation). The authors conclude that the unmet needs of this age 
group leads to risk taking, increased stress and social isolation, and they propose that 
interventions which target public awareness of FHS, as well as the teaching of 
assertiveness and organisation skills for allergic adults would be beneficial.  
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As part of the EuroPrevall project (a multi-centre birth cohort study involving nine 
European countries), potential factors which may predict the HRQL of adults with FHS 
were investigated (Saleh-Langenberg et al., 2015). The prediction model accounted for 
62% of the variance in HRQL and the factors that had a significant contribution to this 
variance were: perceived disease severity, type of symptoms, and gender (with women 
most affected). Of interest, the study also found having a fish or milk allergy had a 
significant and unique contribution to this variance which illustrates that HRQL in FHS 
may be affected by the offending allergen. However the study does not explore reasons for 
this and so subsequent research is needed to explore this finding further. Interestingly, 
Goossens et al. (2011) report a significantly greater impairment in HRQL in American 
adults when compared to Dutch adults, which suggests that cultural differences, such as 
diet, knowledge, attitudes and beliefs, may also be factors which affect HRQL.  
 
In summary, as FHS is a chronic condition and one that requires constant vigilance it is 
important to look at the impact the disease has on the patient’s HRQL. Information on 
HRQL is of use in healthcare planning and food safety assessment to ensure effective 
support to the allergic individual in managing their condition (B. M. Flokstra-de Blok et 
al., 2007). Current literature suggests that FHS has a negative effect on an individual’s 
HRQL, however there are relatively few studies to date which have explored this in an 
adult population. Moreover, even less is known about potential factors which may predict a 
better or poorer HRQL with one study suggesting that the impact of allergies to specific 
foods may differ to that of other foods (Saleh-Langenberg et al., 2015). This would suggest 
that the burden of disease is disproportionate. It is thought that some allergens may be 
easier to avoid than others, in addition allergies to certain foods commonly develop in 
childhood while others are not seen until later on in life, and so it is of interest to see 
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whether these factors play a role in HRQL; currently there is a lack of research to answer 
these questions. The results of such studies would have implications for clinician’s as there 
are likely to be different needs and risks dependent upon the diagnosis of type of FHS.  
 
2.4 Fish and shellfish allergy 
Edible seafood (fish or shellfish that comes from the sea) can be characterised into three 
phyla: Mollusca, Arthropoda and Chordata (Lehrer, Ayuso, & Reese, 2003) (Table 2.1).  
Seafood is an important source of nutrients in the diet, with white fish containing protein, 
iodine, calcium, phosphorus, fluoride, fatty fish containing fat, vitamins A and D, and 
omega-3 fatty acids, and shellfish having similar nutrient properties to white fish as well as 
selenium, zinc, iodine and copper (present in crab and mussels) (Venter & Meyer, 2010). 
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Table 2.1 Classification of seafood species 
Phylum Class Species 
Mollusca Gastropoda Abalone (perlemoen), Snails, 
Alikreukel 
Bivalvia Mussles, Oysters, Clams, Scallops 
Arthropoda Cephalopods Squids (Calamari), Octopus, 
Scallop 
Crustaceans Lobsters, Shrimp, Prawn, Crayfish 
(freshwater), Crab, Rock Lobster 
(Kreef) 
Chordata (fish) Chrondrichthyes (cartilaginious 
fish) 
- Lamniformes 
Sharks, Rays, Skates 
Osteichthyes (bony fish) 
- Cardiformes 
- Salmoniformes 
- Perciformes 
 
- Pleurenectiformes 
Cod, Haddock, Hake 
 
Trout, Salmon, Pike 
Snapper, Mackerel, Tuna, Bonito, 
Grouper 
Sole, Flounder, Halibut, Plaice 
 
Fish, crustacean and molluscs constitute three out of the 14 major allergens identified as 
important by the European Union and, accordingly, covered by legislation on the provision 
of food information to consumers (Regulation (EU) No 1169/2011). Wide variations of 
seafood have reportedly triggered adverse reactions, however, the offending species 
causing symptoms usually reflect the local and national availability and consumption 
patterns. For example, in the UK cod, tuna, salmon, trout, plaice and pollock are often 
reported as causes of adverse reactions (Skypala & Venter, 2009) whereas case reports 
from around the world include reactions to whelk, sea urchin, roe and boiled razor shell 
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(Choi et al., 2009; Martin-Garcia et al., 2007; Yoneyama & Ono, 2002). Adverse reactions 
to seafood include both IgE-mediated and non-IgE mediated allergic responses as well as 
non-allergic reactions.  
 
IgE-mediated reactions are triggered by ingestion and include symptoms from mild 
urticaria to severe and potentially fatal anaphylaxis (Bock, Munoz-Furlong, & Sampson, 
2001). Indeed, IgE-mediated reactions to fish, crustaceans and molluscs are a leading cause 
of anaphylaxis (Sampson, 2003) and in the UK seafood allergens are the cause of 8% of 
fatal anaphylaxis (Pumphrey, 2000). In addition, IgE-mediated allergic reactions, as well 
as other allergic diseases such as asthma, urticaria and contact dermatitis, can also be 
triggered by occupational exposure through skin contact and the inhalation of seafood 
vapours (Lopata & Jeebhay, 2013). Typically allergic reactions to seafood are immediate 
i.e. related to an IgE response, and are not normally implicated in delayed reactions 
(Skypala & Venter, 2009). Although less common and not well described in the current 
literature, especially in adults, allergic reactions may be non-IgE mediated and these 
usually involve severe symptoms, for example, food protein-induced enterocolitis 
syndrome (FPIES) to molluscs (Fernandes, Boyle, Gore, Simpson, & Custovic, 2012) and 
shrimp (Gleich, Sebastian, Firszt, & Wagner, 2016). 
 
The most common non-allergic reactions are caused by Anisakis simplex (including the 
larvae), which is a nematode fish parasite that may infect humans and cause allergic 
reactions ranging from urticaria to anaphylactic shock; other common toxic syndromes 
associated with the consumption of seafood are listed in Table 2.2 (Chegini & Metcalfe, 
2005). 
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Table 2.2 Seafood toxin-induced diseases 
Type of poisoning Type of toxins Source Symptom onset Clinical syndrome 
Scromboid Histamine Tuna, mahi-mahi, 
bonita, marlin, 
bluefish, wahoo, 
mackerel, salmon 
Minutes to 4 hours Severe headache, 
dizziness, nausea, 
vomiting, flushed 
skin, palpitations, 
wheezing 
Ciguatera Ciguatoxins Coral reef fish: 
amberjack, 
snappers, grouper, 
goat fish, 
barracuda, sea 
bass, sturgeon fish, 
ulua, papio 
30 minutes to 4 
hours 
Abdominal pain, 
diarrhoea, 
vomiting, 
paraesthesias, cold-
to-hot sensory 
reversal, weakness, 
myalgias 
Puffer fish 
poisoning 
Tetradotoxin  Ocean sunfishes, 
porcuoine fishes, 
fugu 
10-45 minutes Paraesthesias, 
headache, 
vomiting, 
diaphoresis, 
respiratory 
paralysis 
Paralytic shellfish Saxitoxins  Mussels, clams, 
oysters 
5-30 minutes Vomiting, 
diarrhoea, 
abdominal pain, 
myalgias, 
paresthesias, ataxia 
Amnesic shellfish Domoic acid Mussels, clams, 
crabs, anchovies 
15 minutes to 38 
hours 
Vomiting, 
diarrhoea, 
headache, 
myoclonus, loss of 
short term 
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memory, seizures, 
coma, hemiparesis 
Diarrhetic shellfish Okadaic acid, 
dinophysistoxins, 
pectenotoxins, 
yessotoxin 
Mussels, clams, 
scallops 
30 minutes to 6 
hours 
Diarrhoea, nausea, 
vomiting, 
abdominal pain 
 
There seems to be an increased prevalence of fish and shellfish allergy in countries with a 
high seafood consumption such as Australia, Asia and parts of Europe (Ng, Turner, Kemp, 
& Campbell, 2011). This is the opposite finding when compared to peanut allergy, where it 
is thought that the early and frequent consumption of peanut may actually induce 
tolerance, and so a lower prevalence of peanut allergy is seen in countries with a high 
consumption such as Israel (Du Toit et al., 2008). In China where fish and shellfish is 
widely consumed, the overall prevalence of FHS is 5% and fish and shellfish are the main 
implicating allergens (Hill et al., 1997). Furthermore, shellfish allergy is the most common 
trigger of anaphylaxis in South-East Asia, Hong Kong and Taiwan (Thalayasingam et al., 
2015). Fish and crustacean allergy is more common than mollusc allergy, and seafood 
allergy is more often seen in adults than children (Skypala & Venter, 2009). Having said 
that the term ‘shellfish allergy’ in the literature often refers only to crustacean allergy, and 
although many people with a crustacean allergy also avoid molluscs due to cross 
sensitisation of allergens, the true existence of mollusc allergy remains unconfirmed 
causing uncertainty over the clinical importance of Mollusca shellfish allergy (Taylor, 
2008). Prevalence rates also vary according to the diagnostic methods used to determine 
FHS, with self-reported seafood allergy and sensitisation rates much higher than food-
challenge proven prevalence. In the UK, self reported fish allergy was as high as 2.9% in 
all ages (Young, Stoneham, Petruckevitch, Barton, & Rona, 1994) whereas food challenge 
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proven fish allergy was 0% in six year olds (Venter et al., 2006). For shellfish allergy, the 
highest self reported crustacean allergy prevalence in the UK was 0.7% in 11 and 15 year 
olds (Pereira et al., 2005) however due to the lack of food challenge data for either 
crustacean or molluscs, this prevalence could not be confirmed. To date there are no 
studies in the UK which have examined the challenge-based prevalence of fish and 
shellfish allergy in adults.  
 
In the UK the National Diet and Nutrition Survey collected seven-day dietary records from 
1724 participants in 2006 and found the mean daily intake (g/day) in adults for fish, fish 
products, crustaceans and molluscs was 22.1, 1.7, 2.6 and 0.5 respectively. To put this 
consumption into context with regards to other European countries, the range of 
consumption across Europe was found to be 4.8 to 57.3 for fish, 0.6 to 5.3 for fish 
products, 0.6 to 5.2 for crustaceans, and 0.1 to 12.0 for molluscs (EFSA NDA Panel, 
2014). This therefore demonstrates that the UK has neither the lowest nor highest 
consumption of seafood and thus there is no reason to suspect that the characteristics of 
fish and shellfish allergy may be different in the UK compared to other European 
countries. To provide further detail, Table 2.3 illustrates the contribution of different 
species of seafood to the consumption in the UK. From this, it can be seen that white fish 
(cod and whiting) is the most commonly consumed fish and prawns and squid are the most 
commonly consumed shellfish in the UK. 
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Table 2.3 Contribution of different species to the consumption of seafood in the 
UK in adults
1
 
Fish (%) Crustacean (%) Mollusc (%) 
Anchovy  14 Crab  14 Clam  1 
Bass <0.5 Crayfish  6 Cockle  11 
Cod and 
whiting  
31 Lobster  2 Mussel  32 
Eels  <0.5 Prawn  77 Oyster  6 
Halibut  <0.5 Shrimp  1 Scallop  10 
Herring  2   Squid  32 
Lophiiformes  <0.5   Whelk  7 
Mackerel  4     
Plaice  3     
Salmon/ trout 19     
Sardine/ 
pilchard 
4     
Sole  1     
Tuna  21     
 
In summary, a wide variation of fish and shellfish species are known to trigger allergic 
reactions, however there is usually some pattern depending on the local diet and 
availability of fish and shellfish species. The prevalence is believed to be higher in 
countries with a high consumption of fish and shellfish and reactions are typically IgE-
mediated, and are quick on onset and potentially severe. Furthermore, reactions to fish and 
shellfish can be triggered by ingestion, as well as through inhalation of vapours, thus 
making it a difficult allergen to avoid. As well as IgE-mediated reactions, a few case 
reports have indicated that fish and shellfish may be implicated in FPIES, although this 
                                                 
1
 Only species with at least 1% consumption in at least two countries or with at least 2% consumption in one 
country are shown. 
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requires further study. The main difficulty when diagnosing this type of food allergy is the 
frequency of non-allergic toxin-induced diseases and so it is ever more vital for the 
clinician to take a full detailed medical history. The consumption of fish and shellfish in 
the UK falls in neither the highest or lowest ranges and so the results of a study carried out 
in the UK would be expected to be generalisable to other European countries. The 
following sections will review the current knowledge of the main implicating allergens in 
fish and shellfish species.  
2.4.1 Fish allergens  
Parvalbumins are recognised to be the major and cross-reacting allergenic proteins found 
in several fish species (including fresh and salt water types); over 95% of fish allergic 
individuals have IgE antibodies to parvalbumins (de Martino et al., 1990; Kuehn, 
Scheuermann, Hilger, & Hentges, 2010). Parvalbumins are resistant to denaturation by 
heat, chemicals and enzymatic digestion (Kuehn, Scheuermann, Hilger, & Hentges, 2010) 
and they are distributed widely in the white muscle of fish (Kobayashi et al., 2006). While 
parvalbumin is also present in the dark muscle, this muscle has been found to be much less 
allergenic than the white muscle due to the lower levels of parvalbumin present 
(Kobayashi et al., 2006). Cod hypersensitivity has been extensively studied and the major 
parvalbumin Gad c1 isolated and characterised (Aas & Elsayed, 1969). Using Gad c1 as a 
comparison, Van Do, Elsayed, Florvaag, Hordvik, & Endresen (2005) studied the cross 
reactivity of nine commonly consumed fish and found salmon (Sal s1), pollock (The c1), 
herring and wolfish to have similar antigenic and allergenic determinants to cod (Gad c1) 
whereas halibut, flounder, tuna and mackerel displayed the lowest cross reactivity 
suggesting some tolerance may be possible to the latter. However, these studies were done 
in vitro and this has not been studied at a clinical level which makes the practical 
management of fish allergy very difficult. Furthermore, in raw fish parvalbumin levels 
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were found to decrease significantly in the following order: herring, carp, redfish, 
salmon/trout, cod, mackerel and tuna (Kuehn, Scheuermann, Hilger, & Hentges, 2010). 
Identifying these potentially lower allergenic species would help to clarify the specific 
species fish allergic patients may or may not be able to tolerate. Given that, in addition to 
the complex dietary management needed to avoid all fish species, individuals doing so are 
also abstaining from important nutrients (i.e. iodine, omega 3 in fatty fish, vitamin D, 
iron). The inclusion of some fish species could be hugely beneficial for fish allergic 
patients.  
 
It is now widely recognised that other allergenic proteins may also play a role in adverse 
allergic reactions to fish.  An early study on codfish allergy in adults indicates the presence 
of both general and species-specific allergenic proteins (Hansen & Bindslev-Jensen, 1992). 
For example, fish enolases and aldolases have been shown to be allergenic proteins of 
importance in fish allergy, in particular in those individuals with an absence of 
sensitisation to parvalbumin (Kuehn et al., 2013). Furthermore allergic individuals who are 
sensitised to tropical fish species react mostly to allergenic proteins other than 
parvalbumins (Kuehn et al., 2014). It is believed that fish allergic patients have a risk level 
of 50% of experiencing cross reactions to other species (Sicherer & Sampson, 2010), 
however, mono-sensitivity to specific fish, such as cod, nile perch and mackerel have been 
described in patients who are sensitised to enolases and aldolases but not parvalbumin 
(Kuehn et al., 2014). In addition, fish collagen has been found to be a highly cross-reactive 
panallergen which is of particular importance in countries such as Japan, where the 
consumption of raw fish in the form of sashimi or sushi is common (Kobayashi et al., 
2016). The cooking process denatures collagen to form gelatin which is water soluble, 
easily digested and previously shown to be of little cause for concern with regards to 
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allergy (Andre, Cavagna, & Andre, 2003; Hansen et al., 2004), however collagen in raw 
fish is water insoluble. Kobayashi et al. (2016) found 50% of patients with a fish allergy 
had IgE against mackerel collagen, compared to 44% who had IgE against mackerel 
parvalbumin. The findings of this study suggest that in this population, fish collagen is as 
important as parvalbumin as an allergenic protein and warrants further research to identify 
fish collagen allergens, particularly because diets are becoming more varied and are 
consumed in non-native countries.   
 
In summary, parvalbumins are understood to be the main allergenic proteins that are 
present, albeit in varying amounts, in many fish species and so because of this, fish allergic 
individuals are advised to avoid all types. At present we have limited knowledge on the 
presence of other allergenic proteins (aldolases, enolases, collagen) and which species may 
be less allergenic and therefore safe to consume.  
2.4.2 Crustacean and mollusc allergens 
The major allergenic protein of crustacean and mollusca shellfish is tropomyosin. 
Tropomyosin is water soluble and heat stable. This is illustrated by the detectable trace of 
tropomyosin found in water used to boil shrimps (Daul, Slattery, Reese, & Lehrer, 1994). 
Tropomyosin was first identified as the major allergen from shrimp (Daul, Slattery, Reese, 
& Lehrer 1994; Shanti, Martin, Nagpal, Metcalfe, & Rao, 1993) however tropomyosin has 
since been identified in other crustaceans, molluscs, as well as house dust mite, insects 
such as cockroaches (Reese, Ayuso, & Lehrer, 1999). In addition, other allergenic proteins 
may play a role in crustacean shellfish allergy, for example arginine kinase in red and blue 
crab, myosin light chain and sarcoplasmic calcium-binding protein (Lopata, O'hehir, & 
Lehrer, 2010; Misnan, Murad, Yadzir, & Abdullah, 2012; Shiomi, Sato, Hamamoto, Mita, 
LITERATURE REVIEW 
34 
& Shimakura, 2008). The clinical significance of these allergens is however not yet fully 
known (Taylor, 2008).  
 
Molecular comparisons of tropomyosin from different crustacean species show high 
homologies (similar characteristics due to relatedness) of up to 98%. The homology 
between the tropomyosin allergenic proteins in mollusc shellfish supports the 
recommendation to avoid all molluscs; within the entire mollusca shellfish grouping 
(which includes cephalopods, bivalves and gastropod species) amino acid sequence 
identities for tropomyosin range from 68% to 100% (Taylor, 2008). The homology 
between crustacean and mollusca tropomyosin is lower at 56% to 68% (Lee, Gerez, Shek, 
& Lee, 2012). In addition, the molecular homology between shellfish tropomyosin equates 
to high levels of IgE cross-sensitivity. This IgE cross-sensitivity forms the basis of the 
clinical argument for shellfish allergic individuals to avoid all species in the absence of 
evidence of tolerance (Tsabouri et al., 2012). However, IgE cross-sensitivity may not 
equate to clinical cross-reactivity. Indeed, Sicherer, Munoz-Furlong, & Sampson (2004) 
report that only 38% and 49% of crustacean and mollusc allergic individuals reported 
being allergic to more than one species, which would suggest that clinical cross reactivity 
is not directly correlated with IgE cross-sensitivity. Vidal et al. (2015) studied the 
sensitisation pattern of crustacean allergic patients and concluded that two distinct 
populations exist in terms of clinical and immunological patterns; patients with crustacean 
and mollusc allergy and patients with crustacean allergy only. It is recommended that 
measuring shrimp SIgE and shrimp tropomyosin SIgE could aide clinicians’ 
recommendations to crustacean allergic patients on the risk of mollusc allergy as well as 
recognising that those with a crustacean and mollusc allergy were more atopic and had 
higher concentrations of D. pteronyssinus SIgE, nDer p1 SIgE and nDer p10 SIgE than 
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those tolerant to molluscs (Vidal et al., 2015). Hence, there is a need for further research 
using food challenge data to identify the extent to which there is clinical cross reactivity 
between the two types of shellfish. Such research would help to clarify the advice being 
provided to patients allergic to fish, crustacean and or mollusc regarding which species to 
actually avoid.  
 
Clinical cross reactivity in patients with house dust mite and shellfish allergy has been 
documented and it relates to the similarities in the allergic protein tropomyosin found in 
both species, with an 81% amino acid sequence homology to shellfish tropomyosin 
(Wong, Huang, & Lee, 2016). It is of interest that the prevalence of shellfish allergy in 
Asia is much higher than that of fish allergy despite both being heat stable allergens which 
are widely consumed in an Asian diet. It has been suggested that this is due to high levels 
of sensitisation to house dust mite (Thomas, 2010). Furthermore, 94% of challenge-proven 
shrimp allergic children were sensitised to the house dust mite allergen D. pteronyssinus 
and 96% were sensitised to the house dust mite allergen D. farina (Jirapongsananuruk et 
al., 2008). However, this is purely an association and does not necessarily show causation. 
It has been hypothesised that the role of inhaled tropomyosin from house dust mite may 
allow for the successful immunotherapy treatment for shellfish allergy (Wong, Huang, & 
Lee, 2016).  
 
In summary, tropomyosin is the major allergenic protein in crustacean and molluscan 
shellfish. It is known that there is high homology in the tropomyosin proteins within the 
molluscan grouping and this homology also appears to be present between crustaceans and 
molluscs, yet the clinical cross-reactivity between the two types of shellfish is not fully 
understood. In addition, homologies can also be seen in tropomyosin in house dust mites 
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and shellfish, however, again how this presents as clinical cross-reactivity in individuals 
warrants further research in order to be able to correctly tailor the avoidance advice and 
possible treatments given to shellfish allergic individuals.  
2.4.3 Diagnosis and differential diagnosis 
The wide variety of seafood species often contributes to some difficulty in diagnosing a 
seafood allergy (Tsabouri et al., 2012). A detailed medical history is the starting point for 
the diagnosis of fish and or shellfish allergy. Where fish or shellfish has been a clear 
ingredient the patient may already have attributed their symptoms to fish and or shellfish 
and often have removed these from their diets (Skypala & Venter, 2009). Helbling et al. 
(1999) found the most common symptoms associated with a fish allergy were vomiting as 
well as itching of the mouth and throat. However, seafood poisoning frequently manifests 
itself as an allergic reaction and so questions about the type of fish, symptoms, and 
whether anyone else experienced an adverse reaction are key to uncovering a differential 
diagnosis of seafood poisoning (Tsabouri et al., 2012).  
 
Due to the likelihood of a differential diagnosis when making the diagnosis of a fish or 
shellfish allergy, it is important to ascertain the presence or absence of SIgE antibodies 
(Skypala & Venter, 2009). The predictive accuracy of a positive SPT to fish was 84% and 
78% for SIgE (Helbling et al., 1999). Commercial fish and crustacean extracts used for 
SPTs may be made from a different species to that which was consumed by the patient and 
so it is imperative to check the SPT solution is the correct species. Sometimes the SPT 
solution is not commercially available, for example tiger prawn and king prawn, and so it 
is then appropriate to use a crude extract or prick-to-prick test to ensure testing of the 
appropriate species and avoidance of false negative results. Furthermore the preparation 
methods may alter the allergenicity of the extract, for example boiled versus raw shrimp 
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extracts illicit larger wheal sizes when used in skin prick tests and higher optical density in 
serum SIgE blood tests, suggesting that boiled shrimp extracts are far more effective in 
diagnostic tests (Carnés et al., 2007).  
 
With regards to fish specifically, the predictive accuracy of a positive SPT and serum SIgE 
to fish has been suggested to be 84% and 78% respectively (Bernhisel-Broadbent, Scanlon, 
& Sampson, 1992; Helbling, McCants, Musmand, Schwartz, & Lehrer, 1996). In 
summary, the above studies would suggest the SPT and serum SIgE test are reliable and 
valid tests for the diagnosis of seafood allergy, however the type and preparation method 
of the extract should be carefully considered and ideally a negative SPT or serum SIgE in 
the presence of a clear history should be followed up with a food challenge.  
 
Allergen component diagnostic tests measure IgE to specific allergen components and can 
be used as indicators for specific allergen reactivity, understanding the patient’s risk, 
selecting patients for treatment such as immunotherapy, and understanding cross-reactions 
(Hoffmann-Sommergruber & Mills, 2009). There are two parvalbumin proteins: Cyp c1 
which are present in oily fish such as carp, and Gad c1 which are present in white fish such 
as cod. A negative allergen component test result to both of these proteins would be 
indicative of a low risk of oral challenge and the need for further investigations for other 
possible allergens. There are three tropomyosin proteins available for testing: Pen a1 
(present in shrimp), Der p10 (present in house dust mite), and Bla g7 (present in 
cockroach) (Hoffmann-Sommergruber & Mills, 2009). These are highly cross-reactive 
proteins, with 10% of house dust mite allergic individuals found to have SIgE to 
tropomyosin (Leung et al., 2014).  
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2.4.4 Management and avoidance 
As previously described, the allergenic proteins in fish and shellfish are highly cross-
reactive and can cause symptoms through the inhalation of vapours as well as ingestion 
and so it is fundamental that the individual follows a detailed management and avoidance 
plan to prevent further severe reactions. Fish, crustaceans and molluscs are required by 
European labelling legislation (Regulation (EU) No 1169/2011) to be declared on all 
products which contain them which helps in the recognition of products to avoid, 
especially those products for which it is not obvious. Of note, for ingredients such as fish 
gelatin (which is used in vitamins and alcohol products) and isinglass (used for the 
clarification of wine and beer) labeling is not required as it is considered too low a level to 
cause concern for allergic individuals (Skypala & Venter, 2009).  
 
There is limited available information on the dietary advice currently being provided to 
individuals with fish and shellfish allergies and, more importantly, on the compliance with 
this advice. Ng, Turner, Kemp and Campbell (2011) reviewed the advice given to the 
parents of 94 seafood allergic children presenting to a specialist allergy clinic in Australia. 
They report 56% were advised to avoid all types of seafood and 45% were advised to 
avoid either fish or crustaceans. Eleven percent under adhered to the advice, with the 
majority (52%) over adhering by following more stringent diets and 40% avoided 
restaurants serving seafood. The source of dietary advice, for example a dietitian or 
consultant allergist, had no affect on the compliance rates. Compliance with advice 
assumes sufficient recall of advice. In this study, despite the vast majority of parents (77%) 
being able to recall the same dietary advice documented in the medical notes, a quarter 
(24%) failed to adhere to the advice. The authors concluded that parental dietary adherence 
is variable with a tendency to impose a more stringent diet than recommended by the 
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healthcare professionals (Ng, Turner, Kemp, & Campbell, 2011). There is no available 
data on adherence in adults, however, Jones et al. (2015) report the overall adherence of 
adolescents with FHS to be poor, with only 16% of participants adhering to all the 
investigated aspects of self-care. They conclude that having an anaphylaxis management 
plan was associated with a threefold better adherence, and being a member of a support 
group was associated with a twofold better adherence (Jones et al., 2015). This is an 
interesting finding and it would be beneficial for clinicians to understand these factors 
further so that recommendations could be given to individuals which may then increase 
adherence.  
 
With regards to a fish allergy, confirmation of an allergy to one type of fish species may 
not mean an allergy to other types, however, (in the absence of data on clinical cross-
reactivity) the current evidence on the cross sensitisation of allergenic proteins would 
suggest it is unsafe to advise the consumption of other fish without first undertaking 
further diagnostic tests. In addition there is the challenge of avoiding cross-contamination 
and so avoiding mixed fish stalls, markets and areas where different types of fish are 
prepared is advisable (Skypala & Venter, 2009). It is important to note that no cross-
sensitisation between fish allergens and shellfish allergens has to date been demonstrated 
(Lopata & Lehrer, 2009) and so it is advised that fish allergic individuals are safe to 
consume crustaceans and molluscs. However, data does suggest that in the UK 21-43% of 
fish-allergic individuals are also allergic to shellfish (Venter & Arshad, 2011) perhaps due 
to an increased atopic predisposition. 
 
Recent research indicates a possible clinical cross-reactivity may exist between fish and 
chicken due to homologies in parvalbumin (Gal d8), enolase (Gal d9) and aldolase (Gal 
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d10) which are found in chicken and fish meat (Kuehn et al., 2016). This finding further 
empathises the complexity of fish allergy and thus the need for further research to facilitate 
clear clinical guidelines to ensure safety of individuals.  
 
With regards to crustacean allergy there is a high cross reactivity between species and so 
avoidance of all types is recommended, however the avoidance of molluscs may not be 
necessary although caution should be taken due to cross contamination and should be 
preceded where possible with diagnostic tests to ensure there is no sensitisation and cross 
reactivity (Skypala & Venter, 2009). Due to the heat-stable nature of crustacean allergens 
the individual should also avoid eating in restaurants where crustaceans may be cooked 
using the same utensils or in the same oils as other dishes, as Lehrer et al. (2007) 
investigated the use of cooking oil for allergenic and non allergenic foods and preliminary 
results suggested that shrimp allergenic activity could be detected in oil previously used to 
cook shrimp with the more cooked the greater the activity. 
 
Unlike allergies to some foods, such as milk and egg, it is commonly understood that 
seafood allergy develops in adulthood and does not in general resolve with age and 
therefore appropriate life-long dietary avoidance and allergy management is essential 
(Lopata & Lehrer, 2009). Some emerging case reports suggest that remission may be 
possible for fish allergy, for example Solensky (2003) describes the case of a 68 year old 
male with a previous history of fish-induced anaphylaxis diagnosed at five years of age 
with previous positive SPT results, who successfully underwent SPTs to a number of fish 
species all producing negative results and was able to tolerate an OFC with halibut. To 
date, however, no studies have reported a clear resolution of shellfish allergy. One study 
examining the natural history of shrimp allergy did not find a change in SIgE levels to 
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shrimp over a two year period (Daul, Morgan, & Lehrer, 1990). On the other hand, Ayuso 
et al. (2012) showed that sensitisation to shrimp proteins was greater in children than 
adults which may suggest a decrease in clinical sensitisation with age, however the lack of 
a longitudinal study examining the natural history makes it difficult to explain this finding. 
In summary, case reports provide limited evidence of remission but comparative data 
provides conflicting evidence regarding any change in sensitisation with age, and there is 
not a clear picture regarding natural history (e.g. percentage remission at particular ages). 
The scarcity of available data highlights the lack of attention paid to fish and shellfish 
allergy.  
 
In summary the clinical manifestation of fish and shellfish allergy is varied, sometimes 
even in the same patient, there is evidence of cross-sensitivity between species but it is still 
unknown to what extent this correlates with clinical cross reactivity, and there are few 
studies on the natural history and so further detailed research is needed to better 
understand, and therefore manage fish and shellfish allergy. Clinical symptoms are thought 
to be similar to other allergens, however fish and shellfish allergy pose the risk of reaction 
through inhalation as some allergens are capable of aerosolising and so there is an added 
risk for these individuals. Dietary advice and medical management needs consistency and 
possible new therapeutic strategies are worthy of research given the believed longevity of 
this type of allergy. 
 
2.5 Summary: context of research 
To summarise, it is clear from the current research that fish and shellfish allergy is of 
major concern due to the possible severity of reactions and the longevity of the condition. 
Compared with other common allergens, fish and shellfish allergy is relatively under 
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researched. The further study of fish and shellfish allergy is warranted as it accounts for 
three out of 14 major allergens, it is a difficult allergen to avoid due to the likelihood of 
potentially severe reactions triggered by vapour or steam inhalation, and also because of 
the cross sensitisation and risk of co-existing allergies within and between fish and 
shellfish species. As with any study of disease where little is known, it is important to first 
describe the epidemiology of the disease so that we can understand the burden of disease. 
Next the clinical characteristics will be explored to inform clinicians about how this type 
of allergy typically presents and to identify risk factors. Finally, to complete the overall 
picture of fish and shellfish allergy, a study from the patient’s perspective will aim to 
measure the associated affect of fish and shellfish allergy on HRQL. The results will 
facilitate better management plans and evidence-based decision making in clinical practice 
for patients with the aim to reduce the negative affect on patients’ life as much as possible. 
The results are expected to inform evidence-based practice, the provision and planning of 
allergy services, and management guidelines. As well as informing the research and 
clinical community so that it can be better understood and thus managed. The results 
obtained from this research will add new and essential knowledge to the current 
understanding of fish and shellfish allergy. The results of this research will inform 
healthcare professionals and policy makers on the accurate prevalence, phenotype and 
psychological affect of this type of food allergy, enabling them to target interventions and 
resources in order to better manage this chronic condition.  
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2.6 Aims for this research 
The overall aim of this research is to characterise and describe fish and shellfish allergy. 
The following research aims and objectives will be addressed in this thesis:  
 To carry out a systematic review of published and unpublished data related to the 
prevalence of fish, crustacean and mollusc allergy in order to understand the true 
prevalence of fish and shellfish allergy. 
 To describe the clinical characteristics of fish and or shellfish allergic adults in a 
UK sample. This will be achieved by addressing the following objectives: describe 
the atopic status, history of allergic disease and characteristics of allergic 
participants; describe the prevalence of fish, crustacean and mollusc allergy and the 
common systems experienced; examine co-existing and cross sensitivity within 
seafood allergy; examine other co-existing food and aeroallergen sensitivities; 
examine the level of tolerance of tinned seafood and the reactivity to airborne 
traces; describe the dietary advice and medical management strategies adopted by 
this sample.  
 To investigate how fish and shellfish allergy affects the health-related quality of 
life of adult sufferers in the UK. This will be achieved by addressing the following 
objectives: assess the HRQL of adults with a fish and or shellfish allergy; compare 
the HRQL of adults with an early onset diagnosis with those with a late onset 
diagnosis; compare the HRQL of adults recruited through an allergy clinic with 
those recruited through an allergy support charity.  
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CHAPTER 3 
PREVALENCE OF FISH AND SHELLFISH 
ALLERGY IN EUROPE AND DIFFERENT REGIONS 
OF THE WORLD: A SYSTEMATIC REVIEW 
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3.1 Overview 
The overall aim of this research is to characterise and describe fish and shellfish allergy. 
First it was necessary to understand the epidemiology of fish and shellfish allergy. This 
chapter details the findings of a systematic review on the prevalence of fish and shellfish 
allergy in Europe, as well as the rest of the world, in all age groups. The background 
section reviews the literature relevant to the systematic review methodology as well as 
currently published systematic reviews on the prevalence of FHS. The methodology 
outlines: how the comprehensive literature search was conducted; the eligibility criteria 
used to assess studies for inclusion; and the method used for assessing the quality of 
included studies. Results are described by world region and outcome assessment utilised 
(questionnaire-based methods, sensitisation methods, and food-challenge methods). Due to 
the high heterogeneity of the included studies, it was not appropriate to carry out a meta-
analysis and so data are presented through narrative description and forest plot graphs are 
used to illustrate the findings further. The implications of the findings relevant to both 
clinical practice and management of fish and shellfish allergy and future research are 
discussed. 
              
3.2 Background 
3.2.1 Systematic review methodology 
The ‘hierarchy of evidence’ (the relative weight different types of studies hold) places 
systematic reviews, as well as meta-analysis, at the top as the pinnacle of all research 
methodologies; followed by randomised controlled trials, cohort studies, case-control 
studies and surveys and finally case reports (Greenhalgh, 2014). The key characteristics of 
a systematic review include clearly stated objectives with pre-defined eligibility criteria for 
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studies, an explicit and reproducible methodology, a systematic search that attempts to 
identify all relevant studies meeting the eligibility criteria, the assessment of validity of 
results through assessment of risk of bias of included studies, and the systematic 
presentation and synthesis of the characteristics and findings of included studies (Cochrane 
Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], 
2011). This method differs from that of a narrative review, which may introduce bias 
through the selective presentation of studies and results and involves no set search strategy 
or pre-planned methodology as well as rarely including quality assessment of studies or 
statistical analysis. Thus conclusions are more likely to reflect the reviewers’ own opinions 
than a systematic and balanced understanding of all of the available evidence.  
(Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated 
March 2011], 2011; Mackenzie et al., 2012). As the aim of the current review is to 
accurately collate all of the existing prevalence data in order to understand the 
epidemiology of fish and shellfish allergy, the systematic review methodology was deemed 
the best approach to use. 
3.2.2 Existing systematic review on the prevalence of FHS 
A systematic review conducted by Rona et al. (2007) reviewed  MEDLINE for 
publications (since 1990) that assessed prevalence of cows’ milk, hens’ egg, peanut, fish 
and shellfish allergy. This systematic review was instrumental in the development of the 
National Institute of Allergy and Infectious Diseases (NIAID) guideline for the diagnosis 
and management of food allergy in the United States (Boyce et al., 2010). The majority of 
included studies presented data on self-reported allergy, which ranged from 0% to 2% for 
fish and 0% to 10% for shellfish. Meta-analysis on the prevalence of participants 
symptomatic and sensitised to fish was 0.5% or less, and 0% to 1.4% for shellfish, and the 
prevalence of IgE sensitisation varied from 0% to 2% for fish and 2.5% for shellfish. Only 
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two studies were identified which used food challenges to confirm seafood allergy. In this 
systematic review, the risk of bias was eliminated as much as possible by excluding 
enriched samples, however, any estimate for a single genus to represent the class fish, or 
order shellfish, was used. This may have significantly underestimated the prevalence of 
fish and shellfish allergy; it is important to represent all types of fish, crustacean and 
mollusc when trying to fully understand the prevalence of these separate food allergies and 
also to begin to identify differences between fish, crustacean and mollusc allergy. 
Furthermore, this review was conducted nearly a decade ago and so does not include new 
and important prevalence research studies. The authors concluded the need for more 
standardised methods of diagnosis to minimise the variability across studies and improve 
comparisons to enable an accurate understanding of prevalence.   
3.2.3 Rationale and aims for this study 
Expanding on the previously published systematic review, the aim of the current study was 
to carry out a systematic review of published and unpublished data related to the 
prevalence of fish, crustacean and mollusc allergy (IgE-mediated and non-IgE mediated). 
Unlike the previous systematic review (Rona et al., 2007) this review included studies 
from across the world, of all age groups, and specific searches for the different types of 
fish and shellfish were carried out. This is important as it allows for differences in 
prevalence rates of fish, crustacean and mollusc across populations, due to age and or 
geography, to be identified allowing for more focused allergy service provision. It also 
provides us with an accurate and up to date understanding of the burden that this type of 
food allergy places on societies worldwide. 
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3.3 Methods 
The current review has been informed by the methods of the Cochrane Collaboration, 
according to their handbook, but it has been adapted for a systematic review of prevalence 
rather than intervention studies.(Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 [updated March 2011], 2011). 
3.3.1 Types of studies 
The review set out to include both population-based cross-sectional studies and cohort 
studies examining the prevalence of fish, crustacean and or mollusc allergy (IgE-mediated 
and non-IgE mediated). Included studies had presented an identifiable point (or period) in 
time so that the point prevalence of food allergy could be measured. 
3.3.2 Types of participants 
The review included participants of all age groups from all countries around the world. 
Studies that did not present region or country-specific data were excluded from the review. 
Studies must have been population based, using either a fixed cohort or a whole 
population, random or non-random sampling strategy. Studies conducted in a clinical 
setting (e.g. a survey of the prevalence of fish/shellfish allergy in current outpatients at an 
allergy clinic) or in selected patient groups (e.g. measuring the prevalence of allergy in 
patients with asthma) were excluded since they do not provide information about the 
general prevalence of fish and or shellfish allergy. 
3.3.3 Types of outcome measures 
Studies employing at least one of the following methods of diagnosis to determine the 
prevalence of fish and or shellfish allergy were eligible for inclusion in the review:  
 Self-reported allergy 
PREVALENCE 
49 
 Clinical history of adverse reactions to foods and positive SPT/ serum SIgE (for 
IgE-mediated fish/shellfish allergy) 
 Clinical history of adverse reactions to foods and positive food challenge (open or 
double-blind placebo-controlled: for IgE and non-IgE allergy) 
 
Studies which presented data regarding sensitisation, in the absence of clinical history, as 
determined by the following methods were also eligible for inclusion in this review: 
 Positive SPT 
 Positive serum SIgE 
 
Studies employing the use of atopy patch tests or other diagnostic tests (e.g. IgG measures) 
were excluded as these are not recommended for the routine diagnosis of allergy (Muraro 
et al., 2014). 
3.3.4 Search methods for identification of studies 
The following databases were searched: Web of Science including Social Science Citation 
Index Expanded (1970-present), Social Sciences Citation Index (1970-present), 
Conference Proceedings Citation Index Science (1990-present), Book Citation Index 
Science (2005-present), and PubMed. Searches were conducted between November and 
December 2012. 
 
Searches of conference proceedings were carried out using the Conference Proceedings 
Citations Index in which studies reported in the proceedings of a comprehensive range of 
allergy conferences (including the World Allergy Congress, the Annual meeting of the 
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American Academy of Asthma, Allergy and Immunology and the Congress of the 
European Academy of Allergy and Clinical Immunology) can be identified.  
 
Grey literature was sought via direct contact with a list of topic experts and examination of 
the lists of awards made by researchers in the field (Dr K Allen, Professor S H Arshad, 
Professor P Burney, Dr K Beyer, Professor G Lack, Dr M F Rivas, Professor H Sampson, 
Dr S Sicherer, Dr B Niggemann, Professor U Wahn, Professor J Hourihane, Dr G Roberts, 
Professor S Prescott). To ensure thoroughness, a snowball approach was taken, whereby 
the experts were asked whether they knew of others working in fields directly related to the 
objectives of the systematic review. 
3.3.5 Search terms and Boolean operators 
The systematic review methodology requires a sensitive, objective and reproducible search 
strategy which will identify as many relevant studies as possible. This is one of the biggest 
differences between a systematic review and a narrative review and it aims to eliminate 
bias and therefore achieve reliable estimates of prevalence. (Lefebvre, Manheimer, & 
Glanville, 2011) 
 
Specific search strategies were tailored for the requirements of each database (Table 3.1). 
In order to identify all relevant articles, no language or date restrictions were employed and 
searches were not limited by study type. The sensitivity of the search strategy was 
evaluated by checking that the search results included studies on this topic known by 
experts within the field. 
 
In PubMed the terms were searched for in the title and abstract fields and using MeSH 
terms where appropriate. In Web of Science the terms were searched for in the ‘Topic 
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Search’ field (which includes title, abstract and keywords). Within groups of terms the 
terms were combined using OR, the groups of terms themselves were then combined in the 
following manner: #1 AND #2 AND #3. 
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Table 3.1 Search terms for the prevalence of fish and or shellfish allergy 
Topics Search terms Search terms for PubMed Search terms for Web of Science 
Group 1. Prevalence     
Prevalence Prevalence, point prevalence prevalence[Tiab] OR “point 
prevalence”[Tiab] OR prevalence[MeSH 
Terms] 
prevalence OR “point prevalence” 
Incidence Incidence, cumulative incidence incidence[Tiab] OR “cumulative 
incidence”[Tiab] OR incidence[MeSH 
Terms] 
incidence OR “cumulative incidence” 
Natural history Natural history “natural history”[tiab] OR ((change[tiab] 
OR changes[tiab]) AND (severity[tiab] 
OR prevalence[tiab]) AND time[tiab]) 
“natural history” OR ((change OR 
changes) AND (severity OR 
prevalence) AND time) 
Group 2. Food  food[Tiab] food 
Crustaceans Crustacean, crab, lobster, shrimp, 
prawn, crayfish, shellfish, langoustine 
crustacean[MeSH Terms] OR 
crustacea[Tiab] OR crustacean[Tiab] OR 
crustaceans[Tiab] OR crab[Tiab] OR 
crabs[Tiab] OR lobster[Tiab] OR 
lobsters[Tiab] OR shrimp[Tiab] OR 
shrimps[Tiab] OR prawn[Tiab] OR 
crustacea OR crustacean OR 
crustaceans OR crab OR crabs OR 
lobster OR lobsters OR shrimp OR 
shrimps OR prawn OR prawns OR 
crayfish OR shellfish OR langoustine 
OR langoustines 
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Topics Search terms Search terms for PubMed Search terms for Web of Science 
prawns[Tiab] OR crayfish[Tiab] OR 
shellfish[MeSH Terms] OR 
shellfish[Tiab] OR langoustine[Tiab] OR 
langoustines[Tiab] 
 
Fish Fish, pollock, carp, cod, mackerel, 
salmon, tuna, shark, sea bass, 
swordfish, hake, sole, megrim, 
sardines, halibut, anchovy, catfish, trout 
fishes[MeSH Terms] OR fish[Tiab] OR 
pollock[Tiab] OR carp[Tiab] OR 
cod[Tiab] OR mackerel[Tiab] OR 
salmon[Tiab] OR tuna[Tiab] OR 
shark[tiab] OR “sea bass”[tiab] OR 
swordfish[tiab] OR hake[tiab] OR 
sole[tiab] OR megrim[tiab] OR 
sardine[tiab] OR sardines[tiab] OR 
halibut[tiab] OR anchovy[tiab] OR 
anchovies[tiab] OR catfish[tiab] OR 
trout[tiab] 
fish OR pollock OR carp OR cod OR 
mackerel OR salmon OR tuna OR 
shark OR “sea bass” OR swordfish OR 
hake OR sole OR megrim OR sardine 
OR sardines OR halibut OR anchovy 
OR anchovies OR catfish OR trout 
Molluscs Mollusc, oyster, snail, squid, mussels, 
clams, abalone, octopus, scallop 
mollusca[MeSH Terms] OR 
mollusc[Tiab] OR molluscs[Tiab] OR 
mollusc OR molluscs OR oyster OR 
oysters OR snail  OR snails OR squid 
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Topics Search terms Search terms for PubMed Search terms for Web of Science 
oyster[Tiab] OR oysters[Tiab] OR snail 
[Tiab] OR snails[Tiab] OR squid[Tiab] 
OR mussel[Tiab] OR mussels[Tiab] OR 
clam[Tiab] OR clams[Tiab] OR 
abalone[tiab] OR octopus[tiab] OR 
scallop[tiab] OR scallops[tiab] 
OR mussel OR mussels OR clam OR 
clams OR abalone OR octopus OR 
scallop OR scallops 
Group 3. Allergy    
Allergy Hypersensitivity, allergy, immunology, 
sensitivity, intolerance, anaphylaxis, 
adverse reaction 
hypersensitivity[MeSH Terms] OR 
hypersensitivity[Tiab] OR allergy[Tiab] 
OR "allergy and immunology"[MeSH 
Terms] or immunology[Tiab] OR 
sensitivity[Tiab] OR intolerance[Tiab] OR 
anaphylaxis[MeSH Terms] OR 
anaphylaxis [Tiab] OR “adverse 
reaction”[Tiab] 
hypersensitivity OR allergy OR 
immunology OR sensitivity OR 
intolerance OR anaphylaxis  OR 
“adverse reaction” 
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3.3.6 Management of search results 
Search results were managed using the reference management software (EndNote) and 
duplicates were removed. Search results were then imported into EPPI-Reviewer 4 
(Thomas, Brunton, & Graziosi, 2010) prior to screening for relevance. English language 
versions of articles were obtained via the British Library’s document supply service; where 
articles were not available, translation services were used. Searches were updated prior to 
data analysis/synthesis. 
3.3.7 Criteria for selecting studies for this review 
The current systematic review comes from a larger systematic review which was carried 
out in collaboration with the European Food Safety Agency (EFSA) on the prevalence of 
individual food allergies (milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, 
molluscs, soy, lupin, mustard and sesame). The current review includes only studies which 
reported on fish, crustacean or mollusc allergy.  
 
All identified articles were screened for inclusion in the review as follows. Firstly, the titles 
and abstracts of all identified articles were screened for potential relevance against the 
inclusion criteria. At this stage, articles were excluded if, for example, they were obviously 
unrelated to the topic of review, the sample was inappropriate for the scope of the review, 
or because they did not present primary research data. An inclusion approach was taken, 
whereby if the author was unclear of the potential relevance of an article it was marked as 
‘potentially eligible’. The full text of all potentially eligible studies was then retrieved and 
assessed against the criteria outlined below. If the eligibility of the paper for inclusion was 
still unclear, the paper was discussed with another review author. The reasons for 
exclusion were recorded.  
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3.3.8 Data collection and analysis 
The author (Harriet Moonesinghe) undertook data extraction independently using data 
collection forms developed in EPPI- Reviewer 4. A proportion of these (50%) were double 
checked by a second reviewer. The following data was extracted for all included studies: 
 General information: Authors’ contact details, research funder, year(s) study 
conducted, country(s) in which conducted. 
 Methods: study design (cross-sectional including whether an existing survey was 
utilised, or cohort study including additional information regarding at what ages 
articles have reported on), type of allergy considered (IgE mediated, non-IgE 
mediated or both), food(s) assessed, method of diagnosis (to include additional 
information with regard to the procedure, e.g. whether extracts or prick-to-prick 
method has been used for skin prick testing), sampling strategy (e.g. local or 
general population, random or non-random) and sample characteristics (e.g. age 
group, ethnic background, response rate, withdrawal). 
 
Outcomes [for ease of reporting, this data was recorded in a Microsoft Excel spread sheet]: 
Information on reported outcomes and relevant data (percentage prevalence, raw data and 
confidence intervals; presented by allergen, year of study, method of diagnosis and age). 
Where there was ambiguity in the reporting of results, all efforts were made within the 
given timeframe to contact the study authors to provide additional information.  
3.3.9 Assessing the quality of included studies 
It is important to assess the risk of bias of an included study in a systematic review as it 
informs the interpretation of results; variation in the results may be due to differences in 
risk of bias with low risk of bias studies more likely to yield accurate results (Higgins, 
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Altman, & Sterne, 2011). For the current study, a new tool for assessing the quality of 
included studies was developed. This was because the tool which is recommended in the 
Cochrane Handbook is relevant to studies of interventions and so the tool was adapted to 
be relevant to prevalence studies. Studies were assessed as being at a low, medium or high 
risk of bias on the basis of two quality criteria (Table 3.2). The first related to the risk of 
bias of the diagnostic method employed by the study. In studies utilising more than one 
method of diagnosis, the risk of bias of the highest quality method was judged. Food 
challenges (open or double blind placebo-controlled) were assessed as having the lowest 
risk of bias as these are recognised to be the gold-standard of diagnosis for food allergy, 
adopting strict objective measurements of positive clinical symptoms (Bindslev-Jensen et 
al., 2004). Skin prick tests or serum SIgE tests combined with a clinical history were 
assessed as a medium risk as these methods show both a sensitisation to an allergen in an 
individual combined with a convincing history of an adverse reaction to a food as assessed 
by a clinician and so diagnosis is fairly robust (Skypala & Venter, 2009). Questionnaire-
based methods and sensitisation tests in the absence of a clinical history were assessed as 
the highest risk of bias as both methods yield misleadingly high prevalence figures for food 
allergy. The second criterion related to the method of sampling, specifically, whether the 
sample utilised the whole population (for example, all consecutive births), a random 
sample or a non-random sample.  
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Table 3.2 Quality assessment criteria 
Quality assessment criteria Diagnostic method Sampling strategy: method 
Low risk of bias Food challenges (open or double-
blind) with or without clinical 
history 
Whole population 
Medium risk of bias Sensitisation (skin prick tests and 
or serum SIgE) with clinical 
history 
Random 
High risk of bias Sensitisation (skin prick tests and 
or serum SIgE) without clinical 
history 
Questionnaire- based methods 
(including self-report, clinician 
diagnosed or clinical history) 
Non-random 
3.3.10 Data analysis 
Where possible, the actual data, including the number diagnosed and the sample size, was 
used to calculate the prevalence and 95% confidence intervals. Meta analysis was 
conducted to summarise the prevalence for fish and shellfish allergy according to 
diagnostic method. This is a two-step process which first involved the calculation of the 
difference between means for each study. Secondly a summary pooled effect estimate was 
calculated as a weighted average of the intervention effects estimated in the individual 
studies. This analysis allows power to be increased and gives a pooled estimate of the 
prevalence. However, if there was found to be high heterogeneity between studies, risk of 
bias, or publication/reporting bias then a meta analysis was not conducted as the meta 
analysis may be meaningless (comparing clinically diverse studies) or misleading. (Weeks, 
Higgins, & Altman, 2011). In this instance a detailed narrative presentation of the results 
was carried out. 
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3.4 Results 
The results section is structured by diagnostic method, according to fish and shellfish 
allergy separately, and by region according to the six World Health Organisation regions- 
Europe, Africa, the Americas, Eastern-Mediterranean, South-East Asia and Western 
Pacific. The percentage prevalence is reported along with the 95% confidence interval. In 
some studies it was not possible to calculate the prevalence and 95% confidence intervals, 
due to the lack of raw data presented, and so the data has been reported as per the paper 
and thus some confidence intervals are not included (where this is the case this has been 
identified in the results tables).  
3.4.1 Description of studies 
There were 61 studies identified which presented data on the prevalence of fish and or 
shellfish allergy (Appendix 2). Figure 3.1 outlines the process of study selection. Of the 
included studies, 39 presented data from countries within Europe and 23 presented data 
from countries outside of Europe (one study collected data from both European and other 
countries). Figure 3.2 shows the countries where included studies were from. 
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Figure 3.1 Flowchart of search results and screening for all studies
RESULTS FROM 
DATABASE SEARCH= 9807 
 
DUPLICATES REMOVED= 
2484 
ADDITIONAL PAPERS 
IDENTIFIED (e.g. from 
contact with expert panel)= 10 
SCREENED ON TITLE AND 
ABSTRACT= 7333 
EXCLUDED= 7117 
SCREENED ON FULL 
TEXT= 216 
EXCLUDED= 116 
MAIN REASON 
 Study design= 23 
 Topic= 16 
 Unidentifiable 
time point= 4 
 Sample= 24 
 Unidentifiable 
allergen= 1 
 Method of 
diagnosis= 2 
 Data not 
presented by 
individual 
allergen= 15 
 Linked records 
(i.e. data 
presented 
elsewhere= 26 
 Cannot obtain 
study record= 5 
INCLUDED= 100 
OF WHICH PRESENTED 
DATA ON 
FISH/SHELLFISH = 61 
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Figure 3.2 A map of the world showing the countries from which prevalence data was found
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The majority of studies (48) employed a cross-sectional design and 13 studies used a 
cohort design. A paediatric sample (< 18 years old) was used in 41 studies, an adult sample 
(≥ 18 years old) in 11 studies, and in nine studies all ages were presented collectively. Key 
characteristics of these studies are shown for each country in alphabetical order (Table 
3.3). Further information about the method of diagnosis of included studies is presented in 
a series of tables (Appendix 3): questionnaire-based methods, sensitisation testing, and 
food challenge. Some studies presented the findings for more than one method of diagnosis 
enabling the comparison of prevalence data generated by a variety of methods, as 
exemplified by Gelinick (2008), Kristjansson (1999), Lao-araya (2012), Orhan (2009), 
Santadusit (2005), Schafer (2001). Many studies also reported using a combination of 
methods within an algorithm, for example Osterballe (2005,2009) and Venter (2006,2008); 
almost without exception this two or three step process was applied to food challenges 
where only those who self-reported fish and or shellfish allergy in a questionnaire, or those 
with a positive clinical history or sensitisation were challenged. 
 
Questionnaire-based methods for assessing suspected fish and or shellfish allergy were 
utilised in 44 studies, 25 studies measured sensitisation rates, and ten studies carried out 
food challenges to confirm fish and or shellfish allergy (Table 3.4). Within questionnaire-
based methods data is categorised under the headings self-report, clinician diagnosed and 
clinical history however, there is overlap between these methods as some self-report 
questionnaires included questions on the presence of ‘doctor-diagnosed allergies’, and 
some ‘clinical histories’ were obtained using a structured questionnaire. For this reason all 
three methods have been grouped under ‘questionnaire-based methods’. In addition the 
sensitivity and specificity of these methods was not readily available for some of the 
studies (e.g. Marrugo (2008) used a ten-item questionnaire with no reference to validation) 
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whereas other studies utilised tools that had undergone some validation (e.g. Ben Shoshan 
(2010), Sicherer (2004), Martinez-Gimeno (2000) http://isaac.auckland.ac.nz/, Table 1.7). 
Where a food challenge was conducted this was usually carried out on a subset of the study 
population who reported allergy to fish and or shellfish (via a questionnaire-based method) 
and or were sensitised (determined by SPT or serum SIgE). In addition a proportion of 
study participants (typically those with a convincing clinical history of severe allergic 
reactions, and sensitisation) were not challenged since it is unethical to do so. This aligns 
with the clinical management of patients in practice, and these individuals were typically 
considered to be allergic. Hence for prevalence calculations where possible these have 
been counted alongside those who experienced a positive food challenge outcome. 
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Table 3.3 Characteristics of included studies 
Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
Al-Hammadi 
(2010) 
Cross-
sectiona
l 
2006 
United 
Arab 
Emirates 
6-9 
years 
 Fish 
 Clinician 
diagnosed 
7 years 397 60% 
Arshad 
(2001) 
Cohort 
1993-
1994 
United 
Kingdom 
4 years  Fish (cod) 
 Positive skin 
prick test 
without clinical 
history 
N/R 981 67% 
Ben-
Shoshan 
(2010) 
 
Cross-
sectiona
l 
 
2008-
2009 
Canada All ages 
 Fish 
 Shellfish 
 Self-report 
 Clinician 
diagnosed 
 Clinical history 
N/R 9667 34.6% 
Branum  2005- United < 18  Crustacean  Positive serum N/R 3500 N/R 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
(2009) Cross-
sectiona
l 
2006 States years (shrimp) SIgE without 
clinical history 
Brugman 
(1998) 
Cross-
sectional 
1993-
1994 
 
Netherlands 
 
4-15 
years 
 Fish/ 
crustacean 
 Self-report N/R 4400 99% 
Burney 
(2010) 
Cross-
sectiona
l 
1991-
1992 
follow up 
study 
conducte
d in 2000 
Australia 
Belgium 
Estonia 
France 
Germany 
Iceland 
Italy 
Norway 
20-44 
years 
 Fish 
 Crustacean 
(shrimp) 
 Positive serum 
SIgE without 
clinical history 
33.7 
years 
Australia: 
220 
Belgium: 
323 
Estonia: 137 
France: 467 
Germany: 
372 Iceland: 
58% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
Spain 
Sweden 
Switzerland 
UK 
USA 
326 
Italy: 253 
Norway: 
415 Spain: 
703 
Sweden: 
617 
Switzerland
: 208 
UK: 394 
USA: 87 
Chen 
(2011) 
Cross-
sectiona
l 
2009 China 
<12 
months 
 
 Fish 
 Crustacean 
(shrimp) 
 Positive skin 
prick test 
without clinical 
N/R 497 96% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
history 
Connett 
(2012) 
Cross-
sectiona
l 
2007-
2008 
Philippines 
Singapore 
Thailand 
14-16 
years 
 
 Fish 
 Self-report 
 Clinical history 
N/R 19966 77% 
Dalal 
(2002) 
Cross-
sectiona
l 
N/R Israel <2years  Fish 
 Clinical history 
 Positive skin 
prick test with 
clinical history 
N/R 9070 N/R 
Eggesbo 
(1999) 
 
Cohort 
1992-
1993; 
1993-
1995 
 
Norway 
<24 
months 
 Fish  Self-report N/R 3366 22.6 
Emmett Cross- 1995- United 15+  Fish  Self-report N/R 16420 N/R 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
(1999) sectiona
l 
1996 Kingdom years (stage 1) 
1253 (stage 
2) 
Falcao 
(2004) 
Cross-
sectiona
l 
2000 Portugal 
>39 
years 
 Fish 
 Mollusc 
(octopus, 
squid) 
 Self-report N/R 659 70% 
Gelincik 
(2008) 
Cross-
sectiona
l 
N/R Turkey 
18+ 
years 
 Fish 
 Seafood 
 Self-report 
 Positive 
DBPCFC with 
clinical history 
N/R 11816 69.3% 
Greenhawt 
(2009) 
Cross-
sectiona
l 
N/R 
United 
States 
18+ 
years 
 Fish 
 Shellfish 
 Self-report N/R 513 3.5% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
Gupta 
(2011) 
Cross-
sectiona
l 
2009-
2010 
United 
States 
<18 
years 
 Fish (fin fish) 
 Shellfish 
 Self-report 8.5 years 10514 N/R 
Haahtela 
(1980) 
Cross-
sectiona
l 
N/R Finland 
15-17 
years 
 Fish 
 Positive skin 
prick test 
without clinical 
history 
N/R 
 
708 
 
98% 
Hu (2010) 
Cross-
sectiona
l 
1999 and 
2009 
China 
<24 
months 
 Fish 
 Crustacean 
(shrimp) 
 Positive skin 
prick test 
without clinical 
history 
N/R 
1999: 304 
2009: 382 
96.8% 
95.3% 
Jansen 
(1994) 
Cross-
sectiona
l 
1989 
Netherland
s 
18-70 
years 
 Seafood 
(trassi) 
 Positive 
DBPCFC with 
clinical history 
N/R. 1483 86% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
Johansson 
(2005) 
Cross-
sectiona
l 
N/R 
Norway 
Sweden 
N/R  Fish (cod) 
 Positive serum 
SIgE without 
clinical history 
N/R 1502 N/R 
Kajosaari 
(1982) 
Cross-
sectiona
l 
1980-
1981 
Finland 
1,2,3 
and 6 
years 
 
 Fish 
 Clinical history 
 Elimination and 
home challenge 
(OFC) 
N/R 
1 year: 261 
2 years: 202 
3 years: 200 
6 years: 203 
N/R 
Kavaliunas 
(2012) 
Cross-
sectiona
l 
N/R Lithuania 
Primary
-school 
aged 
children 
 Fish (cod) 
 Crustacean 
(shrimp) 
 Self report 
8.2 
years 
3084 71.2% 
Kim (2011) Cohort 
2006-
2007 
Korea 
<12 
months 
 Seafood  Self report N/R 1177 N/R 
Krause Cross- 1998 Greenland 5-18  Fish  Positive serum N/R 1031 88% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
(2002) sectiona
l 
years SIgE without 
clinical history 
Kristjansson 
(1999) 
Cross-
sectiona
l 
1994 – 
1995 
Iceland 
Sweden 
18 
months 
 Fish 
 Shellfish 
 Self report 
 Positive skin 
prick test with 
clinical history 
 Positive 
DBPCFC with 
clinical history 
Icelandi
c 
children: 
18.8 
years 
Swedish 
children: 
19.3 
years 
328 
Iceland: 
79% 
Sweden: 
90% 
Lao-araya 
(2012) 
Cross-
sectiona
l 
2010 
Northern 
Thailand 
3-7 years 
 Fish 
 Crustacean 
(shrimp, crab) 
 Self-report 
 Positive open 
food challenge 
5.3 452 82.8% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
 Mollusc 
(squid) 
 
with clinical 
history 
Leung 
(2009) 
Cross-
sectiona
l 
2006-
2007 
Hong Kong 
2-7 
years 
 Fish 
 Crustacean 
 Self-report 
 Clinician 
diagnosed 
N/R 3677 96.1% 
Liu (2010) 
Cross-
sectional 
2005-
2006 
United 
States 
All ages 
 Crustacean 
(shrimp) 
 Positive serum 
SIgE without 
clinical history 
N/R 8203 79.3% 
Marklund 
(2004) 
Cross-
sectional 
2003 Sweden 
13-21 
years 
 Fish 
 Shellfish 
 Self-report 16.2 1451 100% 
Marrugo 
(2008) 
Cross-
sectiona
l 
N/R Colombia 
1-83 
years 
 Seafood  Self-report N/R 3099 100% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
Martinez-
Gimeno 
(2000) 
Cross-
sectiona
l 
N/R Spain 
6-13 
years 
 Fish  Self-report N/R 5163 90% 
Mustafayev 
(2012) 
Cross-
sectiona
l 
2010 Turkey 
10-11 
years 
 Fish  Self-report N/R 6963 N/R 
Obeng 
(2011) 
Cross-
sectiona
l 
2006-
2008 
Ghana 
5-16 
years 
 Fish 
 Crustacean 
(shrimp) 
 
 Self-report N/R 1431 83.5% 
Oh (2004) 
Cross-
sectiona
l 
1995-
2000 
Korea 
6-12 
years 
and 12-
15 years 
 Fish 
 Seafood 
 Self-report N/R 27425 97.8% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
Orhan 
(2009) 
Cross-
sectiona
l 
2006 Turkey 
6-9 
years 
 Fish 
 Self-report 
 Positive skin 
prick test with 
clinical history 
 Positive 
DBPCFC with 
clinical history 
N/R 2739 78.2% 
Osborne 
(2011) 
Cohort 
 
2007-
2010 
 
Australia 
 
11-15 
months 
 
 Shellfish  
 
 Positive skin 
prick test 
without clinical 
history 
N/R 
2768 
 
* 
Ostblom 
(2008 a) 
Cohort 
1999-
2000 
Sweden 4 years  Fish (cod) 
 Self-report 
 Positive serum 
SIgE without 
N/R 2563 91% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
clinical history 
 Positive serum 
SIgE with 
clinical history 
Ostblom 
(2008 b) 
Cohort 
1995-
2004 
Sweden 
1, 2, 4, 8 
years 
 Fish 
 Self-report 
 Clinician 
diagnosed 
N/R 3104 84% 
Osterballe 
(2005) 
Cohort 
2001-
2002 
Denmark 
Group 
1: 3 
years, 
Group 
2: <3 
years, 
Group 
 Fish (cod) 
 Crustacean 
(shrimp) 
 Positive open 
food challenge 
with clinical 
history 
 Positive 
DBPCFC with 
clinical history 
Group 
2: 0.7 
years 
Group 
3: 7.6 
years 
Group 
3 years: 486 
<3 years: 
111 
>3 years: 
301 
Adults: 
936 
98% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
3: 
Children 
> 3 
years, 
Group 
4: 
Adults 
 Other 4: 33.7 
years 
Osterballe 
(2009) 
Cohort 
2001-
2002 
Denmark 22 years 
 Fish (cod) 
 Crustacean 
(shrimp) 
 Mollusc 
(octopus) 
 Self-report 
 Positive open 
food challenge 
with clinical 
history 
N/R 843 77.1% 
Penard-
Morand 
Cross-
sectiona
1999-
2000 
France 
9-11 
years 
 Fish 
 Seafood 
 Self-report 10.4 6672 69% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
(2005) l 
Pereira 
(2005) 
Cohort 
2002- 
2003 
United 
Kingdom 
11 and 
15 years 
 Fish (cod) 
 Crustacean 
(prawn) 
 Self-report 
 Positive skin 
prick test 
without clinical 
history 
N/R 
11 years: 
757 
15 years: 775 
48.4% 
52.2% 
Pyrhonen 
(2009) 
Cross-
sectiona
l 
2001-
2009 
Finland 
1-4 
years 
 Fish 
 Self-report 
 Clinician 
diagnosed 
N/R 853 69% 
Rance 
(2005) 
Cross-
sectiona
l 
2002 France 
2-14 
years 
 Fish 
 Crustacean 
(shrimp) 
 Self-report 8.9 years 2716 77.6% 
Ro (2012) Cohort 
2002-
2006 
Norway 2 years  Fish 
 Positive skin 
prick test 
26.6 
months 
352 53% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
without clinical 
history 
 Positive serum 
SIgE without 
clinical history 
Roberts 
(2005) 
Cohort 
1998-
2000 
United 
Kingdom 
7 years  Fish (cod) 
 Positive skin 
prick test 
without clinical 
history 
90 
months 
(median) 
2061 27% 
Sakellariou 
(2008) 
Cross-
sectiona
l 
2007 Greece 
20-54 
years 
 Fish  Self-report N/R 2003 51.6% 
Santadusit 
(2005) 
Cross-
sectiona
N/R Thailand 
6 
months 
 Fish 
 Crustacean 
 Self-report 
 Positive skin 
N/R 656 N/R 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
l – 6 
years 
(shrimp) 
 Shellfish  
prick test with 
clinical history 
 Positive open 
food challenge 
with clinical 
history 
Schafer 
(2001) 
Cross-
sectiona
l 
1997- 
1998 
Germany 
25-74 
years 
 Fish 
(mackerel) 
 Crustacean 
(crab) 
 Seafood 
 Self-report 
 Positive skin 
prick test 
without clinical 
history 
50.4% 
female 
had a 
median 
age of 50 
years 
4178 64% 
Shek (2010) 
Cross-
sectiona
2007-
2008 
Philippines 
Singapore 
4-6 
years, 
 Shellfish 
 Self-report 
 Clinical history 
N/R 11322 74.2% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
l 14-16 
years 
Sicherer 
(2004) 
Cross-
sectiona
l 
2002 
United 
States 
All ages 
 Fish 
 Shellfish 
 Self-report 
 Clinician 
diagnosed 
N/R 4336 67.3% 
Touraine 
(2002) 
Cross-
sectiona
l 
2000-
2001 
France 
5-17 
years 
 
 Fish 
 Crustacean 
 Mollusc 
(oyster) 
 Self-report N/R 1086 69% 
Van 
Bockel-
Geelkerken 
(1992) 
Cross- 
sectiona
l 
1988-
1989 
Netherland
s 
5-6 
years 
 Fish 
 Shellfish 
 
 
 Self-report N/R 1039 84.5% 
Venter Cohort 2003- United 6 years  Fish (cod)  Self-report  798 55.4% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
(2006) 2004 Kingdom  Positive skin 
prick test 
without clinical 
history 
 Positive 
DBPCFC with 
clinical history 
 
N/R 
 
 
Venter 
(2008) 
Cohort 
2002-
2005 
United 
Kingdom 
1, 2, 3 
years 
 Fish (cod) 
 Positive skin 
prick test 
without clinical 
history 
 Other 
N/R 
1 year: 900 
2 years: 858 
3 years: 891 
92.9% 
88.5% 
91.9% 
Vierk 
(2007) 
Cross-
sectiona
2001 
United 
States 
≥18 
years 
 Fish 
 Crustacean 
 Self-report 
 Clinician 
N/R 4482 35.8% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
l  Shellfish diagnosed 
Von 
Hertzen 
(2006) 
Cross-
sectiona
l 
2003 
Finland 
Russia 
11-16 
years 
 Fish 
 Positive skin 
prick test 
without clinical 
history 
10.9 
11.3 
367 
446 
N/R 
Woods 
(1998) 
Cross-
sectiona
l 
1992-
1994 
Australia 
20-44 
years 
 Fish/ shellfish  Self-report N/R 669 72% 
Wu (2012) 
Cross-
sectiona
l 
2004 Taiwan All ages 
 Fish 
 Crustacean 
(shrimp, crab) 
 Mollusc 
 Clinician 
diagnosed 
N/R 
30018 
813 <3 
years, 
15169 4-18 
years 
14036 >19 
77.1% 
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Study ID Study 
design 
Year(s) 
conducted 
Country(s) Target 
age group 
Allergen(s) assessed Method(s) of diagnosis Sample characteristics 
       Age 
Mean 
Sample size 
Respons
e Rate 
years 
Young 
(1994) 
Cross-
sectiona
l 
N/R 
United 
Kingdom 
N/R 
 Fish/ 
crustacean 
 Self-report N/R 18880 70% 
Zannikos 
(2008) 
Cross-
sectiona
l 
2007 
 
Greece 
 
7-13 years 
 Fish 
 Shellfish 
 Self-report 
 
N/R 3821 51% 
Zuberbier 
(2004) 
Cross-
sectiona
l 
1999-
2000 
Germany All ages 
 Fish (herring, 
mackerel) 
 Crustacean 
(crab) 
 Mollusc 
(mussels) 
 Positive skin 
prick test with 
clinical history 
N/R 4093 31% 
Note: N/R= not reported
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Table 3.4 Diagnostic methods utilised in included studies 
Study ID Questionnaire-based Sensitisation Food challenge 
Europe    
Arshad (2001)  ✓  
Brugman (1998) ✓   
Burney (2010)  ✓  
Dalal (2002) ✓ ✓  
Eggesbo (1999) ✓   
Emmett (1999) ✓   
Falcao (2004) ✓   
Gelincik (2008) ✓  ✓ 
Haahtela (1980)  ✓  
Jansen (1994)   ✓ 
Johansson (2005)  ✓  
Kajosaari (1982) ✓  ✓ 
Kavaliunas (2012) ✓   
Krause (2002)  ✓  
Kristjansson (1999) ✓ ✓ ✓ 
Marklund (2004) ✓   
Martinez- Gimeno (2000) ✓   
Mustafayez (2012) ✓   
Orhan (2009) ✓ ✓ ✓ 
Ostblom (2008 a) ✓ ✓  
Ostblom (2008 b) ✓   
Osterballe (2005) ✓ ✓ ✓ 
Osterballe (2009) ✓  ✓ 
Penard-Morand (2005) ✓   
Pereira (2005) ✓ ✓  
Pyrhonen (2009) ✓   
Rance (2005) ✓   
Ro (2012)  ✓  
Roberts (2005)  ✓  
Sakellariou (2008) ✓   
Schafer (2001) ✓ ✓  
Touraine (2002) ✓   
Van Bockel-Geelkerken (1992) ✓   
Venter (2006) ✓ ✓ ✓ 
Venter (2008) ✓ ✓  
Von Hertzen (2006)  ✓  
Young (1994) ✓   
Zannikos (2008) ✓   
Zuberbier (2004)  ✓  
Rest of the World    
Al-Hammadi (2010) ✓   
Ben-Shoshan (2010) ✓   
Branum (2009)  ✓  
Burney (2010)  ✓  
Chen (2011)  ✓  
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Study ID Questionnaire-based Sensitisation Food challenge 
Connett (2012) ✓   
Greenhawt (2009) ✓   
Gupta (2011) ✓   
Hu (2010)  ✓  
Kim (2011) ✓   
Lao-araya (2012) ✓  ✓ 
Leung (2009) ✓   
Liu (2010)  ✓  
Marrugo (2008) ✓   
Obeng (2011) ✓   
Oh (2004) ✓   
Osborne (2011)  ✓  
Santadusit (2005) ✓ ✓ ✓ 
Shek (2010) ✓   
Sicherer (2004) ✓   
Vierk (2007) ✓   
Woods (1998) ✓   
Wu (2012 ✓   
3.4.2 Risk of bias in included studies 
The quality of all included studies was graded according to the diagnostic method utilised 
and the sampling strategy (see section 3.3.9). Table 3.5 reports the outcome for each study. 
In summary, the majority of studies (49) scored a high risk of bias, one scored medium and 
11 scored low according to diagnostic method. With regards to the sampling strategy, ten 
were assessed as a high risk of bias, 31 medium and 12 low. This is an important 
consideration when interpreting the quality of the results found.  
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Table 3.5 Quality assessment of included studies 
Study ID 
Diagnostic Methods: risk of 
bias
2
 
Sampling Strategy Method: 
risk of bias
3
 
Al-Hammadi (2010) 
 
  
Arshad (2001) 
 
  
Ben-Shoshan (2010) 
 
  
Branum (2009) 
 
  
Brugman (1998) 
 
  
Burney (2010) 
 
  
Chen (2011) 
 
  
Connett (2012) 
 
  
Dalal (2002) 
 
  
Eggesbo (1999) 
 
  
Emmett (1999) 
 
 N/R 
Falcao (2004) 
 
  
Gelincik (2008) 
 
  
Greenhawt (2009) 
 
  
Gupta (2011) 
 
  
Haahtela (1980) 
 
  
Hu (2010) 
 
  
Jansen (1994) 
 
  
                                                 
2
 Low risk of bias= food challenges (open or double-blind) with or without clinical history; Medium risk of bias= 
sensitisation (skin prick test and or serum SIgE) with clinical history; High risk of bias = Sensitisation (skin prick test and 
or serum SIgE) without clinical history, questionnaire-based methods (self-report, clinical history or clinician diagnosed) 
3
 Low risk of bias = whole population; Medium risk of bias= random; High risk of bias = non-random. 
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Study ID 
Diagnostic Methods: risk of 
bias
2
 
Sampling Strategy Method: 
risk of bias
3
 
Johansson (2005) 
 
  
Kajosaari (1982) 
 
  
Kavaliunas (2012) 
 
  
Kim (2011) 
 
 N/R 
Krause (2002) 
 
  
Kristjansson (1999) 
 
  
Lao-araya (2012) 
 
  
Leung (2009) 
 
  
Liu (2010) 
 
  
Marklund (2004)   
Marrugo (2008) 
 
  
Martinez-Gimeno 
(2000) 
 
  
Mustafayev (2012) 
 
 N/R 
Obeng (2011) 
 
 N/R 
Oh (2004) 
 
  
Orhan (2009) 
 
  
Osborne (2011) 
 
  
Ostblom (2008 a) 
 
 N/R 
Ostblom (2008 b) 
 
 N/R 
Osterballe (2005) 
 
  
Osterballe (2009) 
 
  
Penard-Morand (2005)   
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Study ID 
Diagnostic Methods: risk of 
bias
2
 
Sampling Strategy Method: 
risk of bias
3
 
Pereira (2005) 
 
  
Pyrhonen (2009) 
 
  
Rance (2005) 
 
  
Ro (2012) 
 
 N/R 
Roberts (2005) 
 
  
Sakellariou (2008) 
 
  
Santadusit (2005) 
 
  
Schafer (2001) 
 
  
Shek (2010) 
 
  
Sicherer (2004) 
 
  
Touraine (2002) 
 
  
Van Bockel-
Geelkerken (1992) 
 N/R 
Venter (2006) 
 
  
Venter (2008) 
 
  
Vierk (2007) 
 
  
Von Hertzen (2006)   
Woods (1998) 
 
  
Wu (2012) 
 
  
Young (1994) 
 
  
Zannikos (2008) 
 
  
Zuberbier (2004) 
 
  
 
High risk of bias 
 
Medium risk of bias 
 
Low risk of bias 
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3.4.3 Fish allergy prevalence across Europe  
Assessed using questionnaire-based methods (Figure 3.3) 
There were 27 studies in Europe which used questionnaire-based methods to calculate the 
prevalence of fish allergy; prevalence rates based on self-reported fish allergy were 
presented in 25 studies, two studies reported clinical history rates and two studies reported 
clinician diagnosed allergy. The highest reported prevalence in adults was found in Greece 
with 1.5% (95% CI: 1.0-2.2) (Sakellariou 2008) of 20-54 year olds reporting an adverse 
reaction to fish. The lowest reported prevalence was seen in Denmark, with only 0.2% 
(95% CI: 0.0-1.0) (Osterballe 2009) of 22 year olds reporting an adverse reaction to fish 
(cod specifically). With regards to children, the highest reported prevalence was found in 
Spain where 6.9% (95% CI: 6.2-7.6) (Martinez-Gimeno 2000) of 6-13 year olds reported 
fish allergy. The lowest reported prevalence rates were seen in 9-11 year olds in France 
(0.1%, 95% CI: 0.1-0.3) (Penard-Mornad 2005). With regards to prevalence based on a 
convincing clinical history there was no data available on adult fish allergy. For children, 
the prevalence ranged from 7.0% (95% CI: 5.4-9.0) (Kajosaari 1982) in one year olds in 
Finland to 0.0% (95% CI: 0.0-0.1) (Dalal 2002) of 0-2 year olds in Israel. Similarly with 
regards to clinician-diagnosed fish allergy, there was no data available for adults. In 
children the highest rates were found in Finland in four year olds (1.0%, 95% CI: 0.5-2.0) 
(Pyrhonen 2009), and the lowest rates were seen in one year olds in both Finland (0.2%, 
95% CI: 0.0-0.9) (Pyrhonen 2009) and Sweden (0.2%, 95% CI: 0.1-0.4) (Ostblom 2008b).  
 
Assessed using sensitisation (via SPT and or serum SIgE) (Figure 3.4) 
Looking at sensitisation, 17 studies reported sensitisation data for fish allergy in Europe. 
There were nine studies which carried out SPT on the whole study population, four studies 
which combined a convincing clinical history with a positive SPT, five studies which 
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carried out serum SIgE testing on the whole study population, and one study which 
combined a convincing clinical history with serum SIgE. Only one study in Germany used 
SPT in an adult population (25-74 year olds) reporting a prevalence of 2.9% (95% CI: 2.2-
3.9) (Schafer 2001) sensitisation to mackerel. In children the highest sensitisation rate was 
found in Finland, where 2.7% (95% CI: 1.7-4.2) (Haahtela 1980) of 15-17 year olds were 
found to be sensitised to fish. The lowest sensitisation rate was seen in the United 
Kingdom, where 0.0% (95% CI: 0.0-0.3) (Roberts 2005) of seven year olds were found to 
be sensitised to fish (cod specifically).  
 
Assessed using clinical history and sensitisation (Figure 3.4) 
When a history of adverse reaction was combined with the SPT result, prevalence ranged 
between 0.6% (95% CI: 0.1-2.5) (Kristjansson 1999) in 18 month olds in Iceland to 0.0% 
(95% CI: 0.0-0.1) (Dalal 2002) of 0-2 year olds in Israel. One study reported 0.1% 
prevalence to herring and mackerel in Germany in all ages (Zuberbier 2004). Adult fish 
allergy prevalence, as measured by serum SIgE plus a clinical history ranged from 0.8% 
(95% CI: 0.2-2.5) (Burney 2010) in 20-44 year olds in Germany, to 0.0% in several other 
studies. In children, the highest prevalence was seen in Norway where 1.1% (95% CI: 0.4-
3.1) (Ro 2012) of two year olds were sensitised to fish, the lowest prevalence was 0.7% 
(95% CI: 0.3-1.5) (Krause 2002) in 5-18 year olds in Greenland. This lowered to 0.4% 
(95% CI: 0.2-0.8) (Ostblom 2008a) of four year olds in Sweden when sensitisation plus a 
clinical history was considered for fish allergy (cod specifically).  
 
Assessed using food challenges (Figure 3.5) 
There were nine studies in Europe which reported fish allergy prevalence based on food 
challenges. Open food challenges were conducted in three studies, double-blind placebo 
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challenges in six studies, and food challenge plus an algorithm used for diagnosis in two 
studies. With regards to open food challenges, only one study in Denmark reported data for 
adult fish (cod) allergy; 0.1% (95% CI: 0.0-0.8) (Osterballe 2009) of 22 year olds. For 
children, the lowest confirmed prevalence was 0.0% (95% CI: 0.0-4.2) (Osterballe 2005) 
of under three year olds in Denmark and the highest was 0.1% (95% CI: 0.0-0.8) 
(Kajosaari 1982) of six year olds in Finland. When a double-blind placebo-controlled food 
challenge was used, in adults the rate of confirmed prevalence ranged between 0.2% (95% 
CI: 0.0-0.9) (Osterballe 2005) in Denmark and 0.0% (95% CI: 0.0-0.1) (Gelincik 2008) in 
Turkey; and in children from 0.3% (95% CI: 0.0-2.0) (Kristjansson 1999) in Iceland to 
0.0% in Denmark (Osterballe 2005), Turkey (Orhan 2009) and the United Kingdom 
(Venter 2006). Using an algorithm for diagnosis Osterballe (2005) found a confirmed 
prevalence rate of 0.6% (95% CI: 0.3-1.5) of adults in Denmark. In addition, 0.8% (95% 
CI: 0.3-2.2) (Osterballe 2005) confirmed prevalence of cod allergy was seen in three year 
olds in Denmark, compared to 0.0% (95% CI: 0.0-0.5) (Venter 2008) of three year olds in 
the United Kingdom. 
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Figure 3.3 Fish allergy prevalence in Europe diagnosed by questionnaire-based methods 
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Figure 3.4 Fish allergy prevalence in Europe diagnosed by sensitisation methods 
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Figure 3.5 Fish allergy prevalence in Europe diagnosed by food-challenge methods 
* Participants with possible FHS; self-reported (questionnaire) FHS or a positive outcome in at least one of the following: skin prick, histamine 
release and SIgE, without a clear negative case history (not regularly eating culprit food during the last year).
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3.4.4 Shellfish allergy prevalence across Europe 
Assessed using questionnaire-based methods (Figure 3.6) 
There were ten studies conducted in Europe which presented reported shellfish prevalence 
data. With regards to adult crustacean allergy, only one study was carried out (in Denmark) 
which found 2.0% (95% CI: 1.2-3.3) (Osterballe 2009) of 22 year olds self-reported an 
allergy to shrimp. In children the reported prevalence ranged from 5.5% (95% CI: 4.3-7.1) 
(Touraine 2002) of 5-17 year olds in France to 0.1% (95% CI: 0.0-0.5) (Kavaliunas 2012) 
of 5-12 year olds in Lithuania. The reported prevalence of mollusc (oyster) allergy was 
1.5% (95% CI: 0.9-2.4) (Touraine 2002) in 5-17 year olds in France, for octopus allergy it 
was 0.4% (95% CI: 0.1-1.1) (Osterballe 2009) of 22 year olds in Denmark, and for octopus 
and squid allergy combined in Portugal it was 0.5% (95% CI: 0.1-1.5) (Falcao 2004) of 39 
year olds and above. Some studies investigated the reported prevalence of ‘shellfish’ 
allergy which ranged from 1.7% (95% CI: 1.1-2.5) (Marklund 2004) of 11-21 year olds in 
Sweden to 0.1% (95% CI: 0.0-0.2) (Zannikos 2008) of 7-13 year olds in Greece. 
 
Assessed using sensitisation (via SPT and or serum SIgE) (Figure 3.7) 
There were two studies in Europe which measured the sensitisation of the study 
population; one reported on SPT and one on serum SIgE. For crustacean allergy (crab) one 
study conducted in Germany found a sensitisation rate of 2.7% (95% CI: 2.0-3.6) (Schafer 
2001) in 25-74 year olds based on SPT alone. Serum SIgE levels were only carried out for 
crustacean allergy, with the highest sensitisation rate reported in Italy in adults (10.3%, 
95% CI: 7.0-14.9) (Burney 2010) and the lowest in Switzerland in adults (0.0%, 95% CI: 
0.0-2.3) (Burney 2010).  
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Assessed using clinical history and sensitisation (Figure 3.7) 
When a clinical history was combined with a positive SPT result, a prevalence rate of 0.2% 
(95% CI: 0.1-0.5) (Zuberbier 2004) was found for crab allergy, and 0.0% (95% CI: 0.0-
0.2) (Zuberbier 2004) for mussel allergy, in all ages in Germany. 
 
Assessed using food challenges (Figure 3.8) 
Two studies in Europe (Denmark) utilised food challenges to confirm the prevalence of 
shellfish allergy. Open food challenges were conducted by both studies and showed a 
shrimp allergy confirmed prevalence rate of 0.0% (95% CI: 0.0-4.2) (Osterballe 2005) for 
under threes, 0.2% (95% CI: 0.0-1.0) (Osterballe 2009) for 22 year olds, and an octopus 
allergy confirmed prevalence rate of 0.1% (95% CI: 0.0-0.8) (Osterballe 2009) for 22 year 
olds. One study carried out double-blind placebo-controlled food challenges to shrimp 
which showed a confirmed prevalence of 0.0% (95% CI 0.0-1.0) (Osterballe 2005) in three 
year olds and 0.3% (95% CI: 0.1-1.0) (Osterballe 2005) in adults. Interestingly in the same 
study, when an algorithm was used which took into consideration a convincing clinical 
history and or positive tests by the same study, the adult prevalence of shrimp allergy was 
1.1% (95% CI: 0.5-2.0). 
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Figure 3.6 Shellfish allergy prevalence in Europe diagnosed by questionnaire-based methods 
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Figure 3.7 Shellfish allergy prevalence in Europe diagnosed by sensitisation methods 
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Figure 3.8 Shellfish allergy prevalence in Europe diagnosed by food-challenge methods 
* Participants with possible FHS; self-reported (questionnaire) FHS or a positive outcome in at least one of the following: skin prick, histamine 
release and SIgE, without a clear negative case history (not regularly eating culprit food during the last year).
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3.4.5 Fish allergy prevalence across different regions of the world 
(See Figures 3.9, 3.10 and 3.11) 
African 
In the African region, only one study reporting fish prevalence data could be found, which 
has been conducted in Ghana. This study found the reported prevalence of 5-16 year old 
children to be 0.3% (95% CI: N/R). 
 
Americas 
In the Americas region, there were six studies which used questionnaire-based methods to 
calculate the prevalence of fish allergy. The highest reported fish allergy in adults was seen 
in the United States (2.7%, 95% CI: 1.6-4.7) (Greenhawt 2009) and the lowest was seen in 
Canada (0.6%, 95% CI: 0.43-0.78) (Ben-Shoshan 2010
4
). One study conducted in the 
United States measured the reported prevalence of fin fish allergy in 0-2 year olds to be 
0.3% (95% CI: 0.1-0.4) (Gupta 2011), and 0.6% (95% CI: 0.4-0.9) in 14-17 year olds. A 
study carried out in Canada which utilised a convincing clinical history as its diagnostic 
method showed that in children under the age of 18 the prevalence of fish allergy was 
0.18% (95% CI: 0.0-0.36) (Ben-Shoshan 2010), whereas the prevalence of adult fish 
allergy was 0.56% (95% CI: 0.39-0.73) (Ben-Shoshan 2010). Using clinician diagnosed 
fish allergy, the highest prevalence for children was 0.2% (95% CI: 0.1-0.5) (Sicherer 
2004) in the United States and the lowest prevalence found in Canada was 0.0% (95% CI: 
N/R) (Ben-Shoshan 2010). For adults the highest prevalence was 0.6% (95% CI: 0.4-0.9) 
(Vierk 2007) in the United States and the lowest was 0.12% (95% CI: 0.08-0.16) in Canada 
(Ben-Shoshan 2010). One study measured sensitisation of the whole study population 
using serum SIgE tests and found that 0.0% (95% CI: 0.0-5.3) (Burney 2010) of 20-44 year 
                                                 
4
 Ben-Shoshan (2010) prevalence and confidence interval are reported to two decimal places, as it was not 
possible to calculate the prevalence based on raw data and therefore we report as per the study. 
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olds were sensitised to fish. Surprisingly, no studies could be found which adopted food 
challenges to confirm the prevalence of fish allergy in the Americas region of the world. 
 
Eastern Mediterranean 
There was only one study identified from the Eastern Mediterranean region of the world, 
this study, conducted in the United Arab Emirates, reported that the clinician diagnosed 
prevalence of fish allergy in children (6-9 years old) was 2.8% (95% CI: 1.5-5.1) (Al 
Hammadi 2010). 
 
South East Asia 
In the South East Asia region, five studies utilised questionnaire-based methods, one skin 
prick tests combined with a clinical history and one food challenges to confirm fish allergy 
prevalence, however none of these studies report on the occurrence of adult fish allergy. 
The highest reported prevalence seen in Thailand was 1.1% (95% CI: 0.4-2.7) (Lao-araya 
2012) for 3-7 year olds, compared to the lowest which was 0.3% (95% CI: 0.1-1.2) 
(Santadusit 2005) of 6 month- 6 year olds also in Thailand. When a convincing clinical 
history was used, the prevalence in 14-16 year olds in Thailand was also 0.3% (95% CI: 
0.1-0.7) (Connett 2012). One study which asked about the prevalence of ‘seafood’ allergy 
in Korea for 12-15 year olds reported a slightly higher reported prevalence of 0.8% (95% 
CI: 0.7-1.0) (Oh 2004). With regards to a convincing clinical history and a positive SPT 
result combined, the prevalence was 0.2% (95% CI: 0.0-1.0) (Santadusit 2005) of 6 month- 
6 year olds in Thailand. This was also the case for 3-7 year olds based on an open food 
challenge (0.2%, 95% CI: 0.0-1.4) (Lao-araya 2012).  
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Western Pacific 
In the Western Pacific region of the world questionnaire-based methods were used by four 
studies and three studies used SPT and serum SIgE. There was no food challenge data for 
fish allergy in this region of the world. The reported prevalence of ‘fish/shellfish’ allergy 
in 20-44 year olds in Australia was 2.1% (95% CI: 1.2-3.6) (Woods 1998). In Taiwan in 
over 19 year olds, the prevalence was lower at 1.2% (95% CI: 1.0-1.4) when a clinician 
diagnosis of fish allergy was used. The reported prevalence of childhood fish allergy was 
4.3% (95% CI: 4.0-4.7) (Connett 2012) in 14-16 year olds in the Phillipines, 2.3% (95% 
CI: 2.0-2.6) (Connett 2012) based on clinical history in 14-16 year olds in the Phillipines, 
and 1.5% (95% CI: 1.3-1.7) (Wu 2012) of 4-18 year olds in Taiwan according to a 
clinician diagnosis. In contrast the lowest prevalence for self-reported, clinical history and 
clinician diagnosed fish allergy were 0.3% (95% CI: 0.2-0.6) (Leung 2009) of 2-7 year 
olds in Hong Kong, 0.3% (95% CI: 0.2-0.4) (Connett 2012) of 14-16 year olds in 
Singapore and 0.2% (95% CI: 0.1-0.5) (Leung 2009) of 27 year olds in Hong Kong 
respectively. A study in Australia showed 0.0% (95% CI: 0.0-2.1) (Burney 2010) fish 
sensitisation in 20-44 year olds. For children the sensitisation rate ranged from 0.2% (95% 
CI: 0.0-1.4) (Chen 2011) to 0.8% (95% CI: 0.2-2.5) (Hu 2010) in China.
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Figure 3.9 Fish allergy prevalence in other regions of the world diagnosed by questionnaire-based methods 
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Figure 3.10 Fish allergy prevalence in other regions of the world diagnosed by sensitisation methods 
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Figure 3.11 Fish allergy prevalence in other regions of the world diagnosed by food-challenge methods
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3.4.6 Shellfish allergy prevalence across different regions of the world 
(See Figures 3.12, 3.13 and 3.14) 
African 
In the African region, only one study reporting shellfish prevalence data could be found 
from Ghana. This study found the reported shrimp allergy prevalence in 5-16 year old 
children to be 0.1% (95% CI: N/R). 
 
Americas 
In the Americas region, there were five studies which used questionnaire-based methods to 
determine the prevalence of shellfish allergy. Only one of these studies, carried out in the 
United States, specifically asked about crustacean allergy, finding that for adults the 
reported prevalence was 0.7% (95% CI: 0.5-1.0) (Vierk 2007) and the clinician diagnosed 
prevalence was 0.4% (95% CI: 0.2-0.7) (Vierk 2007). The remaining studies report on 
‘shellfish allergy’ collectively. With regards to self-reported allergy, the highest reported 
prevalence seen in adults was 9.0% (95% CI: 6.7-11.9) (Greenhawt 2009) and the lowest 
was 1.7% (95% CI: 1.3-2.1) (Vierk 2007). The highest reported shellfish allergy in 
children was 2.0% (95% CI: 1.7-2.5) (Gupta 2011) and the lowest was 0.5% (95% CI: 0.3-
0.8) (Gupta 2011). The prevalence according to a convincing clinical history was 0.5% 
(95% CI: 0.18-0.82) (Ben-Shoshan 2010) for under 18 year olds and 1.69% (95% CI: 1.39-
1.98) (Ben-Shoshan 2010) for over 18 year olds. The clinician diagnosed prevalence for 
adults ranged from 3.1% (95% CI: 2.5-3.7) (Sicherer 2004) to 0.71% (95% CI: 0.58-0.84) 
(Ben-Shoshan 2010), and for children the range was 0.7% (95% CI: 0.4-1.1) (Sicherer 
2004) to 0.06% (95% CI: 0.01-0.10) (Ben-Shoshan 2010). Three studies used serum SIgE 
tests to report on sensitisation to shellfish. The highest sensitisation rates were 6.1% (95% 
CI: N/R) (Liu 2010) of 6-19 year olds and 6.7% (95% CI: N/R) (Liu 2010) of 40-59 year 
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olds, and the lowest were 5.2% (95% CI: N/R) (Branum 2009) of under 18 year olds and 
0.0% (95% CI: 0.0-5.3) (Burney 2010) of 20-44 year olds. As was observed earlier with 
regards to the review of fish allergy in this region, there was no food challenge data on the 
prevalence of shellfish allergy found. 
 
Eastern Mediterranean 
No studies reporting on the prevalence of shellfish allergy could be found from the Eastern 
Mediterranean region of the world. 
 
South East Asia 
Both studies on shellfish allergy in the South East Asia region used questionnaire-based 
methods, sensitisation tests and food challenges. The highest reported crustacean (shrimp) 
allergy was 3.1% (95% CI: 1.8-5.3) (Lao-araya 2012) of 3-7 year olds. The lowest was 
0.7% (95% CI: 0.2-2.1) (Lao-araya 2012) of 3-7 year olds reporting an adverse reaction to 
crab. With regards to mollusc allergy, the reported prevalence was 0.2% (95% CI: 0.0-1.4) 
(Lao-araya 2012) for 3-7 year olds and for ‘shellfish’ was 0.5% (95% CI: 0.1-1.5) 
(Santadusit 2005) of 6 month- 6 year olds. The sensitisation rates (including a clinical 
history) for both shrimp and ‘shellfish’ were 0.3% (Santadusit 2005). Challenge proven 
prevalence ranged from 0.3% (95% CI: 0.1-1.2) (Santadusit 2005) to 0.9% (95% CI: 0.3-
2.4) (Lao-araya 2012) for shrimp allergy, and 0.2% (95% CI: 0.0-1.4) (Lao-araya 2012) for 
crab allergy. No data was available for adult shellfish allergy.  
 
Western Pacific 
Looking at the Western Pacific region prevalence rates were based on; self-report in two 
studies, clinical history in one, clinician-diagnosis in two, SPT in three, and serum SIgE in 
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one. No study used food challenges to confirm the prevalence of either crustacean or 
mollusc allergy. One study reported clinician-diagnosed prevalence for over 19 year olds 
in Taiwan with shrimp allergy affecting 3.3% (95% CI: 3.0-3.6), crab allergy 2.3% (95% 
CI: 2.0-2.5) and mollusc allergy 1.5% (95% CI: 1.3-1.7) (Wu 2012). The highest reported 
shellfish allergy was 11.6% (95% CI: 10.8-12.4) (Shek 2010) of 14-16 year olds and the 
lowest was 7.2% (95% CI: 6.5-8.1) (Shek 2010) in 4-6 year olds, in Singapore. The 
prevalence range was lower when a convincing clinical history was apparent (5.1%, 95% 
CI: 4.3-61 vs 1.2%, 95% CI: 0.9-6.1) (Shek 2010). In Taiwan the clinician diagnosed 
prevalence was 4% (95% CI: 3.7-4.4) for shrimp allergy and 0.4% (95% CI: 0.1-1.2) for 
crab allergy (Wu 2012). Adult shrimp sensitisation was reported to be 2.3% (95% CI: 0.8-
5.5) (Burney 2010) in Australia and in children the latest data from China indicated it was 
0.3% (95% CI: 0.0-1.7) (Hu 2010). For ‘shellfish’ sensitisation, the rate was 0.4% (95% 
CI: 0.2-0.7) (Osborne 2011) of 12-15 month olds in Australia. 
PREVALENCE 
109 
 
Figure 3.12 Shellfish allergy prevalence in other regions of the world diagnosed by questionnaire-based methods  
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Figure 3.13 Shellfish allergy prevalence in other regions of the world diagnosed by sensitisation methods  
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Figure 3.14 Shellfish allergy prevalence in other regions of the world diagnosed by food-challenge methods 
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3.5 Discussion 
The aim of this chapter was to study the epidemiology of fish and shellfish allergy by 
investigating the prevalence of fish and shellfish allergy. This systematic review is the first 
to provide comprehensive data on the prevalence of fish and shellfish allergy across 
different age groups and geographical regions of the world. Overall, the majority of studies 
were graded as having a ‘high’ risk of bias for diagnostic method and ‘medium’ risk of 
bias for sampling strategy. Most of the studies identified presented data from the European 
region, in particular there was a paucity of data from the African and Eastern 
Mediterranean regions, and in all regions there was a predominance towards paediatric 
rather than adult cohorts. There were larger numbers of studies which reported on fish 
compared to shellfish allergy prevalence, and there were even fewer studies which reported 
on mollusc compared to crustacean allergy prevalence.  
3.5.1 Review of findings in light of existing literature 
To summarise, in Europe the range of reported prevalence rates of fish allergy assessed by 
questionnaire-based methods was much higher in children, with a range of 0.0% to 7.0% 
(number of studies= 18; low risk of bias for diagnostic method= 3, low risk of bias for 
sampling strategy=5) than adults where the range was 0.2% to 1.5% (number of studies= 5; 
low risk of bias for diagnostic method= 1, low risk of bias for sampling strategy=1). This 
finding suggests a higher range of reported prevalence rates compared to that of a previous 
review (Rona et al., 2007) who found that the variation in reported prevalence rates of fish 
allergy ranged from 0% to 2%. The difference in prevalence ranges between the two 
reviews is due to an increased number of studies being included in the current review; the 
higher prevalence estimates in the current review come from studies which have not been 
included in Rona et al. (2007) (Kajosaari 1982; Kristjansson 1999; Martinez-Gimeno 2000; 
Mustafayev 2012; Pyrhonen 2009; Touraine 2002; Young 1994). Sensitisation rates 
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identified in this review were between 0.0% and 2.9% for adults (number of studies=3 ; 
low risk of bias for diagnostic method=0 , low risk of bias for sampling strategy=1) and 
0.0% and 2.7% for children (number of studies=9; low risk of bias for diagnostic 
method=2, low risk of bias for sampling strategy=6). When a convincing history was 
combined with evidence of sensitisation to determine prevalence, the reported prevalence 
rates of fish allergy was much lower; 0.1% for all ages and 0.0% to 0.6% for children 
(number of studies=4; low risk of bias for diagnostic method=2, low risk of bias for 
sampling strategy=0). This is similar to the symptomatic and sensitised rates to fish 
reported by Rona et al. (2007) (0.5% or less). Food challenge confirmed prevalence rates 
were between 0.0% to 0.2% in adults (number of studies= 3; low risk of bias for diagnostic 
method=3, low risk of bias for sampling strategy=0) and 0.0% to 0.3% in children (number 
of studies= 5; low risk of bias for diagnostic method=5, low risk of bias for sampling 
strategy=1), which is similar to the prevalence reported by Rona at el. (2007) for children 
(0.4%) however the current review also included three additional studies that food 
challenged adults.  
 
With regards to other regions of the world, the highest reported rates for fish allergy were 
seen in the Americas region for adults (2.7%) and in the Eastern Mediterranean region for 
children (2.8%). Prevalence rates based on a clinical history ranged between 0.56% in 
adults in Canada to 1.2% of adults in Taiwan and from 0.18% of children in Canada to 
2.3% of children in Philippines. Prevalence rates based on a clinician diagnosis ranged 
from 0.12% in Canada to 1.2% in Taiwan for adults and 0% in Canada to 1.5% in Taiwan 
for children. Sensitisation rates were 0.0% of adults in the United States as well as 
Australia and 0.2% to 0.8% of children in the Western Pacific region. The only study to 
report food challenge data indicated that 0.2% of children in the South-East Asia region 
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have a fish allergy. There is currently no published review which includes studies from 
other regions of the world to compare the findings of the current review to.  
 
With regards to shellfish allergy, in Europe the reported prevalence rates of crustacean 
allergy assessed by questionnaire-based methods was 2% for adults and 0.1% to 5.5% for 
children (number of studies= 4; low risk of bias for diagnostic method=0, low risk of bias 
for sampling strategy=2), mollusc allergy ranged from 0.4% to 0.5% for adults (number of 
studies= 2; low risk of bias for diagnostic method=1, low risk of bias for sampling 
strategy=0) and 1.5% for children, and shellfish allergy was reported in the range of 0.1% 
to 1.5% of children (number of studies= 3; low risk of bias for diagnostic method=1, low 
risk of bias for sampling strategy=0). This contradicts previous findings which found self-
reported shellfish allergy prevalence reported by studies to be between 0% and 10% (Rona 
et al., 2007). The reason for this is that the higher prevalence reported by Rona et al. 
(2007) comes from a study which was excluded from the present review as it did not meet 
the inclusion criteria because of the way the data is reported. There was only one study 
which reported sensitisation rates to mollusc, reporting 0% sensitisation in all ages in 
Germany. For crustacean allergy there were no studies which looked at sensitisation status 
in children. For adults this ranged from 0% to 10.3% (number of studies= 3; low risk of 
bias for diagnostic method=0, low risk of bias for sampling strategy=1). Rona et al. (2007) 
found a lower sensitisation rate of 0% to 2.5%, however this discrepancy is due to new 
studies being included in the current review because it was conducted more recently. Food 
challenges confirmed a 0% prevalence of crustacean allergy in children and a 0.3% 
prevalence of crustacean allergy in adults. The confirmed prevalence of mollusc allergy in 
children was not investigated but for adults this was 0.1%. 
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In other regions of the world, the reported prevalence rates, assessed by questionnaire-
based methods, for crustacean allergy was 0.4% of adults and 0.1% of children in the 
United States and 3.3% of adults and 4% of children in Taiwan, for mollusc allergy it was 
0.2% of children in Thailand and 1.5% of adults in Taiwan, and shellfish allergy ranged 
from 0.71% of adults and 0.06% of children in Canada to 9% of adults in the United States 
and 11.6% of children in Singapore. Sensitisation studies indicated 0.0% to 6.7% 
sensitisation to crustacean in adults (number of studies= 2; low risk of bias for diagnostic 
method=0, low risk of bias for sampling strategy=0) and 0.0% to 6.1% for children 
(number of studies= 5; low risk of bias for diagnostic method=1, low risk of bias for 
sampling strategy=1). Two studies from the South East Asia region reported food 
challenge proven prevalence of 0.3% to 0.9% for shrimp allergy and 0.2% for crab allergy 
in children. The findings suggest that the reported prevalence of fish allergy is slightly 
higher in children than in adults in both Europe and other regions of the world. However, it 
is important to note that there were a far greater number of studies which investigated the 
prevalence of childhood fish allergy compared to adult and so the prevalence of adult fish 
allergy could be underestimated. One possible explanation for the disparity in the number 
of studies examining adult versus paediatric fish and shellfish allergy is the perceived ease 
of recruiting children over adults as well as that adults with food allergies are sometimes 
lost to follow up in the healthcare system.  
 
When comparing Europe with the rest of the world, the reported prevalence of fish allergy 
is higher in children but lower in adults, sensitisation is higher in Europe for both adults 
and children, whereas prevalence rates based on food challenges were similar in children in 
Europe and South East Asia. The reported prevalence of shellfish allergy is higher in 
children than adults in Europe however in studies where a food challenge was utilised for 
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the diagnosis of crustacean allergy the prevalence was actually found to be higher in adults 
than children. In other regions of the world, a similar pattern was seen for questionnaire-
based methods. However the sensitisation rates were higher in adults than children. The 
lack of food challenge data means that comparison of food challenge diagnosed shellfish 
allergy between children and adults in other regions of the world is not possible as there 
was only one study utilising food challenges in this context. Overall, there were very few 
studies which investigated mollusc allergy, with the majority looking at crustacean or 
shellfish allergy combined (the study did not distinguish between crustacean and mollusc 
allergy). Therefore further studies are needed which measure the impact this allergy has on 
a population. Comparisons between regions show the self-reported prevalence of 
crustacean allergy is higher in all age groups in Europe than other regions of the world 
however prevalence rates for children are lower in Europe than South East Asia when 
based on a food challenge diagnosed allergy. 
 
This review is restricted by three key limitations which makes understanding the true 
prevalence of fish and shellfish allergy challenging. Firstly, the poor coverage of evidence 
base in many of the world regions especially data reporting on mollusc allergy and adult 
populations. Secondly, the poor quality of methodology found with many of the studies 
included in the review, with few adopting the gold standard of diagnosis (food challenges) 
and instead assessing food allergy prevalence with questionnaire-based methods which are 
known to overestimate the true prevalence (Johansson et al., 2004; Rona et al., 2007; 
Skypala & Venter, 2009). Thirdly, the heterogeneity in the criteria that studies used for the 
diagnosis of allergy and overall description of the study design in the research articles, 
including methodologies for the diagnostic tests and cut off points, which further makes 
comparisons across studies challenging. Furthermore it would have been informative to 
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have been able to discuss the different types of fish and shellfish allergy independently, i.e. 
whether IgE-mediated or non IgE-mediated and the specific species implicated, however 
this was not possible due to the lack of information and clarity provided in the research 
papers. It is important to understand the mechanisms involved in fish and shellfish allergy 
as reactions could be due to other adverse reactions such as toxic poisoning, or sulphite 
sensitivity as well as true food allergy and this would implicate on the prevalence rates 
especially with those studies adopting methods which simply ask about any adverse 
reactions to foods.  
 
Since the onset of the current review, another review has been published which includes 
data on the prevalence of fish and shellfish allergy in Europe (Nwaru et al., 2014), as well 
as cows milk, egg, wheat, soy peanuts and tree nut allergy. Four databases were searched 
for articles published between January 1 2000 and September 30 2012. In terms of study 
design, systematic reviews and meta-analyses as well as cohort studies, case-control 
studies, cross-sectional studies and routine healthcare studies were included. The review 
included studies that assessed food allergy based on; self-report, SPT positivity, serum 
SIgE positivity, OFC/DBPCFC, or convincing clinical history. The risk of bias was 
assessed using a modified version of the Critical Appraisal Skills Programmes quality 
assessment tool. Sixty-five studies were included in the review by Nwaru et al. (2014) 
review, 31 of which examined fish allergy and 15 shellfish allergy. As part of the 
systematic review, a random-effects meta-analysis for clinically and methodologically 
comparable studies was performed to estimate the prevalence of each food allergy based 
on the different assessment methods. The lifetime prevalence of self-reported fish allergy 
was 2.2%, 0.6% for point self-reported prevalence, 0.6% for SPT positivity, 0.7% for SIgE 
positivity, 0.1% for food challenge positivity, and 0.1% for food challenge of history of 
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fish allergy. The lifetime prevalence of self-reported shellfish allergy was 1.3%, 0.7% for 
point self-reported prevalence, and 0.1% for food challenge positivity. In the current 
review, the corresponding highest point prevalence, including all ages, of reported fish 
allergy was 7% and reported shellfish allergy was 11.6%; sensitisation to fish was 2.9% 
and sensitisation to shellfish was 10.3%; food challenge proven prevalence of fish allergy 
0.3% and proven shellfish allergy was 0.9%.  
 
There are some important discrepancies to note between the current review and the Nwaru 
et al. review (2014). Firstly, only European countries were considered in the review by 
Nwaru et al. (2014) whereas all countries worldwide were included in the current review. 
Secondly, shellfish allergy was not reported by crustacean or mollusc allergy separately 
despite being reported separately by many of the included studies whereas, in the current 
review prevalence was reported separately for fish, crustacean and mollusc and where 
possible also by the type of species. Thirdly, there was no time period limitation applied to 
the current review compared with Nwaru et al. (2014) who limited the search strategy to 
articles published between 2000 and 2012. However the current review did not perform 
meta-analysis as it was deemed that due to the high heterogeneity between studies pooling 
may have suggested misleading prevalences of fish and shellfish allergy. The above 
discrepancies can explain the differences found between prevalence estimates. In addition, 
the current review presents the highest prevalence’s found as opposed to the pooled 
estimate as presented by Nwaru et al. (2014) and so some caution should be applied when 
comparing the two reviews. In conclusion, the current review provides a more 
comprehensive and up to date review, as well as a worldwide perspective, of the 
prevalence of fish, crustacean and mollusc allergy when compared to previous reviews 
(Nwaru et al., 2014; Rona et al., 2007) .  
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3.5.2 Strengths 
A strength of the current review is the rigorous search strategy that was used in the initial 
stages of the review which was able to identify all of the studies relevant to the inclusion 
criteria for this topic. In addition, experts within the field of epidemiology of food allergy 
were used to ensure thoroughness of literature searches and in the extraction and 
interpretation of the data and in most cases we were able to present the raw data from the 
studies and calculate the prevalence and 95% confidence intervals so as to avoid 
misreporting or misunderstanding any of the reported results. Furthermore, the current 
review is more comprehensive than previous reviews as it includes studies from Europe as 
well as other regions of the world (including those from America). Finally, an advantage of 
adopting the systematic review methodology is that bias is limited during the selection of 
studies and so the conclusions made are more reliable and accurate.  
3.5.3 Limitations 
There are two main limitations to the current review which are important to note. Firstly, 
the search of ‘grey literature’ could have been further explored by following up emails to 
experts in the field, to ensure thoroughness of the literature search and the inclusion of all 
potentially relevant studies. Secondly, some potentially eligible studies were excluded due 
to the lack of clarity of the results, and despite every efforts being made to contact the 
study authors’ for clarity, not all responded and thus the studies had to be excluded from 
the review. The nature of poor reporting may be indicative of poor study methodology, as 
it is shown that more rigorous studies produce results that are closer to the truth and so it is 
believed that these excluded studies would not have significantly altered the overall 
findings (Higgins, Altman, & Sterne, 2011). 
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3.6 Conclusion and direction for future research 
The current study provides comprehensive and up to date estimates of the prevalence of 
fish and shellfish allergy across age groups and regions of the world. The current 
systematic review was novel and expanded and improved on existing reviews as it 
included studies from across the world, of all age groups, and specific searches for 
shellfish species were carried out. There is some evidence to suggest that the prevalence of 
fish and shellfish allergy varies according to age and region. The wide variation of 
prevalence rates found between studies and regions may be due to differing availability 
and dietary/cultural practices, and it is still unclear to what effect the age of introduction or 
the consumption of raw fish (i.e. sushi) has on the development of clinical food allergy. 
However, there is a marked scarcity of high quality prevalence studies for fish and 
shellfish allergy; only ten were included in the present review.  
 
Future prevalence research should utilise more rigorous diagnostic methods and be 
conducted across all regions of the world in both children and adults. A larger evidence 
base would then allow for the mechanisms involved in fish and shellfish allergy to be 
better understood including identifying ‘at risk’ groups and cross-sensitisation and cross 
reactivity across species, as well as facilitate comparisons across studies which could 
assess the true prevalence of this type of food allergy. In addition, future research should 
be explicit in the types of species implicated in reactions as this would allow for a greater 
understanding of the allergenicity of different species and would also be able to identify 
which species clinicians need to be aware of as a possible risk factor depending on the 
local availability and consumption.  
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This systematic review chapter has furthered our understanding of the epidemiology of fish 
and shellfish allergy, however this is just one part of the picture. We still do not understand 
fully the clinical characteristics of fish and shellfish allergy in adults and so the next 
chapter aims to explore this further. 
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CHAPTER 4 
THE CLINICAL CHARACTERISTICS OF FISH AND 
SHELLFISH ALLERGIC ADULTS 
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4.1 Overview 
The overall aim of this research is to characterise and describe fish and shellfish allergy. 
The previous study looked at the epidemiology of the disease but it is important for both 
clinicians and researchers to understand the phenotype of fish and shellfish allergy so that 
it can be properly diagnosed and managed. This chapter examines the clinical 
characteristics of adults with fish and or shellfish allergy in a UK sample. This was 
achieved by collecting detailed information on allergic status and allergic history from 
adults (>16 years) with a record of fish and or shellfish allergy attending allergy outpatient 
clinics at the Isle of Wight, Royal Brompton and Southampton NHS hospitals, as well as 
members of an allergy patient support group (the Anaphylaxis Campaign). The results are 
discussed in terms of their contribution to the current literature on adult fish and shellfish 
allergy and any clinical implications the findings may have. 
   
4.2 Background 
4.2.1 Clinical characteristics of fish and shellfish allergy 
One novel study that looked to describe the clinical characteristics of children with seafood 
allergy in Australia found that 94% had evidence of co-existent atopic disease. In addition, 
50% of crustacean-allergic individuals were able to tolerate non-crustacean fish. Allergic 
reactions to other fish species however was common, with one third reporting multiple 
clinical reactions to different species and 16% who reported developing symptoms after 
inhalation of fish vapours. Interestingly, in children with an allergy to tuna and or salmon, 
21% were able to tolerate the fish in a tinned form (Turner, Ng, Kemp & Campbell, 2011). 
In addition, a study which investigated the probable prevalence of IgE-mediated shrimp 
allergy in young adults in Australia, as defined by a positive skin prick test, found that 
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those with a positive SPT to shrimp were significantly more likely to have current asthma 
(p=0.009), nasal allergies (p=0.03) and doctor diagnosed asthma (p=0.02) (Woods, Thien, 
Raven, Walters, & Abramson, 2002). Similarly, Chiang et al. (2007) found an increased 
risk of shellfish sensitisation in children with allergic rhinitis and cockroach sensitisation 
and Wu & Williams (2004) found that 90% of individuals with a suspected shellfish 
allergy had a positive SPT to house dust mite. However, caution should be applied to the 
interpretation of these results as a positive SPT indicates sensitisation only and not 
necessarily a clinical crustacean allergy. In summary there is a paucity of published 
literature that describes in detail the typical presentation of fish and shellfish allergy. 
4.2.2 Rationale for this study  
In summary, while there are good estimates for the prevalence of clinical allergy and 
sensitisation to allergens such as milk, peanut and tree nut throughout the lifespan, the 
prevalence and understanding of allergies to fish and shellfish are less understood (Taylor, 
2008). The previous chapter of this thesis suggests possible differences in shellfish allergy 
prevalence due to geographical location, and current literature, although scarce, indicates 
certain characteristics that distinguish fish and shellfish allergies from allergies to other 
foods, such as the severity of symptoms, later onset of disease and persistence. In addition, 
some of the main allergens have been identified in both fish and shellfish, and studies have 
looked at cross sensitisation of fish and shellfish species as well as house dust mites, 
cockroaches and comorbidity with other allergic diseases such as allergic rhinitis. But less 
is currently known about clinical cross reactivity and co-existing allergies. In order to 
improve clinical understanding and successful management of such a prevalent, and 
potentially severe food allergy, research is needed which investigates in detail how these 
individuals typically present with regards to their clinical characteristics. In addition, 
despite fish and shellfish being considered as two of the most important food allergens 
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affecting adults, the majority of studies to date have been performed on paediatric samples 
(Hansen & Bindslev-Jensen, 1992; Helbling, McCants, Musmand, Schwartz, & Lehrer, 
1996). Thus, information about the clinical characteristics of the population understood to 
be most affected by fish and shellfish allergies (adults) is an important gap in the literature 
and worthy of further study. 
4.2.3 Aim and objectives  
The principal aim of this study was to describe the clinical characteristics of fish and or 
shellfish allergic adults in a UK sample. The term clinical characteristic in this chapter 
refers to the typical presentation of these individuals with regards to their food allergy. In 
order to achieve this aim, the following objectives were set to: 
 Describe the atopic status, history of allergic disease and characteristics of the 
allergic participants. 
 Describe the prevalence of fish, crustacean and mollusc allergy and the common 
symptoms experienced. 
 Examine co-existing and cross sensitivity within seafood allergy. 
 Examine other co-existing food and aeroallergen sensitivities. 
 Examine the level of tolerance with regards to tolerance of tinned seafood and the 
reactivity to airborne traces. 
 Describe the dietary advice and medical management strategies adopted by this 
sample. 
 
4.3 Methodology 
4.3.1 Design 
A quantitative cross-sectional questionnaire design was used for this research.  
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4.3.2 Ethical approval and research governance compliance 
Ethical approval for the current study was granted by the NRES Committee London- 
Bloomsbury on the 4
th
 October 2013 (Appendix 5). Subsequent to this, Research and 
Development approval was gained from the Isle of Wight NHS Trust (10
th
 October 2013), 
Royal Brompton and Harefield NHS Foundation Trust (19
th
 December 2013) and 
University Hospital Southampton Foundation Trust (20
th
 December 2013) (Appendix 6-8). 
In accordance with Research Governance procedures honorary contracts were issued for 
the author from the Isle of Wight NHS Trust and Royal Brompton and Harefield NHS 
Foundation Trust valid for the duration of the research study (Appendix 9&10). It was not 
necessary to obtain a honorary contract for University Hospital Southampton Foundation 
Trust. 
 
All participants were fully informed about the aims and nature of the research, the 
procedures used, and their right to withdraw from the study at any point. Written consent 
was obtained from all of the participants. The informed consent form, completed 
questionnaires and pro formas were treated as confidential and stored in a locked cabinet 
with the author being the sole key holder. Electronic data (questionnaires completed 
online) was kept in password-protected files. Each participant was assigned a participant 
identification number for the purpose of analysis. No identifiable data was used on any 
research reports. 
4.3.3 Sample  
This is a cross-sectional study that took place across the UK between October 2013 and 
October 2014. The target population for this study was adults (≥16 years) with a fish and 
or shellfish allergy. For inclusion in the study participants had to meet one of the following 
criteria: 
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 Attending an allergy outpatient clinic at the Isle of Wight, Southampton or Royal 
Brompton hospital for a diagnosed IgE-mediated or non-IgE mediated fish and or 
shellfish allergy. 
 A current member of the patient support group Anaphylaxis Campaign who had 
selected fish and or shellfish allergy on their member profile. 
 
The current study is a novel, descriptive and exploratory study and so it was not possible 
(nor desirable) to calculate desired sample size based on power. The initial aim of the study 
was to recruit 100 participants (50 from allergy clinics and a further 50 from the 
Anaphylaxis Campaign) as it was deemed a sufficient sample size to represent a range of 
different clinical representations of fish and shellfish allergy (in discussion with clinicians 
working in the allergy outpatient clinics) as well as taking into account the expected 
response rate for a questionnaire design (Cummings, Savitz, & Konrad, 2001). 
4.3.4 Recruitment 
Participants were recruited for the current study through two means. Firstly, in accordance 
with Research Governance and the requirements of the trusts involved, a nominated 
gatekeeper (an existing member of staff) at three hospital sites in the UK (University 
Hospital Southampton, Isle of Wight, Royal Brompton and Harefield) identified patients 
who were fish and or shellfish allergic through reviewing the archive of patient letters and 
identifying those individuals who underwent and had a positive SIgE test to fish and or 
shellfish in the last three years. Secondly, a member of staff at a patient support group (the 
Anaphylaxis Campaign) identified adult members who had indicated a fish/shellfish 
allergy on their member profile. 
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Once the desired population had been identified a study invitation letter (Appendix 
11&12), consent form (Appendix 13&14) and allergy questionnaire was posted to the 
patient/member, detailing the aims and purpose of the study and inviting them to 
participate through completing the attached consent form and questionnaire. A link to an 
online version of the questionnaire was also provided for ease of completion. In addition, 
the Anaphylaxis Campaign used their social media platform to advertise the research study 
providing the online link to the questionnaire and contact details for the researcher in case 
further information was required. Non-respondents were followed up two weeks after the 
initial contact with a reminder letter (Appendix 15&16). Participants recruited through the 
allergy outpatient clinics were also asked for their consent for relevant information to be 
extracted from their clinical notes.  
4.3.5 Procedure 
Data collection commenced in October 2013 and ended in October 2014. Participants 
received a recruitment pack, which contained a study invitation, information letter, consent 
form and a questionnaire. They were instructed to return the completed questionnaire and 
consent form in an enclosed envelope or alternatively to complete the questionnaire online 
using the link provided. Reminder letters were sent if the completed questionnaires had not 
been received within two weeks. It is recognised that a reminder phone call may have been 
more personal and so may have increased response rates however the NRES committee 
requested this aspect of the recruitment strategy be removed. The researcher reviewed the 
questionnaires and all participants who had provided contact details were contacted to 
prompt for missing or clarification of details where necessary. For those individuals 
recruited via an allergy outpatient clinic, the pro forma was completed by the gatekeeper 
who extracted any data obtained from clinical tests with regards to the patient’s allergy 
status, for example results of diagnostic tests, sensitisation to aero-allergens and dietary 
CLINICAL CHARACTERISTICS 
129 
advice provided from the individuals’ medical notes (as detailed further under the ‘Pro 
forma’ description provided below). 
 
Survey questionnaire (Appendix 17) 
A self- reported allergy questionnaire was constructed to investigate the allergic status and 
characteristics of the participants. While it is recognised that the way in which questions 
are presented can influence both the reliability and validity of a scale (DeVellis, 2016), the 
current questionnaire was designed on the basis of the FAIR materials (Venter, 2006) and 
further expanded on the areas identified in the literature review to need further research, 
such as the prevalence of air-borne reactions, and so the theoretical considerations for a 
scale development were not applicable in this type of questionnaire design. Furthermore, 
the questions asked replicates those asked by a health care professional during an allergy 
outpatient consultation and where possible medical records of participants were checked 
for clarification and accuracy. The questionnaires were developed with the help of 
dietitians and medical consultants working in the area of food allergy with a specialism in 
fish and shellfish allergy, who have a number of years experience in collecting a detailed 
clinical history from patients as well as constructing questionnaires for the purpose of 
epidemiological research (Dr P Turner, Dr I Skypala). A patient representative of the 
Anaphylaxis Campaign also piloted the questionnaire for clarity and relevance, ease of 
completion and accuracy in recall of clinical details. The questionnaire was made up of 28 
questions, covering seven key sections.  
 
Firstly, the socio-demographic section of the questionnaire included questions on age, 
height, weight, country of birth, ethnicity (White British, White European, White Other, 
Black: British Caribbean, Black: British African, Black: British Other, Asian: British, 
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Asian: British Other, Mixed Background, Chinese, Other) and occupation (in particular 
whether occupation involves close contact with fish and or shellfish). Secondly, questions 
associated with the participants’ current dietary patterns, in particular with regards to the 
main 14 allergens (fish, crustaceans, molluscs, celery, milk/dairy, egg, lupin, mustard, 
peanuts, tree nuts, sesame, soya, wheat, sulphites, other food allergies), including specific 
crustaceans and molluscs were asked. Specifically the questionnaire sought to determine 
whether the food was consumed with no problems, avoided for a reason unrelated to 
allergy, avoided due to a proven allergy (history plus a positive test) or avoided due to a 
suspected allergy (positive test in the absence of a clear history). Thirdly, with regards to 
the participant’s most severe food allergies (up to four), questions were asked about the 
age of diagnosis, symptoms suffered, the time delay after consuming the food and 
experiencing symptoms as well as the method of diagnosis. Fourth, a section on the 
participant’s initial adverse reaction to fish and or shellfish included questions on the type 
and preparation of the seafood, the age when they experienced their first reaction and 
whether it was the first time they had consumed that type of seafood and the initial 
symptoms experienced. Fifth, questions exploring the level of tolerance for seafood, 
including questions on subsequent reactions, reactions to steam and or vapour and tinned 
fish consumption were asked. In the sixth section, questions were asked about the advice 
and management of fish and or shellfish allergy. Finally, the International Study of Asthma 
and Allergies in Childhood (ISAAC) questions were included to provide data on the 
participant’s history of other allergic disease (asthma, eczema, allergic rhinitis and hay 
fever). ISAAC is a worldwide epidemiological research programme which investigated 
asthma, rhinitis and eczema and so it is recognised that these questions are a validated and 
reliable method of obtaining allergy status and history in a questionnaire design (von 
Mutius, 1996).  
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Pro forma (Appendix 18) 
A pro forma was constructed to collect further relevant medical data from the medical 
notes of those patients recruited through allergy outpatient clinics, in order to validate the 
information provided in the allergy questionnaire and provide further information with 
regards to their fish and or shellfish allergy. The pro forma collated the results of any 
diagnostic tests (SPT, serum SIgE, food challenge, and other relevant blood tests) for fish 
and or shellfish as well as any aeroallergens. Questions were also asked about admittance 
to hospital following an allergic reaction, any medications prescribed (including the dose), 
the dietary advice and management provided to the individual during clinic, and the 
patient’s history of other allergic diseases. The pro forma was developed in line with the 
literature on fish and shellfish allergy characteristics, with the help of medical consultants 
working at each of the hospital sites and was piloted for ease of completion and inclusion 
of all relevant information prior to using for the purpose of this research. 
4.3.6 Data analysis 
All data was double entered on SPSS (IBM SPSS Statistics for Mactintosh, Version 22.0). 
Online questionnaire responses were directly exported to SPSS from Bristol Online 
Surveys. To describe sample characteristics categorical variables were expressed as 
numbers and percentage, and continuous variables were expressed as mean and range. 
To try and gain an understanding of the severity of symptoms experienced, a clinical 
grading system was used to code the reported symptoms. There are a number of clinical 
grading systems reported in the literature (Astier et al., 2006; Ewan & Clark, 2001; 
Hourihane et al., 2005; Sampson, 2003) however these systems are complex and rely on a 
depth of knowledge of symptoms as gathered in a clinical consultation conducted shortly 
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after an adverse reaction. Such information would be impossible to collect accurately 
either retrospectively or via a research questionnaire. Brown (2004) however developed a 
simple three level grading system which has potential value for defining reaction severity 
in clinical as well as research settings. Grade one reports a mild reaction, which is defined 
by generalised erythema, urticaria, periorbital edema, or angioedema. Grade two reports a 
moderate reaction, which is defined by dyspnea, stridor, wheeze, nausea, vomiting, 
dizziness (presyncope), diaphoresis, chest or throat tightness or abdominal pain. Grade 
three reports the most severe reaction and is defined by cyanosis, hypotension, confusion, 
collapse, loss of consciousness or incontinence. Hence the current study utilised Brown’s 
(2004) grading system for data analysis purpose. 
 
4.4 Results 
4.4.1 Description of sample 
There were 136 adults from NHS allergy outpatient clinics and 374 members of the 
Anaphylaxis Campaign who were identified as being potentially suitable for the study and 
sent study invitation packs. In total 111 participants took part in the study, 48 from NHS 
allergy outpatient clinics (three from the Isle of Wight, 32 from Southampton University 
Hospital, and 13 from Royal Brompton) (35% response rate) and 63 from the Anaphylaxis 
Campaign (17% response rate). Demographic characteristics of participants are detailed in 
Table 4.1. 
 
There were equal numbers of females and males (47.9%) recruited from NHS allergy 
outpatient clinics and the majority (72.9%) were from a White/British ethnic background. 
Thirty- seven (77.1%) reported a history of hay fever, 35 (72.9%) a history of allergic 
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rhinitis, 32 (66.7%) a history of asthma, 31 (64.6%) a history of eczema, 30 (62.5%) a 
history of wheeze, and 22 (45.8%) a history of a rash. Twenty participants (41.7%) had 
evidence of another confirmed food hypersensitivity. Forty-eight (76.2%) individuals from 
the Anaphylaxis Campaign were female and the majority (87.3%) were White/British. 
Forty-eight (76.2%) reported a history of hay fever, 47 (74.6%) a history of eczema, 45 
(71.4%) a history of wheeze, 42 (66.7%) a history of asthma, 40 (63.5%) a history of 
allergic rhinitis and 29 (46%) a history of a rash. Fifty-six reported another diagnosed food 
allergy with the most common allergens being peanuts and treenuts.  
 
Table 4.1 Demographic characteristics of participants with fish/shellfish allergy 
by group 
 Isle of 
Wight 
(n=3) 
Southampton 
(n=32) 
Royal 
Brompton 
(n=13) 
Anaphylaxis 
Campaign 
(n=63) 
Total 
Clinic 
(n=48) 
Total All 
(n=111) 
Gender (n, %)       
Female 
 
3 
(100) 
16 
(50.0) 
4 
(30.8) 
48 
(76.2) 
23 
(47.9) 
71 
(64.0) 
Male -  14  
(43.8) 
9  
(69.2) 
13  
(20.6) 
23 
(47.9) 
36  
(32.4) 
Ethnicity (n, %)       
White/British 
 
3 
(100) 
27 
(84.4) 
5 
(38.5) 
55 
(87.3) 
35 
(72.9) 
58 
(52.3) 
White/European - 1  
(3.1) 
1  
(7.7) 
3  
(4.8) 
2  
(4.2) 
5  
(4.5) 
White/Other - - 1  
(7.7) 
3  
(4.8) 
1  
(2.1) 
4  
(3.6) 
Black/British 
Caribbean 
- - 1  
(7.7) 
1  
(1.6) 
1  
(2.1) 
2  
(1.8) 
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 Isle of 
Wight 
(n=3) 
Southampton 
(n=32) 
Royal 
Brompton 
(n=13) 
Anaphylaxis 
Campaign 
(n=63) 
Total 
Clinic 
(n=48) 
Total All 
(n=111) 
Asian/British - 3  
(9.4) 
1  
(7.7) 
- 4  
(8.3) 
4  
(3.6) 
Chinese - 1  
(3.1) 
- - 1  
(2.1) 
1  
(0.9) 
Mixed 
Background 
- - 4  
(30.8) 
- 4  
(8.3) 
4  
(3.6) 
Other - - - 1  
(1.6) 
- 1  
(0.9) 
Allergic History (n, %)       
Ever wheeze 2 
(66.6) 
19 
(59.4) 
9 
(69.2) 
45 
(71.4) 
30 
(62.5) 
75 
(67.6) 
Ever asthma 
 
2 
(66.6) 
19  
(59.4) 
11  
(84.6) 
42  
(66.7) 
32 
(66.7) 
74  
(66.7) 
Ever allergic 
rhinitis 
2 
(66.6) 
23  
(71.9) 
10  
(76.9) 
40  
(63.5) 
35 
(72.9) 
75  
(67.6) 
Ever hay fever 
 
3 
(100) 
24  
(75.0) 
10  
(76.9) 
48  
(76.2) 
37 
(77.1) 
85  
(76.6) 
Ever rash - 15  
(46.9) 
7  
(53.8) 
29  
(46.0) 
22 
(45.8) 
51  
(45.9) 
Ever eczema 1 
(33.3) 
20  
(62.5) 
10  
(76.9) 
47  
(74.6) 
31 
(64.6) 
78  
(70.3) 
Other FHS beside seafood 
(n, %) 
2 
(66.6) 
14 
(43.8) 
4 
(30.8) 
36 
(57.1) 
20 
(41.7) 
56 
(50.5) 
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4.4.2 Fish, crustacean and mollusc allergy in this sample 
In the NHS allergy outpatient clinic population, 14.6% adults were diagnosed with fish 
allergy, 27.1% with crustacean allergy and 2.1% with a mollusc allergy. The most common 
crustacean implicated was prawn and for mollusc, mussels. Seventeen (35.4%) adults 
reacted to both fish and shellfish species and 20 (41.7%) were allergic to crustacean and 
mollusc shellfish (Figure 4.1). 
 
Figure 4.1 Breakdown of fish and shellfish allergy in NHS allergy outpatient 
population 
 
Despite the age range for first reaction being very wide (2-68 years), for the majority 
(58.3%) this allergy was late in onset (post 16 years of age). The most common symptoms 
experienced during the initial reaction were itchy rash on the face and mouth (52.1%) and 
facial swelling (52.1%) (Figure 4.5). Other reported symptoms included feeling 
overwhelmed, abdominal pains, diarrhoea, nausea, ingestion and a tingling sensation on 
the face. Symptoms commonly occurred immediately after exposure to the seafood 
(47.9%) (Figure 4.6). Interestingly the majority of individuals reported that they had 
previously consumed seafood without any adverse reactions (62.5%). Half of the 
individuals had suffered further reactions to seafoods, with 68.3% being hospitalised 
Fish 
14.6% (n=7) 
Crustacean 
27.1% (n=13) 
Mollusc 
2.1% (n=1) 
Fish & 
Mollusc 
0% 
All 
20.8% 
(n=10) 
Fish & 
Crustacean 
14.6% (n=7) 
Mollusc & 
Crustacean 
20.8% (n=10) 
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following an adverse reaction (Table 4.2). The breakdown of symptom severity is 
illustrated in Figure 4.2. 
   
Figure 4.2 The breakdown of symptom severity for fish and/ or shellfish allergic 
individuals from the NHS allergy outpatient population 
 
In the Anaphylaxis Campaign population, 39.7% reported a fish allergy, 15.9% reported a 
crustacean allergy and 6.3% reported a mollusc allergy. Similar to the allergy outpatient 
clinic population, the most common shellfish implicated in reactions were prawn and 
mussels. Twenty-seven (42.9%) reported an allergy to both fish and shellfish species and 
16 (25.4%) reported cross reactivity to crustacean and mollusc shellfish (Figure 4.3).  
 
Figure 4.3 Breakdown of fish and shellfish allergy in Anaphylaxis Campaign 
population. 
 
Mild 41.7%
Moderate 39.6%
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Unlike the allergy outpatient clinic population, the majority of individuals (47.6%) 
reported that their seafood allergy was of an early onset (before 16 years of age). The most 
common symptoms reported during the initial adverse reaction were facial swelling 
(68.3%) and feeling faint and or hypotension (39.7%) (Figure 4.5). Abdominal pains, 
diarrhoea, runny nose, dry mouth and ‘anaphylaxis’ were also reported. Similarly the 
majority of reactions (36.5%) were reported to occur immediately (Figure 4.6). Over half 
(52.4%) of seafood allergic individuals had previously consumed the allergen with no 
adverse effect, 57.1% had suffered further reactions and 68.3% were hospitalised following 
an allergic reaction (Table 4.2). The breakdown of symptom severity is illustrated in 
Figure 4.4. 
 
 
Figure 4.4 The breakdown of symptom severity for fish and/ or shellfish allergic 
individuals from the Anaphylaxis Campaign population 
 
Mild 23.8%
Moderate 31.7%
Severe 41.3%
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Figure 4.5 Symptoms experienced during allergic reaction to fish and/ or shellfish
  
 
 
Figure 4.6 Time of onset of symptoms following consumption of fish and/ or 
shellfish 
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Table 4.2 The characteristics of fish and shellfish allergy 
 Isle of 
Wight 
(n=3) 
Southampton 
(n=32) 
Royal 
Brompton 
(n=13) 
Anaphylaxis 
Campaign 
(n=63) 
Total 
Clinic 
(n=48) 
Total 
All 
(n=111) 
Fish Allergy  
(n, %) 
2  
(66.6) 
17  
(53.1) 
2  
(15.4) 
39  
(61.9) 
21 
(43.8) 
60 
(54.1) 
Crustacean Allergy 
(n, %) 
Prawn 
Crab 
Crayfish 
Langoustine 
Lobster 
2  
(66.6) 
2 
1 
1 
1 
1 
26  
(81.3) 
24 
18 
17 
16 
16 
11  
(84.6) 
11 
4 
4 
4 
5 
31  
(49.2) 
26 
24 
16 
19 
18 
39 
(81.3) 
37 
23 
22 
21 
22 
70 
(63.1) 
63 
47 
38 
40 
40 
Mollusc Allergy  
(n, %) 
Mussels 
Oyster 
Scallop 
Clam 
Squid 
Octopus 
1  
(33.3) 
1 
- 
- 
- 
- 
- 
15  
(46.9) 
14 
12 
13 
11 
11 
10 
5  
(38.5) 
3 
3 
4 
4 
3 
2 
17  
(27.0) 
15 
12 
10 
9 
10 
9 
21 
(43.8) 
18 
15 
17 
15 
14 
12 
38 
(34.2) 
33 
27 
27 
24 
24 
21 
Mean age at first 
reaction (range) 
20  29  
(4-68) 
15  
(2-42) 
20  
(0.5-62) 
25 
(2-68) 
22 
(0.5-68) 
Early Onset (<16 
years) (n, %) 
- 11  
(34.4) 
7  
(53.8) 
30  
(47.6) 
18 
(37.5) 
48 
(43.2) 
Late Onset (>16 
years) (n, %) 
1  
(33.3) 
21  
(65.6) 
6  
(46.2) 
27  
(42.9) 
28 
(58.3) 
55 
(49.5) 
First time consumed 
seafood (n, %) 
      
Yes 2 7 7 25 16 41 
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 Isle of 
Wight 
(n=3) 
Southampton 
(n=32) 
Royal 
Brompton 
(n=13) 
Anaphylaxis 
Campaign 
(n=63) 
Total 
Clinic 
(n=48) 
Total 
All 
(n=111) 
(66.6) (21.9) (53.8) (39.7) (33.3) (36.9) 
No - 24 
(75.0) 
6 
(46.2) 
33 
(52.4) 
30 
(62.5) 
63 
(56.8) 
Never eaten 1 
(33.3) 
- - - 1 
(2.1) 
- 
If no, how many times 
previously consumed 
      
Once - 2 1 7 3 10 
Occasionally 1 11 2 14 14 28 
Regularly 1 6 2 9 9 18 
Frequently - 5 1 3 6 9 
Suffered further 
reactions (n,%) 
1 
(33.3) 
16 
(50.0) 
7 
(53.8) 
36 
(57.1) 
24 
(50.0) 
60 
(54.1) 
Hospitalisation 
following an allergic 
reaction (n,%) 
2 
(66.6) 
16 
(50.0) 
10 
(76.9) 
43 
(68.3) 
28 
(58.3) 
71 
(64.0) 
 
 
Figure 4.7 illustrates the seafood species implicated in the initial adverse reactions of all 
participants. The most common species were cod, crab and prawn (type unspecified). In 22 
reactions, the type of seafood could not be recalled by the individual or in the case of the 
allergy outpatient clinic sample, identified retrospectively from the individual’s medical 
notes.  
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Figure 4.7 Reported seafood species implicated in the initial reaction 
Figure 4.8 and Figure 4.9 show the results of the allergy diagnostic tests which were 
carried out at the three allergy outpatient clinics. Of interest there was a large variety of 
skin prick tests, serum SIgE tests carried out at the Royal Brompton than the Isle of Wight 
and Southampton allergy outpatient clinics. With regards to food challenges, at 
Southampton two patients were challenged to prawn with one positive reaction, at the 
Royal Brompton only one patient had a positive reaction to mussels, with all the other food 
challenges negative. Figure 4.10 and Figure 4.11 show the results relating to aero-allergen 
sensitisation. Across the three allergy outpatient clinics it is clear that fish and/shellfish 
allergic individuals were also sensitised to various pollens and moulds as well as house 
dust mite.  
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Figure 4.8 Positive SPT results grouped by NHS allergy outpatient clinic 
 
 
Figure 4.9 Positive SIgE results grouped by NHS allergy outpatient clinic 
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Figure 4.10  Positive Aeroallergen SPT results grouped by NHS allergy outpatient 
clinic 
 
 
Figure 4.11 Positive Aeroallergen SIgE results grouped by NHS allergy outpatient 
clinic 
 
Twelve (25%) participants from the allergy outpatient clinic population and 25 (39.7%) 
participants from the Anaphylaxis Campaign reported a history of reaction when exposed 
to fish/shellfish cooking vapours and or steam, with the most common symptoms 
experienced being facial swelling (45.9%), wheeze and or cough (40.5%) and itchy rash on 
the mouth (27%). Other symptoms reported include itchy rash over the body, immediate 
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vomiting, generalised swelling, feeling faint and or hypotension, nausea and vomiting, 
tingling on the lips, anaphylaxis (self-reported), sneeze and venous collapse. Of the fish 
allergic individuals (n= 60), 17 reported tolerance to fish in a tinned form but not a fresh 
form (Table 4.3).   
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Table 4.3 Reactions to cooking vapours/steam and tinned fish 
 
Isle of 
Wight 
(n=3) 
Southampton 
(n=32) 
Royal 
Brompton 
(n=13) 
Anaphylaxis 
Campaign 
(n=63) 
Total 
Clinic 
(n=48) 
Total 
All 
(n=111) 
History of reaction to 
vapours/steam 
(n, %) 
1 
(33.3) 
5 
(15.6) 
6 
(46.2) 
25 
(39.7) 
12 
(25) 
37 
(33.3) 
Symptoms experienced 
to vapour/steam (n, 
%) 
      
Itchy rash on 
mouth 
- 
1 
(3.1) 
1 
(7.7) 
8 
(12.7) 
2 
(4.2) 
10  
(27) 
Itchy on rash 
body 
- 
1 
(3.1) 
1 
(7.7) 
4 
(6.3) 
2 
(4.2) 
6  
(16.2) 
Immediate 
vomiting 
- - - 
1 
(1.6) 
- 
1  
(2.7) 
Facial 
swelling 
- 
1 
(3.1) 
4 
(30.8) 
12 
(19) 
5 
(10.4) 
17 
(45.9) 
Generalised 
swelling 
- - - 
4 
(6.3) 
- 
4  
(10.8) 
Wheeze/ 
cough 
1 
(33.3) 
3 
(9.4) 
2 
(15.4) 
9 
(14.3) 
6 
(12.5) 
15 
(40.5) 
Faint/ 
hypotension 
- - 
1 
(7.7) 
5 
(7.9) 
1 
(2.1) 
6  
(16.2) 
Other 
1 
(33.3) 
- 
2 
(15.4) 
6 
(9.5) 
3 
(6.3) 
9 
(8.1) 
Able to tolerate fish in 
tinned, but not fresh, 
form (n,%) 
- 
6 
(18.8) 
1 
(7.7) 
10 
(15.9) 
7  
(14.6) 
17 
(15.3) 
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With regards to the dietary advice given to participants by healthcare professionals, across 
the whole sample the most common dietary advice to individuals allergic to shellfish was 
to avoid all species of shellfish. For individuals with a fish allergy the advice varied, with 
the Isle of Wight predominantly advising to avoid only specific fish, whereas Southampton 
and the Royal Brompton varied the advice between avoiding all fish and avoiding specific 
fish. Individuals from the Anaphylaxis Campaign reported that they were more frequently 
advised to avoid all fish. 
 
4.5 Discussion 
The aim of the current study was to investigate the phenotype of fish and shellfish allergy 
in adults in the UK. Fish and shellfish allergy is now considered as one of the most 
important food allergens affecting allergic adults in Europe. The current study provides 
important new understanding of fish and shellfish allergic adults in the UK, which will 
help to facilitate better clinical management of this type of food allergy.  
 
We have found that seafood allergic adults have high rates of allergic history (asthma, 
eczema, allergic rhinitis and hayfever) with hayfever most commonly reported. However, 
not all seafood allergic adults had other allergies. Of significance, half of the participants 
had evidence of another IgE mediated allergy, with peanut and tree nut being the most 
common co-existing allergens. It was found that the most common seafood species 
implicated in reactions were cod, prawn and mussels and interestingly co sensitisation 
between fish and shellfish was high with 58.3% affected in the clinic sample, 38.1% in 
Anaphylaxis Campaign and 46.8% overall. In addition, 30.6% of participants had evidence 
of cross reactivity, or self-reported an allergy to both crustacean and molluscan shellfish. 
In the current sample 49.5% were diagnosed with a seafood allergy after the age of 16 
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years and 43.2% before 16 years of age; the age range was 1-68 years. The common 
symptoms experienced after the ingestion of fish and shellfish were typical of IgE-
mediated food allergies; in the majority of cases there was immediate onset of symptoms 
and 64% reported having required hospitalisation following a reaction. When using a 
grading system for symptoms 31.5% were graded at the lowest level (level 1), 35.1% at 
level 2 and 30.6% at level 3. When investigating levels of reaction in this sample it was 
found that 33.3% experienced a reaction following exposure to steam/cooking vapours and 
the symptoms experienced during these reactions were severe such as facial swelling, 
wheeze and or cough and itchy rash around the mouth. In addition it was shown that 15.3% 
were able to tolerate tinned but not fresh forms of fish. In those patients where aero-
sensitisation was investigated, there was a high prevalence of co sensitisation to pollens, 
moulds and house dust mite.   
4.5.1 Review of findings in light of existing literature  
The finding of the current study that fish and shellfish allergic individuals also commonly 
have other allergic disease is in line with existing research, where it was reported in 
children with seafood allergy that there is a high level of existing atopy (Turner, Ng, 
Kemp, & Campbell, 2011). Despite the current lack of a rigorous natural history study it is 
believed that seafood allergy develops later on in life and is a persistent allergy (Daul, 
Morgan, & Lehrer, 1990) however the findings of the current study does not support this 
notion as there were similar numbers of individuals diagnosed in childhood as in 
adulthood.  
 
The finding that white fish (such as cod), prawns and mussels were the most common 
seafood species implicated in allergic reactions in our sample supports the argument that 
offending species typically reflect the local consumption and availability as these types are 
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widely consumed in the UK (EFSA NDA Panel, 2014). It is therefore important during 
consultation for the specific diet of the population to be taken into account and species-
specific tests to be carried out rather than just relying on a ‘seafood panel’ (a collection of 
common seafood species, for example in Southampton outpatient allergy clinic the seafood 
panel consists of cod, mackerel, tuna, salmon, crab, shrimp and blue mussel) as this may 
not reflect the local species which are consumed and result in a false negative diagnosis. 
 
In the current study about a third of individuals were allergic to both crustacean and 
mollusc species, confirming clinical cross-reactivity exists. Previous research in vitro has 
shown the high degree of IgE cross-sensitisation between shellfish species, which is 
believed to be due to homologies in tropomyosin found in different shellfish (Wu & 
Williams, 2004). It would therefore seem advisable for shellfish allergic individuals to 
adhere to the existing advice to avoid all shellfish species in the absence of evidence of 
tolerance (Tsabouri et al., 2012). In alignment with previous research (Sicherer, Munoz-
Furlong, & Sampson, 2004; Turner, Ng, Kemp, & Campbell, 2011; Venter & Arshad, 
2011) the current study found that a high proportion of participants (46.8%) also had 
evidence of, or self reported, co sensitisation to both fish and shellfish. This is an 
interesting finding as it is known that the two main allergens in seafood, parvalbumin and 
tropomyosin, do not cross react and so it was believed that fish allergics can safely 
consume shellfish and vice versa (Lopata & Lehrer, 2009). A possible explanation for this 
finding is the high atopic predisposition of this population however it is difficult to know 
whether it is other common allergens playing a role or whether it is a cross reacting allergy 
that is being seen; either way clarification is needed to ensure the correct dietary advice on 
avoidance is being given to firstly ensure safety and secondly to avoid the unnecessary 
elimination of a valuable dietary source.  
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The symptoms experienced by this sample are consistent with those associated with an IgE 
mediated food allergy (Skypala & Venter, 2009) and are the same as those previously 
documented in children with seafood allergy in Australia (Turner, Ng, Kemp, & Campbell, 
2011).The application of a clinical grading system of symptoms was a useful tool as it 
highlighted that the majority of reactions fall within the moderate category, and an equal 
number are experiencing severe reactions as those who experience mild reactions. This is 
an important finding as it illustrates the potential severity of a fish and shellfish allergy. 
However there are limitations of applying a grading system as this tool was designed for 
use by clinicians whereas the current study relied solely on limited data from a 
questionnaire survey. Hence, caution should be applied to the interpretation of this finding. 
A clinician applying a grading system may be more conservative due to their objective role 
and so the data in this study may overestimate the severity of reactions experienced.   
 
The current study found a higher proportion of individuals had experienced reactions to 
steam and or cooking vapours than previously reported in children, however the types of 
symptoms experienced were similar to those experienced in children, with predominantly 
upper respiratory and ocular symptoms (Turner, Ng, Kemp, & Campbell, 2011). Steam and 
cooking vapours have been recognised as a potential problem for seafood allergics (Lopata 
& Jeebhay, 2013) which has huge implications for the management and lifestyle 
restrictions for a seafood allergic, such as having to avoid restaurants, food shops or areas 
where seafood is prepared and so clinicians need to be aware of reactions to steam and 
gather the full information as part of a detailed clinical history. In addition, a small 
proportion of participants allergic to fish were found to be able to safely consume fish in a 
tinned form but not in a fresh form. This was previously reported in children (Turner, Ng, 
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Kemp, & Campbell, 2011) and reinforces the need for clinicians to advise the avoidance of 
canned fish in fish allergic individuals unless tolerance to canned fish has been 
demonstrated. This would preferably be by means of an open food challenge, as a SPT to 
canned fish and extracts indicates sensitivity but not necessarily a clinical allergy.  
 
In the current sample, there was evidence of co sensitisation to aeroallergens such as 
pollens, moulds and house dust mite. The possible link with crustacean allergy and house 
dust mite allergy has been well documented, and is believed to be due to the high sequence 
homology that shellfish tropomyosins and tropomyosin from house dust mite share (Wong, 
Huang, & Lee, 2016). However, it is difficult to draw a conclusive link between shellfish 
allergy and house dust mite allergy in the current sample as not all of the participants had 
had their aero-allergen sensitisation status examined.  
 
An interesting and unexpected secondary finding of this research was the wide variation in 
the practice and management of fish and shellfish allergy between the three allergy 
outpatient clinics in the UK, with regards to the diagnostic and investigatory tests routinely 
performed. For example, Southampton were more likely to investigate the aeroallergen 
sensitisation status of patients enabling the further investigation of cross sensitisation to 
house dust mite and shellfish allergens (tropomyosin). Whereas the Royal Brompton were 
more likely to carry out diagnostic tests to multiple species of shellfish, for example the 
different species of prawn, in order to tease out cross sensitisation within shellfish allergy. 
This had an implication on the overall findings, as it was difficult to build up a detailed 
picture of fish and shellfish allergy when not all participants had received the same 
diagnostic tests. Furthermore, as there were few food challenges carried out across the 
three allergy outpatient clinics, caution must be applied to the sample as there was only 
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evidence of one challenge proven allergy to prawn and one challenge proven allergy to 
mussels. A possible explanation for this finding could be the lack of research and clinical 
guidelines for the management of fish and shellfish allergy. It is recommended that the 
development of a clinical guideline for fish and shellfish allergy would allow for continuity 
of care across UK allergy outpatient clinics, which would allow for comparisons to be 
made in multi-centre research studies. 
4.5.2 Strengths 
The quantitative approach used in this study has provided the largest and most in depth 
investigation into adult fish and shellfish allergy to date. The findings support and extend 
the findings of previous research and the study also highlights important avenues for 
further research, such as a longevity study to investigate the resolution of fish and shellfish 
allergy, the use of DBPCFC to investigate clinical cross reactivity between and within fish 
and shellfish species, and the need for the development of clinical management guidelines 
for fish and shellfish allergy. The validity and transferability of the findings was ensured 
by a large sample and rigorous data collection tools.  
4.5.3 Limitations 
This study is not without limitations. As is common with postal questionnaires, the 
response rate was fairly low which limited the sample size (Edwards et al., 2002). A bigger 
sample size would have given increased reliability and validity to the results enabling the 
generalisation and transferability of the findings to the wider allergic population. 
Nonetheless, this study is still the largest in-depth descriptive investigation into adult 
seafood allergy to date and provides important and new insights into this type of food 
allergy. Another possible limitation of this research relates to the recruitment of 
participants. Seafood-allergic participants were selected through three NHS allergy 
outpatient clinics based in the south of England as well as a support charity. The 
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participants were mainly of White/British ethnicity and so may not be representative of the 
whole allergic population. In addition the local availability and therefore consumption of 
seafood species may have been similar. It is plausible that participants who volunteered to 
participate in this research had an interest in allergy or perceived their allergy to cause 
significant concern and so the answers may not reflect those of others with a fish and or 
shellfish allergy. Finally it could be argued that the responses of individuals recruited 
through the support charity may not be entirely accurate, as these are self-reported and 
could not be confirmed by medical notes. However, it was of value to include the support 
charity as it enabled a larger sample size. When the findings from the two samples were 
compared it was found the participants from the support charity report higher levels of 
atopy and additional FHS as well as higher levels of severe symptoms and the need for 
hospitalisation following a reaction. 
 
4.6 Conclusion and direction for future research 
In summary, this is a novel study which describes the clinical characteristics of fish and 
shellfish allergy in an adult population in the UK. It was found that 1) fish and shellfish 
allergy often co-exist, 2) seafood-allergic individuals frequently have other atopic 
conditions and 3) the clinical phenotype with regards to reactivity to vapours and tolerance 
of tinned fish varies hugely between individuals. The findings of this research raises 
several questions and so future research should look to carry out a natural history study 
which would show longevity and possible resolution of this type of allergy. In addition, the 
use of double blind food challenges would provide valuable data on cross reactivity 
between and within fish and shellfish species as well as possible tolerance to potentially 
lower allergenic forms (i.e. tinned) and species of seafood. Additionally, uniform SPT and 
serum SIgE tests to aero allergens, fish allergenic proteins and shellfish allergenic proteins 
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would map out the clinical profile of fish and shellfish allergy further. Furthermore, 
analysing prevalence data to determine whether individuals with a fish allergy are more 
likely to have shellfish allergy compared to other allergens would help to further clarify 
whether these two allergies often co-exist and if so the clinical significance of this. Finally, 
it would be imperative to carry out a multi centre trial where there was uniformity between 
centres with regards to the clinical tests being conducted in order to be able to make 
comparisons and draw conclusions. Clearer clinical guidelines are needed, such as in the 
case of cows’ milk and egg allergy (Clark et al., 2010; Fiocchi et al., 2010; Luyt et al., 
2014; Venter, Brown, Shah, Walsh, & Fox, 2013) as to date nothing exists for fish and 
shellfish allergy.  
 
The current study has added to the understanding of how fish and or shellfish allergic 
adults in the UK typically present. Now that we have some further understanding of both 
the epidemiology (prevalence) and clinical characteristics of this type of food allergy, it is 
important to look from the patient’s perspective at how this type of allergic disease impacts 
on their life. The next chapter aims to explore the associated affect of fish and or shellfish 
allergy on the health-related quality of life. 
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CHAPTER 5 
THE HEALTH RELATED QUALITY OF LIFE OF 
FISH AND SHELLFISH ALLERGIC ADULTS 
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5.1 Overview 
The overall aim of this research is to characterise and describe fish and shellfish allergy, 
previous chapters have examined the epidemiology and phenotype of disease; it is also of 
worth to investigate how disease impacts on a patients life. This chapter examines the 
health-related quality of life of adult fish and shellfish allergy sufferers in a UK sample. 
This was achieved by administering a validated disease specific health-related quality of 
life questionnaire to adults (>16 years) with a record of fish and or shellfish allergy 
attending allergy outpatient clinics at the Isle of Wight, Royal Brompton and Southampton 
NHS hospitals as well as members of an allergy patient support group (the Anaphylaxis 
Campaign). The findings are discussed in terms of their contribution to the current 
literature on health-related quality of life and FHS.  
 
5.2 Background 
Research on HRQL in FHS has to date established the impact of FHS generally on HRQL, 
relative to other diseases in children and adults as well as parents/caregivers. In addition 
extensive work has been carried out to develop reliable and valid disease-specific HRQL 
measures for different age groups (Muraro et al., 2014). Disease-specific measures to 
assess health-related quality of life have been developed under Europrevall (a multi-centre 
birth cohort study involving nine European countries, with the aim to study regional 
differences in the prevalence and risk factors of food allergies in children) and include the 
Food Allergy Quality of Life Questionnaire- Parent Form (DunnGalvin, Flokstra-de Blok, 
Burks, Dubois, & Hourihane, 2008), the Food Allergy Quality of Life Questionnaire- 
Child Form (Flokstra-de Blok et al, 2009), the Food Allergy Quality of Life Questionnaire- 
Teenager Form (Flokstra-de Blok et al, 2008), and the Food Allergy Quality of Life 
Questionnaire- Adult Form (Flokstra-de Blok et al, 2009). These instruments were 
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developed and validated in 5 stages: item generation using focus groups, expert opinion 
and literature review; item reduction using clinical impact and factor analysis; evaluation 
of internal and test-retest reliability and construct validity; evaluation of cross-cultural and 
content validity; and longitudinal validity over several time points (Flokstra-de Blok et al, 
2009; van der Velde et al., 2009). To further this body of research, it is recognised that the 
focus now needs to be on ways in which HRQL measurement can inform clinical decision-
making, health care provision and evaluation. Similarities in the responses to FHS across 
countries would suggest that policies and programmes which address HRQL issues may be 
of relevance to different populations (DunnGalvin, Dubois, Flokstra-de Blok, & 
Hourihane, 2015). Furthermore, a greater understanding of how different FHS may impact 
on HRQL provides further understanding of the specific FHS, such as fish and shellfish 
allergy, and are helpful in the development of clinician guidelines for the management of 
specific allergies as well as providing evidence-based decision making in practice.  
5.2.1 Current state of HRQL research in FHS in adults 
Another question of interest in HRQL research is the potential difference in HRQL 
between individuals attending allergy outpatient clinics and those who are members of 
allergy patient support groups. Despite a large proportion of FHS research being conducted 
with individuals recruited through consumer organisations, little comparisons have been 
made of the characteristics of such individuals with those attending allergy clinics. Indeed 
only one study has explored this in relation to food allergic individuals. In that study 
potential differences were investigated in families with food allergic children with 
significantly more differences in the number of reported food allergies, seeking of second 
opinions, adrenaline auto injector possession and sources of food allergy information were 
shown (Hu, Loblay, Ziegler, & Kemp, 2008). A possible explanation provided for why 
individuals recruited through consumer organisations report higher numbers of food 
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allergies was that families of severely allergic children may be more likely to seek support, 
as well as families reporting on the basis of self-report or sensitisation as opposed to 
challenge-proven allergy, which is known to be an overestimate of the prevalence of FHS. 
The finding that individuals from a consumer organisation are more informed from a range 
of sources suggests a sense of self-efficacy (an individual’s belief in their ability to manage 
their FHS), a phenomena which has been previously shown to be the result of having a 
membership with a consumer organisation (Trojan, 1989). Literature to date has not 
explored whether these differences are also present in adults, nor has it explored whether 
an individual’s HRQL differs as a result of membership with an allergy support group or 
attending an allergy outpatient clinic. However it has been shown that an individual’s 
FAQLQ-AF total score (i.e. FHS-related QOL) was statistically and clinically significantly 
higher (suggesting poorer HRQL) in adults who visited a doctor, suggesting that a more 
impaired HRQL could be a reason to seek medical care (i.e. ask for a referral to an allergy 
clinic) irrespective of symptom severity (Le et al., 2013) although it is challenging to know 
which way round this effect may work.  
5.2.2 Rationale for this study 
Currently there is no cure for individuals with FHS and a high degree of vigilance is 
required for the successful management of this chronic allergic disease. Specifically, fish 
and shellfish allergy may have a significant effect on anxiety and stress in the family, who 
tend to adopt more stringent dietary avoidance of seafood than they were advised, perhaps 
resulting in a greater impact on quality of life (Ng, Turner, Kemp, & Campbell, 2011). It 
has previously been suggested that fish allergy, as an isolated factor, represents a 
significant and unique contribution to the overall negative affect of FHS on HRQL (Saleh-
Langenberg et al., 2015). In addition, as fish and shellfish allergy often develops later on in 
life and is thought to be persistent throughout an individual’s life, the effect of this type of 
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food allergy on HRQL is of particular interest. Yet, to date, there is a paucity of existing 
literature on the effect of FHS on HRQL within an adult population. Understanding of the 
total effect on HRQL will enable the comparison of the impact that fish and shellfish 
allergy has on an individual with that published on other foods in the same population. It 
will also provide clinicians with a greater understanding of the emotional support needed 
from fish and shellfish allergic patients.  
 
The research to date suggests that FHS has an impact on various factors, both social, 
dietary, and psychological, which lead to a reduced HRQL. It is hypothesised that the time 
of onset of FHS may affect HRQL, as an individual who develops an allergy in childhood 
may be more accustomed to life with FHS and the management strategies needed to 
prevent adverse reactions. Hence their HRQL may be less impaired by these restrictions. In 
addition whether being a member of an allergy patient support group improves HRQL will 
be investigated, due to the increased support and reduced isolation associated with such a 
membership (Trojan, 1989).  This information will contribute to a better understanding of 
which factors are important in predicting HRQL, which can facilitate preventative and 
therapeutic interventions and help clinicians identify at risk patients. 
5.2.3 Aim and objectives 
The principle aim of this study was to investigate how fish and shellfish allergy affects the 
HRQL of adult sufferers in the UK. In particular the study investigated the following 
questions: is it worse compared with other food allergies? And what specific factors affect 
it? 
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In order to achieve this the following objectives were set: 
1. To assess the HRQL of adults with a fish and or shellfish allergy. 
2. To compare the HRQL of adults with an early onset diagnosis with those with a 
late onset diagnosis. 
3. To compare the HRQL of adults recruited through an allergy clinic with those 
recruited through a allergy support charity. 
 
5.3 Methodology 
Full details of the design, ethical approval and research governance compliance, sample 
and recruitment for this study have been reported in detail in the previous chapter (see 
sections 4.3.1, 4.3.2, 4.3.3, 4.3.4). 
5.3.1 Procedure 
Data collection commenced in October 2013 and ended in October 2014. Participants 
received a recruitment pack, which contained a study invitation, information letter, consent 
form and a validated HRQL questionnaire (Flokstra-de Blok et al, 2009) (Appendix 19). 
They were instructed to return the completed questionnaire and consent form in an 
enclosed envelope or alternatively to complete the questionnaire online using the link 
provided. Reminder letters were sent if the completed questionnaires had not been received 
within two weeks.  
 
Justification for choice of HRQL  
The Food Allergy Quality of Life Questionnaire- Adult Form (FAQLQ-AF) was first 
developed in The Netherlands and was originally written in Dutch. It is currently the only 
validated disease-specific HRQL scale for adults (≥18 years of age) with FHS, excluding 
those whose symptoms relate to oral allergy syndrome only.  The self-administered 
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measure consists of 29 items and four domains: allergen avoidance and dietary restrictions 
(AADR), emotional impact (EI), risk of accidental exposure (RAE), and food allergy-
related health (FAH). It has been translated into English (using the guidelines of the WHO) 
and validated in the US and a number of European countries. In the US an online version 
was found to be feasible, consistent and valid (DunnGalvin, Dubois, Flokstra-de Blok, & 
Hourihane, 2015; N.J. Goossens et al., 2011). Assessment of this tool has supported its 
reliability; it has demonstrated excellent internal consistency (Cronbach’s a=0.97) 
(Flokstra-de Blok et al, 2009) and test-retest reliability (van der Velde et al., 2009). There 
is also evidence to support the instrument’s validity; it is able to discriminate between 
patients who differ in severity of symptoms, as well as the number of food allergies and a 
good correlation between the FAQLQ-AF and the Food Allergy Independent Measure has 
been demonstrated (Flokstra-de Blok et al, 2009). 
5.3.2 Data analysis 
Data cleaning and management 
The FAQL-AF questionnaires were scored and coded according to the published 
guidelines by the original authors (Flokstra-de Blok et al, 2009). Each question is answered 
on a 7-point scale (0 to 6) and was recoded as 1 to 7. Total FAQL scores and domain 
scores were calculated by dividing the sum of completed items by the number of 
completed items to give a mean score, where 1 equals no impairment and 7 equals 
maximum impairment. The questionnaire responses were only analysed when 80% or 
more had been completed.  
 
All data was double entered on SPSS (IBM SPSS Statistics for Mactintosh, Version 22.0). 
Online questionnaire responses were directly exported to SPSS from Bristol Online 
Surveys. Missing values were computed as -100. The data set was double checked for any 
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outliers and errors. A coding logbook was maintained to ensure consistency during the data 
cleaning and coding stage. 
 
Data analysis 
In order to evaluate the difference in HRQL sub domain scores a multivariate analysis of 
variance (MANOVA) was conducted comparing the HRQL scores of clinic participants 
and participants recruited through a support group. The mean HRQL score was not 
incorporated into the MANOVA because an assumption of MANOVA is that the 
dependent variables are not too highly correlated (mulicollinearity). The mean HRQL 
score is a composite of each subscale score and so it can be expected to correlate highly 
with each of these. Hence a t-test was conducted to compare the total HRQL scores of the 
two groups. Preliminary assumption testing was conducted to check for sample size, 
normality, linearity, univariate and multivariate outliers, homogeneity of variance-
covariance matrices, and multicollinearity. 
 
To make comparisons between the HRQL of fish and or shellfish allergic individuals in 
this sample and adults with ‘any food’ allergy, the sample mean and variance was 
compared with previously reported European data on adult HRQL collected using the 
FAQLQ-AF (N. J. Goossens et al., 2014) by computing t (independent samples t-test). 
This was done using the mean, standard deviation and sample size and a Welch test 
(employed when there is a difference in sample sizes). Where the study did not present the 
standard deviation, this was calculated from the confidence intervals using the following 
equation: SD=√N x (upper limit – lower limit) / 3.92 (Higgins & Weeks, 2011). European 
data was used as there are currently no published studies reporting HRQL based on the 
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FAQLQ-AF in adults in the UK, and so Europe is the second best comparison due to the 
similar allergy labeling laws and practices that are in place.  
 
As well as testing for statistical significance, the minimal clinically important difference 
(MCID) was also tested for. MCID defines the smallest difference in score perceived as 
beneficial to patients which would mandate a change in patient’s management (Greenhawt, 
2014). The specific MCID of the FAQLQ-AF measure still needs to be estimated through 
means of a longitudinal study, and so in its absence, a value of 0.5 will be used. This value 
has been described previously (Jaeschke, Singer, & Guyatt, 1989) for use on a 7-point 
HRQL questionnaire instrument and is commonly used, including by other studies 
examining the HRQL of food allergic individuals (B.M. Flokstra-de Blok et al., 2010).  
 
5.4 Results 
5.4.1 Description of sample 
In total 111 participants took part in the study, 48 from NHS allergy outpatient clinics 
(35% response rate) and 63 from the Anaphylaxis Campaign (17% response rate). 
Completed HRQL measures were available for analysis from 109 participants (98.2%). 
Key allergy characteristics of the participants are detailed in Table 5.1. Briefly, fish, 
crustacean and mollusc allergy was present in 54.1%, 63.1% and 34.2% of the total 
population respectively. About half of the participants reported an allergy to both fish and 
shellfish and 30.6% reported to react to crustacean and molluscan shellfish.  
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Table 5.1 Key characteristics of participants with fish/shellfish allergy by group 
 Isle of 
Wight 
(n=3) 
Southampton 
(n=32) 
Royal 
Brompton 
(n=13) 
Anaphylaxis 
Campaign 
(n=63) 
Total 
Clinic 
(n=48) 
Total 
All 
(n=111) 
Gender (n,%) 
Male 
 
 
3  
(100) 
 
16  
(50.0) 
 
4  
(30.8) 
 
48  
(76.2) 
 
23 
(47.9) 
 
71 
(64.0) 
Female 0  
(0) 
14  
(43.8) 
9  
(69.2) 
13  
(20.6) 
23 
(47.9) 
36 
(32.4) 
Fish Allergy (n, %) 
 
2  
(66.6) 
17  
(53.1) 
2  
(15.4) 
39  
(61.9) 
21 
(43.8) 
60 
(54.1) 
Crustacean Allergy 
(n, %) 
2  
(66.6) 
26  
(81.3) 
11  
(84.6) 
31  
(49.2) 
39 
(81.3) 
70 
(63.1) 
Mollusc Allergy (n, 
%) 
1  
(33.3) 
15  
(46.9) 
5  
(38.5) 
17  
(27.0) 
21 
(43.8) 
38 
(34.2) 
Fish AND Shellfish 
Allergy (n, %) 
2  
(66.6) 
20  
(62.5) 
6  
(46.2) 
24  
(38.1) 
28 
(58.3) 
52 
(46.8) 
Crustacean AND 
Mollusc Allergy (n,%) 
1 
(33.3) 
14 
(43.8) 
5 
(38.5) 
14 
(22.2) 
20 
(41.7) 
34 
(30.6%) 
 
5.4.2 Objective one: Assess the HRQL of adults with a fish and or shellfish allergy 
The scores in the four domains of the FAQLQ-AF are shown in Figure 5.1 by group, the 
mean score for individual questions are grouped by domain and presented in Figures 5.2-
5.5. For all participants, the highest score (lowest HRQL) was found in the domain 
emotional impact (M= 4.97, SD= 1.59) and the lowest score (highest HRQL) was found in 
the domain food allergy related health (M= 4.32, SD= 1.65). The mean total score was 
calculated as 4.78 (SD= 1.50). 
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Figure 5.1 Domains of the FAQLQ-AF (mean score) in fish/shellfish allergic adults 
by group 
The FAQLQ-AF scores were based on a 7-point scale, where 1 equates to the best possible 
score (highest HRQL). The questions were divided into four domains: Allergen avoidance 
and dietary restrictions (AADR), Emotional impact (EI), Risk of accidental exposure 
(RAE), and Food allergy related health (FAH). Based on the results of the four domains, 
the overall HRQL was calculated. 
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Figure 5.2 FAH domain questions mean score by group 
 
 
Figure 5.3 RAE domain questions mean score by group 
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Figure 5.4 EI domain questions mean score by group 
 
 
Figure 5.5 AADR domain questions mean score by group 
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When these results are compared to previously reported data collected using the same 
FAQLQ-AF measure with adults with FHS, no statistically or clinically significant 
difference was found compared to Dutch adults (van der Velde et al., 2009) allergic to a 
range of foods (peanuts, nuts, milk, eggs, wheat, soy, sesame, fish, shellfish, celery, fruit, 
vegetables and ‘others’) (mean=4.41) t(59)= 1.28, p= 0.20, or compared to Swedish adults 
(Jansson et al., 2013) with an allergy to ‘staple foods’ ( cow’s milk, hen’s egg or wheat) 
(mean=4.85) t(185)= 0.37, p= 0.71. Interestingly, compared to a large European study of 
425 participants with FHS which was carried out across 8 countries (Iceland, Netherlands, 
Poland, France, Spain, Italy, Greece, Sweden) (N. J. Goossens et al., 2014), a statistically 
and clinically significant difference was found, with fish and shellfish adults from the 
current study reporting higher total FAQLQ-AF scores (poorer HRQL) than individuals 
with ‘any’ food allergy, (mean=3.71) t(116)= 7.31, p=>0.001. 
5.4.3 Objective two: Compare the HRQL of adults with an early onset diagnosis with 
those with a late onset diagnosis. 
An independent samples t-test was conducted which used the total HRQL scores as the 
dependent variable and whether the participant developed the allergy early (0-15 years) or 
late (≥16 years) as the independent variables. In total, 47 (43.1%) individuals were 
categorised as ‘early onset’ and 54 (49.5%) were categorised as ‘late onset’. Homogeneity 
of variance was assumed and there was no significant difference found in the total HRQL 
for participants with an early onset (M=4.8, SD= 1.41) or late onset (M= 4.75, SD= 1.63) 
(t(99)=.168, p=.867).  
5.4.4 Objective three: Compare the HRQL of adults recruited through a clinic with those 
recruited through an allergy support charity 
A one-way between-group multivariate analysis of variance was performed to investigate 
differences in HRQL sub domain scores between the two samples (allergy outpatient clinic 
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and Anaphylaxis Campaign). Four dependent variables were used: allergen avoidance and 
dietary restrictions score (AADR), emotional impact score (EI), risk of accidental exposure 
score (RAE), and food allergy related health score (FAH). An independent samples t-test 
was then conducted using the total HRQL score as the dependent variable and whether the 
participant was recruited via an allergy outpatient clinic or allergy support group as the 
independent variables. 
 
Results of the assumption testing prior to MANOVA 
Preliminary assumption testing was conducted and the following results were found. With 
regards to sample size, it is necessary to have more cases in each cell than there are 
dependent variables. There were a total of eight cells (two levels for independent variable: 
clinic sample/support group sample, and four dependent variables for each) and there were 
more than the required number of cases per cell (see MANOVA output). Kolmogorov-
Smirnov statistics were produced to check for univariate normality. These were significant 
for EI score, RAE score and FAH score, indicating the violation of the assumption of 
normality; this however is common in larger sample sizes and so no transformation was 
performed on the data and the original data was used in the subsequent analysis 
(Tabachnick & Fidell, 2013). The presence of univariate outliers was checked for each of 
the dependent variables and Q-Q plots revealed that there were no significant outliers. 
Mahalanobis distances were calculated in order to detect multivariate outliers. Using a 
criterion of four degrees of freedom and p<0.001, the critical value of Chi square (and 
therefore of Mahalanobis distance) was 18.47. One individual had a score that exceeded 
the critical value (ID=2, score=25.096); as there is only one individual this person was left 
in the data file. To check for linearity a matrix of scatterplots between each pair of 
variables was conducted separately for each group, which showed no obvious evidence of 
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non-linearity. A MANOVA works best when the dependent variables are moderately 
correlated and so checks for multicollinearity correlations were run which showed some 
high correlations (0.8 or above). Box’s test of equality of covariance matrices showed that 
the data does not violate the assumption of homogeneity of variance-covariance matrices 
(p=0.104) however Levene’s test of equality of error variance indicated that the 
assumption of equality of variance is violated for RAE score (p=0.004). With these results 
in mind, Pillai’s Trace statistic will be reported as it is more robust and therefore controls 
for the violation of some assumptions (Tabachnick & Fidell, 2013).  
 
Results of the MANOVA: Comparing sub-domain scores 
There was no statistically significant difference between participants recruited via an 
allergy outpatient clinic and those recruited from an allergy support group on the combined 
dependent variables (AADR score, EI score, RAE score, and FAH score), F (4,104) = 2.17, 
p=0.077; Pillai’s Trace= 0.077; partial eta squared=0.08. 
 
However, a clinically significant difference was found between the mean scores from those 
recruited through an allergy clinic and support group in the Allergen avoidance and dietary 
restrictions (4.47 vs. 5.12) and risk of accidental exposure (4.41 vs. 5.01) domains (Table 
5.2). This finding suggests individuals recruited through the support group have poorer 
HRQL with respect to these two domains.  
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Table 5.2 Mean scores and standard deviations for domains of the FAQLQ-AF 
Group AADR EI RAE FAH 
M SD M SD M SD M SD 
Allergy Clinic 4.47 1.71 4.84 1.77 4.41 1.90 4.22 1.76 
Support 
Group 
5.12 1.47 5.06 1.45 5.01 1.49 4.39 1.57 
 
An independent-samples t-test was conducted using the total HRQL score as the dependent 
variable and whether the participant was recruited via an allergy outpatient clinic or allergy 
support group as the independent variables. For the total HRQL score, Levene’s test was 
not significant and homogeneity of variance was assumed. There was no significant 
difference in total HRQL scores for participants recruited through a clinic (M=4.49, 
SD=1.61) compared with an allergy support group (M=4.99, SD=1.37) (t(107)= -1.765, 
p=0.08). The magnitude of the differences in the means (mean difference= -.51, 95% CI -
1.07 to 0.06) was large (eta squared= -.16). In addition, the difference found in means 
suggests a clinically significant difference in the total HRQL score, with individuals from a 
support group reporting a clinically relevant poorer HRQL than individuals from an allergy 
outpatient clinic.  
 
5.5 Discussion 
The aim of the current study was to investigate how fish and shellfish allergy affects an 
individual’s HRQL. Individuals with a fish and or shellfish allergy have to strictly manage 
their everyday lives in order to prevent a reaction occurring and consequently may 
experience impaired quality of life. Understanding this effect is important to inform the 
healthcare provision, policy and clinical practice for fish and shellfish allergy more 
generally. Since fish and shellfish allergy are often persistent and develop later on in life, it 
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was hypothesised that there may be a negative impact on HRQL, and of interest was how 
this may have differed from an individual excluding other allergens from their diet. This 
study administered the validated FAQLQ-AF to investigate the HRQL of adults with fish 
and or shellfish allergy in the UK.  
 
There were three objectives which were addressed in the current study. With regards to 
objective one, we found that HRQL is negatively impaired in individuals with a fish and or 
shellfish allergy, with factors associated with emotional impact (i.e. feeling of less control 
when eating out, frightened of an allergic reaction, feeling a nuisance due to FHS, feelings 
of discouragement and apprehension) having the largest negative effect on HRQL. 
Compared to published data (Jansson et al., 2013; van der Velde et al., 2009) we found no 
significant difference between the HRQL scores previously reported in Dutch adults 
allergic to a range of foods as well as Swedish adults allergic to ‘staple foods’. The current 
study did however find a significantly higher total HRQL score for fish and/ or shellfish 
allergic individuals when compared to a large European study of adults allergic to a range 
of foods (N. J. Goossens et al., 2014). With regards to objective two, there was no 
difference in total score found between those individuals with an early onset diagnosis and 
those with a late onset diagnosis, suggesting that the age an individual develops an allergy 
has no effect on their HRQL. Finally, with regards to objective three, we found a clinically 
significant difference between those individuals recruited through a NHS allergy outpatient 
clinic and those from an allergy support group, with individuals from an allergy support 
group indicating a poorer total HRQL as well as a greater negative impairment in factors 
related to allergen avoidance and dietary restrictions and the risk of accidental exposure. 
However, this difference was not statistically significant. 
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5.5.1 Review of findings in light of existing literature 
There are only a few published studies in adults that utilise a disease-specific validated 
questionnaire for food allergy, and no studies to date have explored the HRQL of fish and 
shellfish allergy specifically and so comparisons are limited. Adults with a peanut allergy 
have previously been shown to experience less familial/social disruption, less personal 
strain and less financial burden than adults with a rheumatalogical disease but were less 
effective in developing coping skills (Primeau et al., 2000). The study did show a 
disruption in their quality of life, similar to the results of the current study but as a disease-
specific measure was not utilised in the previous study it is not possible to compare this 
findings to see if there is a difference between peanut allergy and seafood allergy sufferers.  
 
A more comparable study is that of Jansson et al. (2013), who similarly used the FAQLQ-
AF to investigate HRQL in adults allergic to ‘staple foods’. They found the mean score to 
be 4.85; this is similar to the overall mean score found in the current study (4.78) which 
suggests fish and or shellfish allergy affects quality of life in a similar way as an allergy to 
staple foods. Of difference however was the finding that allergen avoidance and dietary 
restrictions had the largest negative effect on HRQL, whereas in the current study 
emotional impact overall had the largest negative effect. This is an interesting finding as it 
suggests that fish and shellfish allergy restrictions on the diet are not as problematic as 
restricting ‘staple foods’ which are ingredients in many food products, however the feeling 
of a lack of control and fear of an allergic reaction is of greater concern. One possible 
explanation for this could be because in contrast with many food allergies, for those 
allergic to fish and or shellfish there is the possibility that a reaction can be caused by the 
inhalation of steam and or cooking vapours (Lopata & Jeebhay, 2013). It is recommended 
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that clinicians are aware of this limitation for fish and shellfish allergic patients, and 
provide support and advice on how to manage this risk.  
 
Saleh-Langenberg et al. (2015) showed that adults with a fish or milk allergy experienced a 
more impaired HRQL compared to other food allergic individuals and the current study 
certainly supports this notion as the HRQL was more impaired than adults with an allergy 
to ‘any food’ (N. J. Goossens et al., 2014). Further, this shows how HRQL can be affected 
by the type of food allergy and so this should be an important consideration when planning 
an individual’s health care following the diagnosis of food allergy as there are likely 
differing needs, risks and patient reported outcomes dependent on the type of food allergy.  
 
There are a number of plausible explanations for the finding that individuals recruited 
through an allergy support group reported a poorer HRQL than those recruited through an 
allergy outpatient clinic, such as those individuals more severely affected by their allergies 
may be more likely to seek support, or the lack of medical support from a specialist clinic 
may increase an individual’s anxiety. However it is not possible to conclusively say which 
factors explain this finding as more likely it is possibly due to a combination of factors or 
individual differences. Of interest are the similar findings from a study in America which 
compared the quality of life of caregivers self reporting a child with food allergy (recruited 
via a food advocacy group) and caregivers with children followed up at a food allergy 
referral centre (Ward & Greenhawt, 2016). It was shown that the caregivers from the 
referral clinic had a lower (better) mean total QoL score, furthermore having a peanut or 
tree nut allergic child (compared with milk or egg) was associated with a lower QoL score. 
This furthers the findings of the current study, which suggest that the burden of FHS is 
disproportionate. This finding warrants further exploration by means of a qualitative study 
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whereby the overall aim could be to examine in detail the positives and negatives 
associated with being a member of an allergy support group for fish and shellfish allergic 
patients, in addition to those with other food allergies.  
5.5.2 Strengths 
The current study’s main strength is that it is the first to look at the specific effect that fish 
and shellfish allergy has on HRQL in a large adult sample, where to date there is limited 
existing HRQL research. Furthermore this study used a disease-specific HRQL 
questionnaire which has been previously validated and shown to be an invaluable tool in 
research which looks to give an insight into the quality of life of adults with FHS 
(Flokstra-de Blok et al, 2009). The inclusion of individuals from both an allergy outpatient 
clinic and allergy support group is a strength of the current research as it reflects the full 
breadth of the population allergic to fish and shellfish. It is known that individuals 
recruited from these two groups have important differences and so the recruitment from 
one or the other would have implicated the generalisability of the research (Hu, Loblay, 
Ziegler, & Kemp, 2008). 
5.5.3 Limitations  
The current study is not without limitations. Firstly, the validated HRQL measure which 
was used was primarily designed and developed for the use of adults over the age of 18 
years, however in the current cohort participants were recruited from the age of 16 years 
and over as this is the age that they are referred to the adult allergy services in the NHS. 
Therefore it could be argued that the validity and reliability of the tool for those individuals 
aged 16-18 years is not known. However, as there was only one individual who was 
recruited under the age of 18 years it is not thought that this will have impacted the overall 
findings of the study. Secondly, the FAQLQ-AF was developed with an IgE-mediated 
allergy focus (clinician diagnosed). Fish and shellfish allergy is often typical of an IgE-
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mediated allergy and rarely implicated in non-IgE mediated reactions (Skypala & Venter, 
2009), however caution should be applied for those individuals who were recruited via the 
Anaphylaxis Campaign as these answers were self-reported and therefore the possibility of 
a non-IgE mediated reaction cannot be entirely ruled out. In addition, the inclusion of ‘self-
reported’ fish and/ or shellfish allergy may skew the results as they may not be 
representative of a ‘true’ clinician diagnosed allergy, however it has been previously 
shown, in a paediatric population, that there is no difference in HRQL scores between 
proven FHS and perceived FHS (Venter et al., 2015) and so this limitation should not 
affect the findings. Thirdly, it is not possible to conclusively say that the HRQL scores 
were not affected by the presence of other food allergies or allergic disease. Finally, a 
limitation of the current study is the potential sample bias resulting from the volunteer 
completion of the questionnaire. The overall response rate for the study was 22% and so it 
could be argued that those individuals choosing to respond felt that their condition had a 
significant negative impact on their life. Although this is likely to affect all groups equally, 
including the data collected by other studies, and so the comparison findings are likely to 
hold regardless of this fact.  
 
5.6 Conclusion and direction for future research 
In summary, this is a novel study which reports the associated HRQL of fish and shellfish 
allergic adults in the UK. The study findings suggest that the impairment of fish and 
shellfish allergy on HRQL may be greater than that of adults with FHS generally. 
Moreover, in the current sample, an individual’s HRQL was found to be negatively 
associated with being a member of an allergy support organisation. Future research is 
needed to assess the HRQL of individuals with other food allergies, using the same HRQL 
measure. This would then allow for further comparisons to be made, with the overall aim 
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of implementing the findings into healthcare provision and clinical decision making to 
allow those ‘at risk’ individuals to be targeted for interventions to minimise the burden of 
fish and shellfish allergy on their quality of life. The results of the current study have 
contributed to the primary aim of this thesis, by providing information on the burden of 
fish and shellfish allergy from the perspective of the patient. The following chapter will 
focus on the consolidation of the research findings and outline the possible implications of 
this research.  
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CHAPTER 6 
DISCUSSION OF FINDINGS FROM THIS PHD 
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6.1 Overview 
This chapter collates the findings of the programme of research. The chapter begins with a 
brief summary of the rationale and aims for this research. This is followed by a summary 
of the main findings of the three studies in relation to the existing body of literature and 
then the strengths and limitations of the research are discussed. In conclusion, the 
implications of the research findings are discussed and future research needs are outlined.  
 
6.2 Rationale and aims for this research 
As little is currently understood about fish and shellfish allergy, in particular in adults, 
compared to other common allergens such as milk, egg and peanut, the rationale for this 
thesis was built around the need for a more comprehensive understanding of fish and 
shellfish allergy, so that the clinical and research community can diagnosed and manage it 
more effectively. The main aim of this research was therefore to characterise and describe 
fish and shellfish allergy, in relation to the prevalence, phenotype and affect on an 
individual’s health-related quality of life. 
 
To address this aim, three studies were undertaken using a quantitative methodology 
approach and the following research aims and objectives were addressed:  
 Perform a systematic review of published and unpublished data related to the 
prevalence of fish, crustacean and mollusc allergy. 
 Describe the clinical characteristics of fish and or shellfish allergic adults in a UK 
sample. This was achieved by addressing the following objectives: describe the 
atopic status, history of allergic disease and characteristics of allergic participants; 
describe the prevalence of fish, crustacean and mollusc allergy and the common 
symptoms experienced in this sample; examine cross sensitivity within fish and 
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shellfish species and co-existing allergy between the two types of seafood; examine 
other co-existing food and aeroallergen sensitivities; examine the level of tolerance 
to tinned fish and shellfish and the reactivity to airborne traces; and describe the 
dietary advice and medical management strategies adopted by this sample.  
 Investigate how fish and shellfish allergy affects the HRQL of adult sufferers in the 
UK. This was achieved by addressing the following objectives: assess the HRQL of 
adults with a fish and or shellfish allergy; compare the HRQL of adults with an 
early onset diagnosis with those with a late onset diagnosis; compare the HRQL of 
adults recruited through an allergy outpatient clinic with those recruited through an 
allergy support charity. 
 
6.3 Summary and implications of findings 
6.3.1 Findings in relation to the epidemiology of fish and shellfish allergy 
As previously discussed in detail in the literature review chapter of this thesis, fish and 
shellfish allergy constitutes a major health concern, with the risk of severe and potentially 
fatal reactions high (Pumphrey, 2000; Sampson, 2003). Even though fish and shellfish 
allergy are considered major food allergens (Boyce et al., 2010; Burks et al., 2012), the 
population prevalence is difficult to comprehend due to differences in the diagnostic 
methods employed in studies and also due to the vagueness in reporting what species are 
implicated in reported adverse reactions, as well as the type of food allergy (IgE-mediated 
or non-IgE mediated). It is thought that the prevalence of fish and shellfish allergy may 
vary according to factors such as age and geographical location (Ng, Turner, Kemp, & 
Campbell, 2011), and it is vitally important for both the clinical and research community to 
further understand these differences, in order to identify potential risk factors.  
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The results of the current systematic review found fish allergy prevalence rates to be 0-7% 
according to self-diagnosed, 0-2.9% according to sensitisation, and 0-0.3% according to 
food-challenges. Crustacean allergy prevalence rates were found to be 0.1-5.5% according 
to self-diagnosed, 0-10.3% according to sensitisation, and 0-0.9% according to food-
challenges. Mollusc allergy prevalence rates were found to be 0.4-1.5% according to self-
diagnosed, 0% according to sensitisation, and 0.1% according to food challenge. The 
reported prevalence of fish allergy was marginally higher in children than the prevalence in 
adults worldwide; this conflicts the current notion that adults are more affected than 
children. However, caution needs to be applied to this finding as there was a far greater 
number of prevalence studies which looked at children than adults and few studies which 
confirmed prevalence rates based on food-challenges and so further research is required in 
order to investigate this further. Interestingly, with regards to shellfish allergy, the reported 
prevalence in European countries was higher in children than adults, but based on 
challenge-proven data it was shown that the prevalence of crustacean allergy was actually 
higher in adults than children. This further emphasizes the need for rigorous methodology 
prevalence studies, which adopt the gold standard diagnosis for food allergy (food 
challenges). With regards to geographical differences in prevalence rates, the current 
review found fish allergy to be similar worldwide but shellfish allergy was found to be 
more prevalent in the South East Asian region. This has been previously suggested (Ng, 
Turner, Kemp, & Campbell, 2011) and could be caused by dietary exposure, but also the 
possible cross sensitisation between house dust mite and shellfish allergens and how this 
presents clinically warrants further investigation.  
 
The findings of the systematic review on the prevalence of fish and shellfish allergy 
highlights the difficulty of the comprehension of the true prevalence of fish and shellfish 
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allergy worldwide, with the majority of existing prevalence data from children, and so 
even though it is believed that adults are more affected it is difficult to say this 
conclusively. Therefore clinicians are advised to be aware of the occurrence of this type of 
food allergy in children. Fish and shellfish allergy appears to be predominately IgE-
mediated with only case reports about the prevalence of non-IgE mediated seafood 
allergies i.e. FPIES however clinicians are recommended to be aware of the possible 
prevalence, in particular in adults, of FPIES.  
 
The main limitation of the systematic review undertaken in this research was in relation to 
the included studies themselves. There was a considerable lack of challenge-proven 
prevalence data outside of Europe which made comparisons extremely difficult. The need 
for this type of data is critical if we are ever to truly understand and identify the potential 
differences in prevalence across countries, thus giving an indication of how factors such as 
diet and the timing of introduction of food impact on the prevalence of fish and shellfish 
allergy. Such data would be able to inform prevention policies and guidelines. Despite 
mollusc allergy being considered a major allergen, there was a lack of studies which 
looked at mollusc allergy prevalence and so there is a gap in our understanding of how 
common and problematic this type of shellfish allergy is, and indeed whether it is even a 
major allergen.  
 
In conclusion, it was found that there was a poor quality of methodology of prevalence 
studies, limiting our understanding of the epidemiology of fish and shellfish allergy. 
However, the current systematic review did add and improve on existing reviews (Nwaru 
et al., 2014; Rona et al., 2007) by providing a more comprehensive and up to date estimate 
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of fish and shellfish allergy. Future prevalence research is needed which performs high 
quality, rigorous food-challenges to confirm prevalence rates.  
6.3.2 Findings in relation to the clinical characteristics of fish and shellfish allergy  
As described fully throughout the literature review, there is currently a lack of research 
which has sought to describe fish and shellfish allergy in detail. Indeed, there is only one 
published comparable study which had a similar primary aim to this study, but the sample 
was a paediatric population (Turner, Ng, Kemp, & Campbell, 2011), with most research in 
this field instead focusing on identifying allergens and cross sensitisation (predominately 
in vitro studies) across species. The study detailed in chapter four of this thesis has 
provided an important new comprehension of the phenotype of fish and shellfish allergy, 
which will help to improve the clinical management of fish and shellfish allergy.  
 
The results of the current research found fish and shellfish allergy to be a complex allergic 
disease. Fish and shellfish allergic adults commonly have co-existing allergic disease, co-
existing IgE mediated food allergy (with peanut and tree nut being the most common), and 
co sensitisation to pollens, moulds and house dust mite were seen. It was not possible to 
examine fully the possible cross reactivity between shellfish allergy and house dust mite as 
this was not the primary aim of the current study and so not all shellfish allergic 
participants had sensitisation tests to house dust mite. More importantly, data was only 
available on those who had a positive test and so the number of negative tests are not 
known. However it is an important observation to note, and as previous research suggests 
(Thomas, 2010; Wong, Huang, & Lee2016) requires further investigation. The symptoms 
experienced by this sample were typical of other IgE mediated reactions, however the 
experience of severe reactions following the inhalation of vapours was also commonplace. 
Furthermore, as well as the expected cross reactions seen between fish species and 
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shellfish species (including between crustaceans and mollusc), the current research also 
found a high prevalence of co sensitisation between fish and shellfish species. This is an 
interesting finding which has been noted before (Venter & Arshad, 2011), however the 
cause of this is unknown as it is not believed that the allergenic proteins are the same or 
have similar structures, based on our current knowledge. A far more plausible explanation 
of this finding is that fish and shellfish allergic individuals represent a highly atopic 
population and so there is an atopic predisposition to having co-existing sensitisation. 
Furthermore, the possibility of cross contamination from fish markets and fish counters 
should not be ruled out as a possible cause of these reactions. As a proportion of the 
participants were able to tolerate tinned, but not fresh forms of fish, it may be that 
individuals can consume safely some forms of seafood which are less allergenic. Results 
were in line with the notion that the type of species triggering allergic reactions is 
reflective of both the local consumption and availability of seafood; in this UK sample cod, 
prawn and mussels were the most common species implicated in reactions. The current 
sample found equal number of participants who were diagnosed with a fish and or shellfish 
allergy in childhood as in adulthood. This finding is in contrast with the common belief 
that this type of food allergy is more prevalent in adulthood (Lopata, O'hehir, & Lehrer, 
2010), however the results of the previous chapter also suggest that the prevalence may be 
fairly equal.  
 
There are several clinical implications which arise from the findings of the current study. 
Firstly, due to the commonly reported co-existing allergy to fish and shellfish, it is 
important for clinicians to advise patients of this relationship following the diagnosis of 
either a fish or shellfish allergy, however caution should be applied, as the unnecessary 
exclusion of allergens from the diet is not desirable. In the case of a proven allergy to 
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shellfish, it is recommended that clinicians continue to adhere to the existing advice to 
avoid all shellfish species (crustaceans and mollusc) in the absence of challenge-proven 
tolerance. Secondly, as the occurrence of a fish and or shellfish allergy during childhood 
was equal to the appearance in adulthood, it is recommended that clinicians are aware of 
this as a potential childhood allergy. Thirdly, the findings of the current study suggest that 
there is variability in the tolerance to tinned fish and so it is recommended for the possible 
tolerance to be further investigated in a clinical setting. The sensitivity to vapours and 
steam should be managed effectively, with individuals being made aware of the possible 
risk and clinicians being aware of the implication for the successful avoidance of adverse 
reactions and potential affect this may have on an individuals HRQL and anxiety. Fourthly, 
there is a need for the local diet and availability of fish and shellfish species to be taken 
into account during clinical consultations as these have been shown to be reflective in the 
implicating species causing adverse reactions. Finally, the main implication arising from 
the current study is the need for management guidelines for fish and shellfish allergy; there 
was a marked difference between the diagnostic tests used in clinical practice and the 
nutritional and avoidance advice given between the three allergy outpatient clinics 
included in this research and so evidence-based guidelines would allow the management of 
fish and shellfish allergy to be formalized and consistent.  
 
The main limitation of this cross sectional study was the inconsistency with the clinical 
diagnostic tests performed on the participants recruited from allergy outpatient clinics 
which made it difficult to draw conclusive findings with regards to cross sensitisation and 
co sensitisation. Further research which combined sensitisation tests and food challenges 
as methods of diagnosis would allow for cross reactivity and co-existing allergies to be 
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investigated further. In addition, a larger sample size, involving more allergy outpatient 
clinics would have allowed for more detailed statistical analysis.  
6.3.3 Findings in relation to the health-related quality of life of fish and shellfish allergy  
Data on the health-related quality of life of allergic individuals is able to inform health care 
provision and evidence-based decision making in clinical practice (DunnGalvin, Dubois, 
Flokstra-de Blok, & Hourihane, 2015) and provides an in depth comprehension of a 
chronic condition by examining patient outcomes. In addition, previous research has 
identified fish and shellfish allergy to be a particular contributing factor to the negative 
affect of FHS upon health-related quality of life (Saleh-Langenberg et al., 2015), possibly 
due to longevity of the condition, and so further investigation was needed to explore this 
finding further. As there are no previously reported studies which measure the HRQL of 
fish and shellfish allergic individuals, per se, comparisons are limited.   
 
The results of the current study found the HRQL of fish and or shellfish sufferers to be 
negatively impaired, more so than that reported by a previous study of individuals allergic 
to a range of foods. The lowest HRQL was found in the emotional domain impact 
suggesting that fear and anxiety are factors of importance in fish and shellfish allergy. The 
age of diagnosis was found to have no effect on an individual’s HRQL score, but 
membership of an allergy support group appeared to be linked to a poorer quality of life. 
This finding is interesting and needs further investigation as there have been found to be 
many other benefits also associated with the membership of a patient support group, such 
as good adherence in adolescents with a food allergy (Jones et al., 2015). The above 
findings suggest that the burden of allergic disease, namely food allergy, is 
disproportionate, with some individuals experiencing poorer health-related quality of life 
than others. This is an important notion for clinicians and policy makers to be aware of as 
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it indicates the great need for personal and tailored medical care following the diagnosis of 
a fish and or shellfish allergy.  
 
As patient outcomes such as HRQL has been shown to be linked to patient adherence, and 
currently the only ‘cure’ for fish and shellfish allergy is avoidance of allergens and the 
prompt treatment of allergic reactions, it is vital for clinicians to tackle issues linked to 
HRQL in a clinical setting in order to improve the overall management of allergic disease. 
Further, clinician’s knowledge of factors that contribute to poorer HRQL may enable them 
to identify ‘at risk’ groups to target interventions at.   
 
The main limitation of this research study was the lack of comparison with other food 
allergens. Instead, comparisons have relied on published literature, with varying 
methodologies. Furthermore, as over half of participants also had other co-existing 
allergies it cannot be conclusively said that the reported affect on their HRQL is solely 
caused by their fish and or shellfish allergy. However, it was made clear to the participants 
before the completion of the HRQL measure that they should answer the questions based 
on the impact of their fish and or shellfish allergy specifically. This may be difficult to 
answer in isolation because the restrictions and feelings may cross over when an individual 
is allergic to multiple allergens.  
 
6.4 Methodological consideration 
6.4.1 Strengths 
This thesis has a number of key strengths. Firstly, the use of a worldwide systematic 
review methodology, which is rated at the top of the ‘hierarchy of evidence’ (Greenhalgh, 
2014), allowed for a non-biased, accurate account of the prevalence of fish and shellfish 
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allergy worldwide. The detailed search strategy, with no restrictions placed on country and 
age, and which actively searched for the different types of fish and shellfish species, 
resulted in the inclusion of all relevant research studies and so the findings of the study can 
be argued to be robust. Secondly, the current study is to date the largest adult sample, 
which investigates the clinical characteristics of fish and shellfish allergy. The results of 
this study have provided several new insights into this type of food allergy, which will aid 
the effective management and treatment of fish and shellfish allergy. Thirdly, the use of a 
pre-validated disease-specific health-related quality of life questionnaire enabled the 
validity and reliability of the study results and has enabled comparisons with previously 
published data.  
6.4.2 Limitations 
There are also some limitations to the research which are noteworthy and of important 
consideration when interpreting the study findings. Firstly, a recruitment bias may exist as 
those individuals with an interest in health or food allergy, or those who perceive their 
allergy to be of significance and concern may have been more likely to take part. 
Unfortunately it was not possible to follow up the non-responders and so there is no data 
available to compare the two. Secondly, the three NHS allergy outpatient clinics that were 
chosen for this research are all based in the south of England, and so may not be 
representative of the larger allergic population and so caution should be applied to the 
generalisability of the study findings. However the inclusion of a national allergy support 
charity would have widened the sample geographically as this invited individuals from 
across the UK to participate. Thirdly, as the current thesis included a cross-sectional study 
it was not possible for the natural history of disease, such as the age of onset and 
persistency to be investigated. 
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6.5 Directions for future research 
This study has demonstrated several novel findings that have added to the body of 
understanding of fish and shellfish allergy but it has also uncovered possible future 
avenues for research. The development of evidence-based clinical guidelines for fish and 
shellfish allergy, similar to what currently exists for milk and egg allergy (Clark et al., 
2010; Luyt et al., 2014) would be of great worth, and could include information uncovered 
from this thesis as well as other published studies on the prevalence, clinical presentation, 
diagnosis, dietary avoidance including cross reactions and management including HRQL 
factors for fish and shellfish allergy. Information regarding the mechanism, natural history 
(including the onset and resolution) of non-IgE mediated reactions to fish and shellfish 
allergy would also be informative, however further research is required in these areas. 
More robust prevalence studies utilising food challenges, in particular those conducted in 
countries outside of Europe and America, are needed. A longitudinal research study is 
needed to be able to investigate the resolution and age of development for fish and 
shellfish allergy, as prognosis has been shown to reduce the impact of FHS on HRQL 
(Savage et al., 2016), it would also then be possible to further investigate the clinical 
relevance of cross reacting allergens and the existence of co-existing fish and shellfish 
allergy and cross reactions with aero-allergens. More information is also needed about the 
specific allergens involved in triggering allergic reactions and diagnostic tools to detect 
these sensitisations i.e. there are currently five peanut proteins that can be tested for (ara 
h1, 2, 3, 5 and 8, and they are developing for 6) but for fish the only test is for parvalbumin 
and for shellfish is tropomyosin (Hoffmann-Sommergruber & Mills, 2009).  
 
A promising new method, which is also warranted in fish and shellfish allergy, is food 
allergen immunotherapy, which is based on the delivery of increasing doses of allergens 
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over time with the end goal being the desensitisation and tolerance of the individual to the 
allergen, and which includes oral immunotherapy (OIT), sublingual immunotherapy 
(SLIT) and epicutaneous immunotherphy (EPIT) (Wood, 2016). To date, these treatments 
have been shown to have some success in peanut, egg and milk however there is the 
potential for this method to be applied to other food allergens, and trials including fish are 
currently underway (Moneret-Vautrin & Morisset, 2005). Further research is needed to 
uncover the long-term outcomes of these as treatment for food allergy, as the effectiveness 
for desensitisation has been shown but the effect on inducing tolerance is currently 
unknown.  However, in order to develop targeted OIT protocols, there needs to be clarity 
about the main allergens that individuals are reacting to. 
 
6.6 Overall conclusion 
Fish and shellfish allergy are major food allergens (recognised by the European 
Community) and are a leading cause of anaphylaxis. Allergic reactions to fish and shellfish 
are generally immediate (related to an IgE-mediated allergy), although non-IgE-mediated 
responses can be implicated. Reactions can be triggered by ingestion, skin contact, and in 
some cases through inhalation of cooking vapours, thus making it a difficult allergen to 
successfully avoid. Unlike some allergens (milk, egg), fish and shellfish allergy does not 
seem to resolve with age and therefore lifelong dietary avoidance, based on valid and 
consistent clinical dietary management advice is necessary. The findings from the current 
study agree with existing literature but also some novel findings have been shown. The 
original contribution to knowledge made by this research is, firstly, that it has provided a 
systematic review of up to date prevalence rates, in all ages and all countries, allowing for 
the comparison between the prevalence in children and adults, as well as geographical 
differences to be seen. Although a previous review had sought to describe the prevalence 
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of fish and shellfish allergy, a worldwide search strategy had not been applied. Secondly, 
this research has described in detail the clinical characteristics of a sample of 111 adult 
sufferers in the UK, something which has previously not been done in this population. 
Thirdly, this research measured the HRQL of fish and shellfish allergy to further develop 
the understanding of fish and shellfish allergy. Previous research has looked predominately 
at children, and where adults HRQL have been measured, literature has looked at FHS as a 
whole or other allergens, such as peanut, cow’s milk, wheat and egg.  
 
In conclusion the main findings of this research are, where food-challenges have been used 
the prevalence of fish allergy was found to be 0-0.3% and for shellfish allergy was 0-0.9%, 
with shellfish allergy more prevalent in South-East Asia. Fish and shellfish allergy often 
co-exist, fish and shellfish allergic individuals are highly atopic and sensitised to aero-
allergens, and the clinical phenotype with regards to tinned fish and reactivity to vapours 
and steam is varied. Different diagnostic methods are used by the three allergy outpatient 
clinics involved in the current research and the dietary advice given is inconsistent. The 
HRQL of individuals allergic to fish and shellfish allergy was negatively impaired overall, 
affecting the emotional domain the most, perhaps more so than that of individuals allergic 
to other foods. 
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Appendix 1 Literature review search strategy 
The following electronic databases were searched: PubMed, Web of Science, Zetoc, 
Cochrane Library. Specific search strategies were tailored for the requirements of each 
database and search terms were combined using Boolean operators. 
Topic Search terms 
Allergy Hypersensitivity, allergy, immunology, 
sensitivity, intolerance, anaphylaxis, adverse 
reaction 
Crustacean Crustacean, crab(s), lobster(s), shrimp(s), 
prawn(s), crayfish, langoustine(s), shellfish 
Fish Fish. Fishes, Pollock, carp, cod, mackerel, 
salmon, tuna, shark, sea bass, swordfish, hake, 
sole, megrim, sardine(s), halibut, anchovy, 
anchovies, catfish, trout 
Health-related quality of life Health-related quality of life, quality of life, 
anxiety, stress, mental health 
Mollusc Mollusc(s), oyster(s), snail(s), squid, mussel(s), 
clam(s), abalone, octopus, scallop(s) 
 
Conference proceedings and abstracts from the American Academy of Allergy & Clinical 
Immunology (2012-2016), The British Society for Allergy and Clinical Immunology 
(2012-2016), and European Academy of Allergy and Clinical Immunology (2012-2016) 
were searched. Key authors were identified and hand searching of reference lists was 
undertaken. To prevent bias, no restrictions were placed on the year of publication, 
language or study type.  
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Appendix 3 Chapter 3: Further information tables 
Further information for questionnaire-based methods of diagnosis 
Study ID Self-report Clinician-diagnosed Clinical history 
Al- Hammadi 
(2010) 
_  Parents completed a questionnaire regarding 
allergic disease and atopic family history. A child 
was considered to have food allergy or other 
allergic illness only if it was reported to have 
been diagnosed by a physician. 
_ 
Ben-Shoshan 
(2010) 
A standardised questionnaire developed 
previously by Sicherer et al (1999; 2004) to 
determine the general population prevalence of 
peanut, tree nut, fish, and shellfish allergy in the 
United States, and modified it to incorporate 
questions regarding sesame allergy 
Confirmed allergy only if one of the following 
was fulfilled: a) Convincing history of an IgE-
mediated reaction attributed to food and 
physician confirmation of a positive SPT, serum 
food-SIgE >0.35 kU/L or a positive food 
challenge. B) Never exposed to the food or had 
an uncertain history of an IgE-mediated reaction 
and physician confirmation of a positive SPT and 
a food-SIgE above previously published 
thresholds (i.e., >15 kU/L for peanut and tree nut 
and >20 kU/L for fish) or a positive SPT and a 
positive food challenge or a positive food 
challenge alone 
A convincing history of an IgE-mediated reaction 
to a specific food was defined as a minimum of 2 
mild signs/symptoms or 1 moderate or 1 severe 
sign/symptom that was likely IgE-mediated and 
occurred within 120 minutes after ingestion or 
contact (or inhalation in the case of fish and 
shellfish). Reactions were classified as mild, 
moderate or severe based on the same criteria 
outlined for Ben-Shoshan 2010. 
Brugman (1998) A questionnaire on FHS was mailed to parents. 
Once completed this was then checked by the 
_ _ 
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Study ID Self-report Clinician-diagnosed Clinical history 
school physician or nurse, where some aspects of 
the child’s health were added based on school 
records of absence, medicinal use, medical 
treatment and overall health evaluation. 
Connett (2012) This survey was constructed in two parts. The 
first part collected demographic data, the 
presence of physician-diagnosed asthma, eczema 
and rhinitis and the occurrence of specific food 
allergies. 
All respondents reporting the occurrence of 
specific food allergies completed the second part 
of the questionnaire, which asked more detailed 
questions about symptoms and their timing to 
determine whether convincing reactions had 
occurred. 
 _ 
Dalal (2002) _ _ Information was obtained from patient medical 
records at the family health centre, and from the 
family health centre staff, including nurses and 
dieticians. 
Eggesbo (1999) The parents of infants were asked to complete a 
self-administered questionnaire on the maternity 
ward. Further information was collected by 
postal questionnaire every 6 months until the 
child reached the age of two. The operational 
definition of the outcome, parentally perceived 
reactions to food, was based on the question 
‘does the child react to any food items?’. Possible 
symptoms were listed for parents to mark off 
_ _ 
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Study ID Self-report Clinician-diagnosed Clinical history 
what symptoms the child had experienced. 
Emmett (1999) Identification of food allergies suffered within 
the household. Questions on source of diagnosis, 
doctor consultation, number of reactions, age at 
first reaction, type of contact with peanuts 
causing the reactions, amount of peanuts taken, 
symptoms occurring, medication taken, and 
hospitalisation if necessary 
_ _ 
Falcoa (2004) Participants completed a large questionnaire as 
part of an on-going health and nutrition survey of 
residents of Porto. 
_ _ 
Gelinick (2008) An initial screening questionnaire contained two 
questions relating to foods, those who disclosed 
food-related complaints were called once more 
and a similar questionnaire was repeated. Those 
suspected of having a food allergy were invited 
for a personal investigation at the clinic. 
_ _ 
Greenhawt (2009) Questions asked about the occurrence of a 
specific allergic reaction, the symptoms and 
foods attributable to the reaction, emergency 
medications maintained. 
_ _ 
Gupta (2011) A convincing food allergy based on self report in 
conjunction with one or more of the following 
_ _ 
APPENDICES 
220 
Study ID Self-report Clinician-diagnosed Clinical history 
reaction symptoms: anaphylaxis, angioedema, 
coughing, other oropharyngeal symptoms, 
eczema, flushing, hives, low blood pressure, 
pruritus, trouble breathing, vomiting, or 
wheezing. A confirmed food allergy also 
included report of physician-diagnosis with 
serum-specific immunoglobulin E testing, skin 
prick testing, or an oral food challenge 
Kajosaari (1982) _ Information was obtained from the mothers by 
questionnaire. The family history of atopy, the 
child’s possible atopic symptoms and signs, 
duration of breast-feeding, and the introduction 
age for fish, citrus and eggs were recorded. The 
history was confirmed and checked by telephone 
interviews whenever symptoms or signs of atopy 
were suspected. Allergy to fish was confirmed by 
elimination and challenge at home. 
_ 
Kavaliunas (2012) A community-based survey was undertaken 
aimed at collecting basic information on adverse 
reactions to foods using a short questionnaire. 
Participants were asked if they had adverse 
reactions to one or more of 24 priority foods. 
_ _ 
Kim (2011) Food allergy was defined as a convincing history _ _ 
APPENDICES 
221 
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of reproducible symptoms within 2 hours after 
ingestion of single food 
Kristjansson (1999) A questionnaire was designed based on a 
questionnaire developed by the Allergology 
section of the Swedish Paediatric Association. It 
included 17 questions relating to the duration of 
breast-feeding, food habits, symptoms relating to 
adverse food reactions, other manifestations of 
allergy and family atopic history. 
_ _ 
Lao-araya (2012) Parents were asked about the child’s 
demographics, number of siblings, feeding 
history during infancy and the child’s and family 
history of atopic disease. 
_ _ 
Leung (2009) Parents were asked about the occurrence and 
frequency of any AFR (adverse food reaction) in 
their children. ‘Current’ symptoms referred to 
symptoms in the past 12 months, whereas ‘AFR 
ever’ was defined as suffering from AFR in the 
subjects’ life time 
An additional question of whether they received 
a doctor’s diagnosis for AFR, children who 
answered ‘yes’ were defined as having parent-
reporting and doctor-diagnosed AFR. 
_ 
Marklund (2004) Question asked: ‘are you allergic or 
hypersensitive to any of the following: food’ 
Unclear how the individual food was determined 
_ _ 
Marrugo (2008) Questions were asked about personal data and _ _ 
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occupation and personal history of atopic disease. 
Martinez-Gimeno 
(2000) 
Extension of the International Study of Asthma 
and Allergy in Children (ISAAC study) 
questionnaire. 
_ _ 
Mustafayev (2012) Any person answering yes to the question ‘did 
your child have any allergic complaint after any 
food intake within the last year’ was contacted 
via telephone by a paediatrician trained in food 
allergy. 
_ _ 
Obeng (2011) The questionnaire included questions from the 
EuroPrevall study on the symptoms of adverse 
reactions to food (www.europrevall.org) 
_ _ 
Oh (2004) The Korean version of the ISAAC questionnaire 
was administered to the parents of the children 
and to the student themselves in middle schools. 
_ _ 
Orhan (2009) Questionnaire asking ‘Has your child ever had an 
adverse reaction to any food within two hours 
following consumption?’. If the parent responded 
‘yes’ then a further series of questions were 
asked to gain information about the reaction. 
_ _ 
Ostblom (2008a) Any of the following parentally reported 
symptoms related to ingestion of a certain food 
were defined as food allergy: asthma, itchy eyes 
_ _ 
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and or runny nose, oedema of lips/eyes, urticaria, 
eczema or vomiting/diarrhoea 
Ostblom (2008b) Parents asked to report on any reactions to foods 
experienced by their child 
Parental report of doctor diagnosed food allergy _ 
Osterballe (2005) Food hypersensitivity to the most common foods 
was examined by a questionnaire.  
_ _ 
Osterballe (2009) A questionnaire with the main question: ‘do you 
suspect hypersensitivity to foods and or drinks?’ 
_ _ 
Penard-Morand 
(2005) 
Enriched version of the ISAAC questionnaire 
was used. 
_ _ 
Pereira (2005) The parent and child completed questionnaires 
and where a current adverse reaction to any food 
was stated, they were asked to describe the 
symptoms that they experienced. 
_ _ 
Pyrhonen (2009) The baseline questionnaire asked structured 
questions about the child’s background and food 
allergy or hypersensitivity. Parents were asked to 
indicate, per food, whether they never perceived 
symptoms, never tasted the foods, parents 
perceived allergy, physician diagnosed allergy, 
symptoms occurred in last 12 months and 
symptoms occurred more than 12 months ago. 
The definition of food allergy and FHS was 
based on a diagnosis reached by a physician. 
_ 
Rance (2005) A standard, anonymous questionnaire asked ‘Has _ _ 
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your child ever had an allergic reaction to food?’ 
If  ‘Yes’ parents were asked additional questions 
about clinical and treatment data and the results 
of allergy tests. 
Sakellariou (2208) A survey was conducted in the context of 
EUROPREVALL. 
_ _ 
Santadusit (2005) Parents completed a 16-item food allergy 
questionnaire. Families reporting adverse food 
reactions were invited to participate in further 
diagnostic investigations. 
_ _ 
Schafer (2001) A computer-assisted standardised interview 
asked whether participants had allergic reactions 
to foods and if so the type of reaction was 
recorded in detail. The reported reactions were 
catergorised according to reaction site, 
furthermore history and doctor’s diagnosis were 
recorded. 
_ _ 
Shek (2010) Survey conducted using a structured 
questionnaire used in the US population 
(Sicherer et al. 2003). 
 
_ Reactions considered convincing if organ 
systems were affected and symptoms were 
typical of allergic reactions (skin: hives and 
angioedema; respiratory system: trouble 
breathing, wheezing, and throat tightness; 
gastrointestinal system: vomiting and diarrhoea) 
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occurring within 2 hours of ingestion. 
Sicherer (2004) _ Telephone script with computerized algorithms. 
Screening questions, to identify individuals, 
additional questions administered depending on 
responses and included those regarding, severe 
reactions, lifetime recurrence, seafood related 
medical history. Algorithms categorised people 
into no allergy, physician diagnosed (self 
reported), convincing allergy (levels 1-4) and 
probable allergy (levels 1-3). 
_ 
Touraine (2002) Questionnaire distributed to schools for parents 
to answer. The questionnaire asked ‘Does your 
child have a food allergy?’. If answered yes, 
further information was gathered about the types 
of symptoms, and the presence of allergies to 
pollen, house dust mites and mould. Also asked 
about family atopic disease and any treatment 
received. 
_ _ 
Van Bockel- 
Geelkerken (1992) 
Schools sent out questionnaire to parents asking 
them to give details on any adverse reactions to 
foods (including symptoms, offending foods and 
type of diagnosis). 
_ _ 
Venter (2006) Parents completed a questionnaire, asking ‘Does _ _ 
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your child currently have a problem with any of 
the following foods: Milk, egg, peanut, tree nuts 
(e.g. almond, brazil), wheat, fish, sesame and 
other? If yes to any of the above foods, can you 
describe the problem’ 
Venter (2008) As above. _ _ 
Vierk (2007) Persons who answered yes to the question about 
currently having any food allergy or suspecting 
that they have a food allergy were defined as 
persons who self-reported food allergy 
On the basis of additional questions, this food 
allergic group was further subdivided on the 
basis of whether they had received a doctor 
diagnosis. 
_ 
Woods (1998) Participants completed detailed second phase 
ECRHS questionnaire administered by a trained 
interviewer. The questionnaire covered 
respiratory symptoms during the last 12 months, 
history of asthma, home and work environment, 
allergic symptoms, smoking, demographics, 
medications and dietary information. 
_ _ 
Wu (2012) _ Self-administered questionnaire. Six reviewed 
and analysed questionnaire descriptions of 
symptoms and records of physicians’ evaluations 
to distinguish food allergy from non-
immunologic adverse food reactions. Cases 
diagnosed by clinicians and confirmed by 
_ 
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positive laboratory tests were enrolled as definite 
cases. If symptoms occurred within minutes 
diagnosis was presumed to be food allergy on the 
basis of type I immediate hypersensitivity 
reaction. Non-allergic FHS was usually 
characterized by a delayed reaction, occurring 
hours or even days after eating certain food. 
Allergic reactions did not depend on the amount 
of ingested food, whereas food intolerance 
worsened as more food was consumed. 
Young (1994) Questions were about perceived connection 
between food ingestion and allergic symptoms. 
_ _ 
Zannikos (2008) A survey was conducted in the context of 
EUROPREVALL. 
_ _ 
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Further information for sensitisation-based methods of diagnosis 
Study ID Skin Prick Test Serum SIgE Test 
 Method of 
determining positive 
test 
Time to read 
response 
Allergen for testing Method of determining 
positive test 
Test used 
 
Arshad (2001) Wheal with mean 
diameter >3mm larger 
than the negative 
control 
 
15 minutes 
 
Extracts 
Standardized extracts were 
used when available. All 
extracts were from 
Biodiagnostics (Reinbek, 
Germany) Histamine (0.1%) 
in phosphate buffered saline 
and physiologic saline as 
positive and negative 
controls, respectively 
_ _ 
Branum (2009) _ _ _ The range of detectable 
serum IgE levels was 0.35 to 
1000 kU/L 
ImmunoCAP 1000 
 
Burney (2010) _ _ _ Detection limit 0.35kU/L ImmunoCAP 
Chen (2011) Wheal with mean 
diameter >3mm larger 
15 minutes 
 
Extracts 
GREER, Lenoir, NC, USA 
_ _ 
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Study ID Skin Prick Test Serum SIgE Test 
 Method of 
determining positive 
test 
Time to read 
response 
Allergen for testing Method of determining 
positive test 
Test used 
 
than the negative 
control 
 
Dalal (2002) Wheal with mean 
diameter >3mm 
 
N/R 
 
Extracts 
Commercial extracts 
(Centre laboratories, Port 
Washington, NY, USA) 
_ _ 
Haahtela (1980) N/R >15 minutes N/R _ _ 
Hu (2010) Wheal with mean 
diameter >3mm 
15 minutes 
 
Extracts 
Glycerinated food extract 
supplied by Greer Company 
(Taibei, China) 
_ _ 
Johansson (2005) _ _ _ Detection limit 0.35kU/L ImmunoCAP 
Krause (2002) _ _ _ The cut off for a positive 
reaction was set at ≥0.7 
kU/L 
Pharmacia CAP 
 
Kristjansson (1999) Wheal with mean >15 minutes Prick-to-prick _ _ 
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Study ID Skin Prick Test Serum SIgE Test 
 Method of 
determining positive 
test 
Time to read 
response 
Allergen for testing Method of determining 
positive test 
Test used 
 
diameter >3mm   
Liu (2010) _ _ _ There is a lack of data 
correlating outcomes of 
allergy for shrimp with IgE 
levels, and thus no well 
established IgE cut off point 
for likely shrimp allergy. 
Therefore, shrimp was 
treated in accordance with 
the typical patterns 
described, using a threshold 
of 5 kU/L.  
ImmunoCAP 1000 
 
Orhan (2009) Wheal with mean 
diameter >3mm 
 
15 minutes 
 
SPT carried out with 
commercially available 
extracts of standard food 
allergens (Allergopharma, 
Reinbek, Germany) 
_ _ 
Osborne (2011) Wheal with mean N/R Extracts _ _ 
APPENDICES 
231 
Study ID Skin Prick Test Serum SIgE Test 
 Method of 
determining positive 
test 
Time to read 
response 
Allergen for testing Method of determining 
positive test 
Test used 
 
diameter >3mm  ALK, Madrid 
Ostblom (2008a) _ _ _ Detection limit 0.35kU/L 
Serum samples  scoring 
positive for fx5® were 
further analysed towards the 
individual allergens included 
in the mix 
ImmunoCAP 
 
Osterballe (2005) Wheal with mean 
diameter >3mm larger 
than the negative 
control 
 
15 minutes 
 
Skin prick test was 
performed by the prick-
prick technique using a 
selected panel of fresh 
unprocessed foods 
 
Measurable SIgE was 
classified as a positive test 
result (ML > 1.43 SU/ml, 
CAP > 0.35 kUA/l) 
 
Pharmacia CAP 
Adults and siblings 
only. 
Magic Lite 
3 year olds, adults 
and siblings 
 
Pereira (2005) Wheal with mean 
diameter >3mm 
 
>15 minutes 
 
N/R 
 
_ _ 
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 Method of 
determining positive 
test 
Time to read 
response 
Allergen for testing Method of determining 
positive test 
Test used 
 
Ro (2012) Wheal with mean 
diameter >3mm larger 
than the negative 
control 
 
15 minutes 
 
Extracts 
SPT allergen extracts were 
purchased from Soluprick® 
(ALKAbello, Copenhagen, 
Denmark) 
 
The reference value for total 
IgE in two-year-old children, 
specified by the 
manufacturer, was 0–45 
kU/L. The detection limit for 
sIgE tests was 0.1 kU/L.  
Concentrations of 0.35 kU/L 
or above were regarded as 
positive 
Immulite 2000 
 
Roberts (2005) Wheal with mean 
diameter >3mm 
<15 minutes 
 
N/R 
 
_ _ 
Santadusit (2005) Wheal with mean 
diameter >3mm or 
greater than saline 
control 
15 minutes Commercial food extracts 
(Center Laboratories, Port 
Washington, NY) 
_ _ 
Schafer (2001) Wheal with mean 
diameter >3mm 
>2mm 
>15 minutes 
 
Unclear 
 
_ _ 
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 Method of 
determining positive 
test 
Time to read 
response 
Allergen for testing Method of determining 
positive test 
Test used 
 
Venter (2006) Wheal with mean 
diameter >3mm 
 
15 minutes 
 
Commercially available 
extracts (Soluprick SQ 
allergens-ALK 
Allergologisk Laboratorium 
A/S, Horsholm, Denmark) 
to a predefined panel of 
foods (milk, egg, wheat, cod 
fish, peanut and sesame) 
and to additional foods 
reported to be a problem. 
_ _ 
Venter (2008) As above As above As above _ _ 
Von Hertzen (2006) Wheal with mean 
diameter >3mm 
N/R Fish extract _ _ 
Zuberbier (2004) Wheal with mean 
diameter >3mm 
N/R 
 
Prick-to-prick 
 
N/R 
 
Pharmacia CAP 
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Further information for food-challenge procedures for methods of diagnosis 
Study ID Time-frame for 
monitoring reactions 
Active and placebo 
food carriers 
Dosing schedule Method of determining positive 
test 
Additional 
information 
Gelincik (2008) 2-12 hours depending on 
patient history. 
Peppermint oil, pure 
cacao powder, cereal 
flakes, wheat flour, lemon 
juice, honey, sugar, 
mashed potato, milkshake, 
rice-pudding, carob, 
cinnamon and various 
vegetables. 
N/R N/R N/R 
Jansen (1994) 2 hours. Whenever possible, the 
double-blind 
provocation was 
performed with the food 
substance in freeze-
dried form, packed in 
opaque titanium dioxide 
coated gelatin capsules.  
If the food was not 
available in dried form, 
if the indicated test dose 
was too large, or if the 
symptoms were mainly 
Amount usually 
ingested, if no reaction, 
larger dose after 2-7 
days. 
 
Confirmation was accepted if the 
subject had clear symptoms after 
the active dose and no symptoms 
after placebo. 
 
N/R 
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Study ID Time-frame for 
monitoring reactions 
Active and placebo 
food carriers 
Dosing schedule Method of determining positive 
test 
Additional 
information 
oropharyngeal in nature 
the suspected food was 
masked in unspecified 
vehicle.  
Kajosaari (1982) 1 week. N/R One meal of fish given 
daily until symptoms 
appeared or for 1 week. 
A skin rash, exacerbation of atopic 
eczema or urticaria with or 
without gastrointestinal 
disturbances was defined as a 
positive result. 
The allergen was 
first eliminated 
from the diet for at 
least 4 weeks or 
until the child was 
symptom free. 
Kristjansson (1999) N/R N/R Initial test dose =1g 
5 and 10g given with 30 
minute intervals. 
DBPCFC positive when the patient 
showed a reaction to the allergen but 
not to the placebo. 
N/R 
Lao-araya (2012) Min 4hours. 
 
N/R N/R N/R N/R 
Orhan (2009) Negative DBPCFCs were 
followed by open 
challenges. Duration 
between a negative 
DBPCFC and open 
challenge was 2 hours. In 
the open challenge, 
patients received a larger 
A wide variety of foods 
were used to mask the 
active doses. All active 
and placebo foods were 
as similar as possible in 
colour, flavour-taste, 
consistency, and texture 
so as not to be 
15 minutes 
The titrated doses used 
for fish were 1, 2, 7, 15, 
25, and 50 g. 
 
DBPCFC were considered 
positive if a single or a 
combination of the clinical 
reactions, including cutaneous 
(eruption, itching, rash, swelling), 
nasal (sneezing, itching, secretion, 
blockage), ocular (redness, 
itching, secretion), bronchial 
N/R 
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monitoring reactions 
Active and placebo 
food carriers 
Dosing schedule Method of determining positive 
test 
Additional 
information 
quantity of food (a meal-
size portion for age). 
 
differentiated by the 
patients. 
(cough, wheezing, shortness of 
breath), gastrointestinal (vomiting, 
diarrhoea), laryngeal (difficulty in 
swallowing, difficulty in 
speaking), cardiovascular 
(tachycardia, hypotension), and 
other (sweating, pallor, fainting, 
loss of consciousness) symptoms 
were noted. 
Osterballe (2005) 
 
The dose interval was 15 
minutes. A positive 
challenge was divided 
into immediate or late 
reactions. The immediate 
reactions were defined as 
a reaction taking place 
within 2 h after the last 
dose administered, 
whereas late reactions 
occurred between 2 and 
24 h after the last dose. 
All participants with a 
positive outcome in food 
Codfish was masked in 
chocolate bars with 
basic ingredients of 
margarine, dark 
chocolate, salt, icing 
sugar, oat grains, soy 
flour, oat flour and mint.  
 
The titrated doses of 
codfish were: 125, 250, 
1000, 2000, 4000, 8000 
and 23,750. Total=39g. 
N/R 
 
The open 
controlled 
standardized food 
challenge was 
performed in all 
children <3 yr of 
age. The double-
blind placebo 
controlled food 
challenge was 
performed in 
children older than 
3 yr of age. 
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monitoring reactions 
Active and placebo 
food carriers 
Dosing schedule Method of determining positive 
test 
Additional 
information 
challenge were examined 
for late reactions by 
telephone interview and 
reported symptoms were 
subsequently 
verified/excluded by 
clinical examination. 
Osterballe (2009) A positive challenge was 
divided into immediate 
or late reactions. The 
immediate reactions were 
defined as a reaction 
taking place within 2 h 
after the last dose 
administered, whereas 
late reactions occurred 
between 2 and 24 h after 
the last dose of the food 
had been administered. 
All participants with a 
positive immediate 
reaction after food 
challenge were examined 
Codfish was masked in 
chocolate bars with 
basic ingredients of 
margarine, dark 
chocolate, salt, icing 
sugar, oat grains, soy 
flour, oat flour and mint.  
 
The dose interval was 15 
min. 
The titrated doses of 
codfish were: 125, 250, 
1000, 2000, 4000, 8000, 
23,750 mg of codfish. 
Total=39g 
Open controlled 
standardized food 
challenge (OCFC) was 
performed with the 
following dose steps: 
0.5, 1, 2, 4, 8, 16, 32 g, 
in total 63.5 g of octopus 
and shrimp.  
 
N/R 
 
Open controlled 
standardized food 
challenge (OCFC) 
was performed 
with additives, 
octopus and shrimp 
as no standardized 
procedures for 
masking the culprit 
food in double-
blind placebo-
controlled food 
challenge 
(DBPCFC) were 
available. Double-
blind placebo-
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Study ID Time-frame for 
monitoring reactions 
Active and placebo 
food carriers 
Dosing schedule Method of determining positive 
test 
Additional 
information 
for late reactions by 
telephone interview and 
reported symptoms were 
subsequently evaluated 
by clinical examination. 
 
 controlled food 
challenge was 
performed with 
codfish, cow’s 
milk, hen’s egg, 
peanut and soy 
according to 
EAACI guidelines. 
Santadusit (2005) Up to 24 hours after the 
initial introduction of 
foods. 
N/R The dose interval was 30 
minutes. 
Total= normal serving 
portion. 
Positive reactions were classified 
as early reaction if occurring 
within 6 hours and as late reaction 
if occurring between 6-24 hours. 
Any doubtful reactions to OFC 
were followed by a DBPCFC. 
Food challenges 
performed when 
children were 
completely well 
and had 
discontinued 
antihistamines for 
at least 72 hours 
before challenges. 
Venter (2006) 1 day in hospital for 
immediate and 1 week at 
home for non-generalised 
late reactions. 
 
N/R One-day challenge 
protocols were based on 
the consumption of the 
equivalent of 8-10g of 
dried food, unless the 
history clearly indicated a 
N/R N/R 
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Study ID Time-frame for 
monitoring reactions 
Active and placebo 
food carriers 
Dosing schedule Method of determining positive 
test 
Additional 
information 
different approach. If 
negative, the parent was 
asked to give the child 
further doses of the food at 
home. One week 
challenges were based on 
normal daily consumption 
for the specific age group. 
APPENDICES 
240 
Appendix 4 Chapter 3: Results tables 
Fish allergy prevalence: Europe 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Osterballe 
(2009) 
Denmark 2001-2002 22 years Fish (cod) 
0.2 
(0.0-1.0) 
 
 
Kajosaari (1982) Finland 1980-1981 1 year Fish  
7.0 
(5.4-9.0) 
 
Pyrhonen (2009) Finland 2001-2009 1 year Fish 
3.5 
(2.4-5.1) 
 0.2 
(0.0-0.9) 
Kajosaari (1982) Finland 1980-1981 2 years Fish  
6.0 
(4.5-7.9) 
 
Pyrhonen (2009) Finland 2001-2009 2 years Fish 
4.7 
(3.4-6.4) 
 0.4 
(0.1-1.1) 
Kajosaari (1982) Finland 1980-1981 3 years Fish  
5.0 
(3.6-6.8) 
 
Pyrhonen (2009) Finland 2001-2009 3 years Fish 
3.6 
(2.4-5.2) 
 0.9 
(0.4-1.9) 
Pyrhonen (2009) Finland 2001-2009 4 years Fish 
4.2 
(2.9-5.8) 
 1.0 
(0.5-2.0) 
Kajosaari (1982) Finland 1980-1981 6 years Fish  
0.1 
(0.0-0.8) 
 
Penard-Morand 
(2005) 
France 1999-2000 9-11 years Fish 
0.1 
(0.1-0.3) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Rance (2005) France 2002 2-14 years Fish 
0.7 
(0.4-1.1) 
 
 
Penard-Morand 
(2005) 
France 1999-2000 9-11 years Seafood 
0.5 
(0.3-0.7) 
 
 
Touraine (2002) France 2000-2001 5-17 years Fish 
4.0 
(2.9-5.3) 
 
 
Schafer (2001) Germany 1997-1998 25-74 years Fish /seafood 
1.4 
(0.9-2.2) 
 
 
Zannikos (2008) Greece 2007 7-13 years Fish 
1.9 
(1.3-2.6) 
 
 
Sakellariou 
(2008) 
Greece 2007 20-54 years Fish 
1.5 
(1.0-2.2) 
 
 
Kristjansson 
(1999) 
Iceland 1994 18 months Fish 
2.2 
(1.0-4.6) 
 
 
Dalal (2002) Israel N/R 0-2years Fish  
0.0 
(0.0-0.1) 
 
Kavaliunas 
(2012) 
Lithuania N/R 5-12 years Fish (cod) 
5.9 
(4.8-7.3) 
 
 
Brugman (1998) Netherlands 1993- 1994 4-15 years Fish /crustacean 
0.7 
(0.5-1.0) 
 
 
Van Bockel- 
Geelkerken 
(1992) 
Netherlands 1988- 1989 5-6 years Fish 
0.3 
(0.1-0.9) 
 
 
Eggesbo (1999) Norway 1993-1995 1 year Fish 
1.2 * 
(0.9-1.7) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Eggesbo (1999) Norway 1993-1995 18 months Fish 
1.5 * 
(1.1-2.0) 
 
 
Eggesbo (1999) Norway 1993-1995 2 years Fish 
1.5 * 
(1.1-2.1) 
 
 
Falcao (2004) Portugal 2000 >39 years Fish 
0.9 
(0.4-2.1) 
 
 
Martinez-
Gimeno (2000) 
Spain N/R 6-13 years Fish 
6.9 
(6.2-7.6) 
 
 
Ostblom (2008 
b) 
Sweden 1995-2004 1 year Fish 
1.5 
(1.1-2.0) 
 0.2 
(0.1-0.4) 
Kristjansson 
(1999) 
Sweden 1994 18 months Fish 
3.1 
(1.6-5.7) 
 
 
Ostblom (2008 
b) 
Sweden 1996-1998 2 years Fish 
1.8 
(1.4-2.4) 
 0.6 
(0.4-1.0) 
Ostblom (2008 
b) 
Sweden 1998-2000 4 years Fish 
1.2 
(0.9-1.7) 
 0.8 
(0.5-1.2) 
Ostblom (2008 
a) 
Sweden 1999-2000 4 years Fish (cod) 
1.6 
(1.2-2.2) 
 
 
Ostblom (2008 
b) 
Sweden 2002-2004 8 years Fish 
0.8 
(0.5-1.2) 
 0.6 
(0.4-1.0) 
Marklund (2004) Sweden 2003 13-21 years Fish 
1.0 
(0.6-1.7) 
 
 
Orhan (2009) Turkey 2006 6-9 years Fish 
0.3 
(0.2-0.7) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Mustafayev 
(2012) 
Turkey 2010 10-11 years Fish 
2.3 
(2.0-2.7) 
 
 
Gelincik (2008) Turkey N/R >18 years Seafood 
0.4
5
 
(0.3-0.6) 
 
 
Venter (2006) United Kingdom 2003-2004 6 years Fish (cod) 
0.3 
(0.0-1.0) 
 
 
Pereira (2005) United Kingdom 2002-2003 11 years Fish 
0.9 
(0.4-1.9) 
 
 
Pereira (2005) United Kingdom 2002-2003 15 years Fish 
1.8 
(1.1-3.2) 
 
 
Emmett (1999) United Kingdom 1995-1996 15 + years Fish 
0.5 
(0.4-0.6) 
 
 
Young (1994) United Kingdom N/R N/R Fish /crustacean 
2.9 
(2.7-3.1) 
 
 
Note: *= Study reported prevalence and confidence interval 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen  
SPT % 
prevalence 
History & 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Burney (2010) Belgium 2000 20-44 years Fish   
0.0 
(0.0-1.5) 
 
                                                 
5
 Data interpreted from a graph 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen  
SPT % 
prevalence 
History & 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Burney (2010) Estonia 2000 20-44 years Fish   
0.0 
(0.0-3.4) 
 
Von Hertzen 
(2006) 
Finland 2003 7-16 years Fish 
0.3 
(0.0-1.8) 
   
Haahtela 
(1980) 
Finland N/R 15-17 years Fish 
2.7 
(1.7-4.2) 
   
Burney (2010) France 2000 20-44 years Fish   
0.0 
(0.0-1.0) 
 
Burney (2010) Germany 2000 20-44 years Fish   
0.8 
(0.2-2.5) 
 
Zuberbier 
(2004) 
Germany 1999-2000 0-80+ years Fish (herring)  
0.1 
(0.0-0.3) 
  
Zuberbier 
(2004) 
Germany 1999-2000 0-80+ years 
Fish  
(mackerel) 
 
0.1 
(0.0-0.2) 
  
Schafer (2001) Germany 1997-1998 25-74 years 
Fish  
(mackerel) 
2.9 
(2.2-3.9) 
   
Krause (2002) Greenland 1998 5-18 years Fish   
0.7 
(0.3-1.5) 
 
Kristjansson 
(1999) 
Iceland 1994 18 months Fish  
0.6 
(0.1-2.5) 
  
Burney (2010) Iceland 2000 20-44 years Fish   
0.0 
(0.0-1.5) 
 
Dalal (2002) Israel N/R 0-2years Fish  
0.0 
(0.0-0.1) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen  
SPT % 
prevalence 
History & 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Burney (2010) Italy 2000 20-44 years Fish   
0.0 
(0.0-1.9) 
 
Ro (2012) Norway 2002-2006 2 years Fish 
0.3 
(0.0-1.8) 
 
1.1 
(0.4-3.1) 
 
Burney (2010) Norway 2000 20-44 years Fish   
0.2 
(0.0-1.6) 
 
Johansson 
(2005) 
Norway N/R > 18 years Fish (cod)   
0.0 
(0.0-1.0) 
 
Von Hertzen 
(2006) 
Russia 2003 7-16 years Fish 
0.2 
(0.0-1.8) 
   
Burney (2010) Spain 2000 20-44 years Fish   
0.4 
(0.1-1.4) 
 
Kristjansson 
(1999) 
Sweden 1994 18 months Fish  
0.3 
(0.0-2.0) 
  
Ostblom (2008 
a) 
Sweden 1999-2000 4 years Fish (cod)   
1.0 
(0.7-1.5) 
0.4 
(0.2-0.8) 
Johansson 
(2005) 
Sweden N/R > 18 years Fish (cod)   
0.1 
(0.0-0.7) 
 
Burney (2010) Sweden 2000 20-44 years Fish   
0.3 
(0.1-1.3) 
 
Orhan (2009) Turkey 2006 6-9 years Fish  
0.2 
(0.1-0.5) 
  
Venter (2008) 
United 
Kingdom 
2001-2005 1 year Fish (cod) 
0.3 
(0.0-1.0) 
   
APPENDICES 
246 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen  
SPT % 
prevalence 
History & 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Venter (2008) 
United 
Kingdom 
2001-2005 2 years Fish (cod) 
0.5 
(0.1-1.4) 
   
Venter (2008) 
United 
Kingdom 
2001-2005 3 years Fish (cod) 
0.5 
(0.1-1.5) 
   
Arshad (2001) 
United 
Kingdom 
1993-1994 4 years Fish (cod) 
0.7 
(0.3-1.5) 
   
Venter (2006) 
United 
Kingdom 
2003-2004 6 years Fish (cod) 
1.0 
(0.4-2.1) 
   
Roberts (2005) 
United 
Kingdom 
1998-2000 7 years Fish (cod) 
0.0 
(0.0-0.3) 
   
Pereira (2005) 
United 
Kingdom 
2002-2003 11 years Fish (cod) 
1.3 
(0.6-2.5) 
   
Pereira (2005) 
United 
Kingdom 
2002-2003 15 years Fish (cod) 
1.4 
(0.7-2.7) 
   
Burney (2010) 
United 
Kingdom 
2000 20-44 years Fish (cod)   
0.3 
(0.0-1.6) 
 
 
 
 
 
APPENDICES 
247 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
History and 
OFC % 
prevalence 
History and 
DBPCFC % 
prevalence 
Other % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Osterballe 
(2005) 
Denmark 2000-2001 < 3 years Fish (cod) 
0.0 
(0.0-4.2) 
 
0.0 ** 
(0.0-4.2) 
 Osterballe 
(2005) 
Denmark 2000-2001 3 years Fish (cod)  
0.0 
(0.0-1.0) 
0.8 ** 
(0.3-2.2) 
Osterballe 
(2005) 
Denmark 2000-2001 3-22 years Fish (cod)  
0.0 
(0.0-1.6) 
0.3 ** 
(0.0-2.1) 
Osterballe 
(2009) 
Denmark 2001-2002 22 years Fish (cod) 
0.1 
(0.0-0.8) 
  
Osterballe 
(2005) 
Denmark 2000-2001 >22 years Fish (cod)  
0.2 
(0.0-0.9) 
0.6 ** 
(0.3-1.5) 
Kajosaari (1982) Finland 1980-1981 6 years Fish 
0.1 
(0.0-0.8) 
  
Kristjansson 
(1999)  
Iceland 1994 18 months Fish  
0.3 
(0.0-2.0) 
 
Jansen (1994) Netherlands 1990 18-69 years Seafood  
0.1 
(0.0-0.4) 
 
Orhan (2009) Turkey 2006 6-9 years Fish  
0.0 
(0.0-0.2) 
 
Gelincik (2008) Turkey N/R > 18 years Fish  
0.0 
(0.0-0.1) 
 
Venter (2008) United Kingdom 2001-2005 1 year Fish  (cod)   
0.1** 
(0.0-0.7) 
Venter (2008) United Kingdom 2001-2005 2 years Fish  (cod)   
0.0** 
(0.0-0.6) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
History and 
OFC % 
prevalence 
History and 
DBPCFC % 
prevalence 
Other % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Venter (2008) United Kingdom 2001-2005 3 years Fish  (cod)   
0.0** 
(0.0-0.5) 
Venter (2006) United Kingdom 2003-2004 6 years Fish  (cod)  
0.0 
(0.0-0.6) 
 
Note: **= Participants with possible FHS; self-reported (questionnaire) FHS or a positive outcome in at least one of the following: skin prick, histamine 
release and SIgE, without a clear negative case history (not regularly eating culprit food during the last year). 
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Shellfish allergy prevalence: Europe 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Osterballe 
(2009) 
Denmark 2001-2002 22 years 
Crustacean  
(shrimp) 
2.0 
(1.2-3.3) 
 
 
Osterballe 
(2009) 
Denmark 2001-2002 22 years 
Mollusc  
(octopus) 
0.4 
(0.1-1.1) 
 
 
Rance (2005) France 2002 2-14 years 
Crustacean 
(shrimp) 
0.5 
(0.3-0.8) 
 
 
Touraine (2002) France 2000-2001 5-17 years Crustacean 
5.5 
(4.3-7.1) 
 
 
Touraine (2002) France 2000-2001 5-17 years Mollusc  (oyster) 
1.5 
(0.9-2.4) 
 
 
Zannikos (2008) Greece 2007 7-13 years Shellfish  
0.1 
(0.0-0.2) 
 
 
Kristjansson 
(1999) 
Iceland 1994 18 months Shellfish  
1.5 
(0.6-3.8) 
 
 
Kavaliunas 
(2012) 
Lithuania N/R 5-12 years 
Crustacean  
(shrimp) 
0.1 
(0.0-0.5) 
 
 
Van Bockel- 
Geelkerken 
(1992) 
Netherlands 1988- 1989 5-6 years Shellfish 
0.2 
(0.0-0.8) 
 
 
Falcao (2004) Portugal 2000 >39 years 
Mollusc 
(Octopus, squid) 
0.5 
(0.1-1.5) 
 
 
Kristjansson 
(1999) 
Sweden 1994 18 months Shellfish  
1.2 
(0.4-3.3) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Marklund (2004) Sweden 2003 13-21 years Shellfish 
1.7 
(1.1-2.5) 
 
 
Pereira (2005) United Kingdom 2002-2003 11 years 
Crustacean  
(prawn) 
0.3 
(0.1-1.0) 
 
 
Pereira (2005) United Kingdom 2002-2003 15 years 
Crustacean  
(prawn) 
0.7 
(0.2-1.6) 
 
 
 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
SPT % 
prevalence 
History & 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Burney (2010) Belgium 2000 20-44 years 
Crustacean  
(shrimp) 
  
5.0 
(3.0-8.1) 
 
Burney (2010) France 2000 20-44 years 
Crustacean  
(shrimp) 
  
7.1 
(5.0-9.9) 
 
Burney (2010) Germany 2000 20-44 years 
Crustacean  
(shrimp) 
  
4.3 
(2.6-7.0) 
 
Zuberbier 
(2004) 
Germany 1999-2000 0-80+ years 
Crustacean  
(crab) 
 
0.2 
(0.1-0.5) 
  
Schafer (2001) Germany 1997-1998 25-74 years 
Crustacean  
(crab) 
2.7 
(2.0-3.6) 
   
Zuberbier 
(2004) 
Germany 1999-2000 0-80+ years 
Mollusc 
(mussels) 
 
0.0 
(0.0-0.2) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
SPT % 
prevalence 
History & 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Burney (2010) Iceland 2000 20-44 years 
Crustacean  
(shrimp) 
  
2.8 
(1.4-5.4) 
 
Burney (2010) Italy 2000 20-44 years 
Crustacean  
(shrimp) 
  
10.3 
(7.0-14.9) 
 
Burney (2010) Norway 2000 20-44 years 
Crustacean  
(shrimp) 
  
6.3 
(4.2-9.2) 
 
Burney (2010) Spain 2000 20-44 years 
Crustacean  
(shrimp) 
  
4.8 
(3.4-6.8) 
 
Burney (2010) Sweden 2000 20-44 years 
Crustacean  
(shrimp) 
  
4.9 
(3.4-7.0) 
 
Burney (2010) Switzerland 2000 20-44 years 
Crustacean  
(shrimp) 
  
0.0 
(0.0-2.3) 
 
Burney (2010) 
United 
Kingdom 
2000 20-44 years 
Crustacean  
(shrimp) 
  
6.1 
(4.0-9.1) 
 
 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen  
History and 
OFC % 
prevalence 
History and 
DBPCFC % 
prevalence 
Other % 
prevalence  
     (95% CONFIDENCE INTERVAL) 
Osterballe 
(2005) 
Denmark 2000-2001 < 3 years 
Crustacean  
(shrimp) 
0.0 
(0.0-4.2) 
 
0.0 ** 
(0.0-4.2) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen  
History and 
OFC % 
prevalence 
History and 
DBPCFC % 
prevalence 
Other % 
prevalence  
     (95% CONFIDENCE INTERVAL) 
Osterballe 
(2005) 
Denmark 2000-2001 3 years 
Crustacean  
(shrimp) 
 
0.0 
(0.0-1.0) 
0.0 ** 
(0.0-1.0) 
Osterballe 
(2005) 
Denmark 2000-2001 3-22 years 
Crustacean  
(shrimp) 
 
0.0 
(0.0-1.6) 
0.3 ** 
(0.0-2.1) 
Osterballe 
(2009) 
Denmark 2001-2002 22 years 
Crustacean  
(shrimp) 
  
0.2 ** 
(0.0-0.9) 
Osterballe 
(2005) 
Denmark 2000-2001 >22 years 
Crustacean  
(shrimp) 
 
0.3 
(0.1-1.0) 
1.1 ** 
(0.5-2.0) 
Osterballe 
(2009) 
Denmark 2001-2002 22 years 
Mollusc  
(octopus) 
  
0.1 ** 
(0.0-0.8) 
Note: **= Participants with possible FHS; self-reported (questionnaire) FHS or a positive outcome in at least one of the following: skin prick, histamine 
release and SIgE, without a clear negative case history (not regularly eating culprit food during the last year). 
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Fish allergy prevalence: Other regions of the world 
Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
African 
Obeng (2011) Ghana 2006-2008 5-16 years Fish 
0.3 * 
(N/R) 
  
Americas 
Ben-Shoshan 
(2010) 
Canada 2008-2009 < 18 years Fish 
0.18 * 
(0.0-0.36) 
0.18 * 
(0.0-0.36) 
0* 
(N/R) 
Ben-Shoshan 
(2010) 
Canada 2008-2009 > 18 years Fish 
0.6 * 
(0.43-0.78) 
0.56 * 
(0.39-0.73) 
0.12* 
(0.08-0.16) 
Marrugo (2008) Colombia N/R All ages Seafood 
4.0 
(3.3-4.7) 
  
Sicherer (2004) United States 2002 0-5 years Fish   
0.0 
(0.0-0.5) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Sicherer (2004) United States 2002 6-17 years Fish   
0.2 
(0.1-0.5) 
Vierk (2007) United States 2001 >18 years Fish 
0.7 
(0.5-1.0) 
 
0.6 
(0.4-0.9) 
Greenhawt 
(2009) 
United States N/R >18 years Fish 
2.7 
(1.6-4.7) 
  
Sicherer (2004) United States 2002 18-40 years Fish   
0.5 
(0.3-0.8) 
Sicherer (2004) United States 2002 41-60 years Fish   
0.5 
(0.3-0.8) 
Sicherer (2004) United States 2002 61 + Fish   
0.3 
(0.1-0.7) 
Sicherer (2004) United States 2002 All ages Fish 
0.8 
(0.7-1.0) 
 
0.4 
(0.3-0.5) 
Gupta (2011) United States 2009-2010 0-2 years 
Fish 
(fin fish) 
0.3 * 
(0.1-0.4) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Gupta (2011) United States 2009-2010 3-5 years 
Fish 
(fin fish) 
0.5 * 
(0.3-0.8) 
  
Gupta (2011) United States 2009-2010 6-10 years 
Fish 
(fin fish) 
0.5 * 
(0.3-0.7) 
  
Gupta (2011) United States 2009-2010 11-13 years 
Fish 
(fin fish) 
0.6 * 
(0.4-0.8) 
  
Gupta (2011) United States 2009-2010 14-17 years 
Fish 
(fin fish) 
0.6 * 
(0.4-0.9) 
  
Gupta (2011) United States 2009-2010 <18 years 
Fish 
(fin fish) 
0.5 * 
(0.4-0.6) 
  
Eastern Mediterranean  
Al-Hammadi 
(2010) 
United Arab 
Emirates 
2006 6-9 years Fish   
2.8 
(1.5-5.1) 
South East Asia 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Oh (2004) Korea 2000 6-12 years Fish 
0.7 
(0.6-0.8) 
  
Oh (2004) Korea 2000 12-15 years Fish 
0.6 
(0.5-0.8) 
  
Kim (2011) Korea 2006-2007 0-12 months Seafood 
0.5 
(0.2-1.2) 
  
Oh (2004) Korea 2000 6-12 years Seafood 
0.4 
(0.3-0.4) 
  
Oh (2004) Korea 2000 12-15 years Seafood 
0.8 
(0.7-1.0) 
  
Santadusit 
(2005) 
Thailand N/R 
6 months – 6 
years 
Fish 
0.3 
(0.1-1.2) 
  
Lao-araya (2012) Thailand 2010 3-7 years Fish 
1.1 
(0.4-2.7) 
  
Connett (2012) Thailand 2007- 2008 14 - 16 years Fish 
0.4 
(0.2-0.8) 
0.3 
(0.1-0.7) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Western Pacific 
Woods (1998) Australia 1998 20-44years Fish /shellfish 
2.1 
(1.2-3.6) 
  
Leung (2009) Hong Kong 2006-2007 2-7 years Fish 
0.3 
(0.2-0.6) 
 
0.2 
(0.1-0.5) 
Connett (2012) Philippines 2007 - 2008 14 - 16 years Fish 
4.3 
(4.0-4.7) 
2.3 
(2.0-2.6) 
 
Connett (2012) Singapore 2007- 2008 14 - 16 years Fish 
0.6 
(0.4-0.8) 
0.3 
(0.2-0.4) 
 
Wu (2012) Taiwan 2004 <3 years Fish   
0.5 
(0.2-1.3) 
Wu (2012) Taiwan 2004 4-18 years Fish   
1.5 
(1.3-1.7) 
Wu (2012) Taiwan 2004 >19 years Fish   
1.2 
(1.0-1.4) 
Note: *= Study reported prevalence and confidence interval 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
SPT % 
prevalence 
History & 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Americas 
Burney (2010) United States 2000 20-44 years Fish   
0.0 
(0.0-5.3) 
 
South East Asia 
Santadusit 
(2005) 
Thailand N/R 
6 months- 6 
years 
Fish  
0.2 
(0.0-1.0) 
 
  
Western Pacific 
Burney (2010) Australia 2000 20-44 years Fish   
0.0 
(0.0-2.1) 
 
Chen (2011) China 2009 0-12 months Fish 
0.2 
(0.0-1.4) 
   
Hu (2010) China 1999 0-24 months Fish 
0.3 
(0.0-2.1) 
   
Hu (2010) China 2009 0-24 months Fish 
0.8 
(0.2-2.5) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
History and OFC 
% prevalence 
History and 
DBPCFC % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
South East Asia 
Lao-araya (2012) Thailand 2010 3-7years Fish 
0.2 
(0.0-1.4) 
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Shellfish allergy prevalence: Other regions of the world 
Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
African 
Obeng (2011) Ghana 2006-2008 5-16 years 
Crustacean 
(shrimp) 
0.1 * 
(N/R) 
  
Americas 
Ben-Shoshan 
(2010) 
Canada 2008-2009 < 18 years Shellfish 
0.55 * 
(0.21-0.88) 
0.5 * 
(0.18-0.82) 
0.06 * 
(0.01-0.10) 
Ben-Shoshan 
(2010) 
Canada 2008-2009 > 18 years Shellfish 
1.91 * 
(1.60-2.23) 
1.69 * 
(1.39-1.98) 
0.71 * 
(0.58-0.84) 
Vierk (2007) United States 2001 18 years + Crustacean 
0.7 
(0.5-1.0) 
 
0.4 
(0.2-0.7) 
Gupta (2011) United States 2009-2010 0-2 years Shellfish 
0.5 * 
(0.3-0.8) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Sicherer (2004) United States 2002 0-5 years Shellfish   
0.1 
(0.0-0.7) 
Gupta (2011) United States 2009-2010 3-5 years Shellfish 
1.2 * 
(0.8-1.6) 
  
Gupta (2011) United States 2009-2010 6-10 years Shellfish 
1.3 * 
(1.1-1.6) 
  
Sicherer (2004) United States 2002 6-17 years Shellfish   
0.7 
(0.4-1.1) 
Gupta (2011) United States 2009-2010 11-13 years Shellfish 
1.7 * 
(1.3-2.1) 
  
Gupta (2011) United States 2009-2010 14-17 years Shellfish 
2.0 * 
(1.7-2.5) 
  
Vierk (2007) United States 2001 >18 years Shellfish 
1.7 
(1.3-2.1) 
 
1.1 
(0.8-1.5) 
Greenhawt 
(2009) 
United States N/R >18 years Shellfish 
9.0 
(6.7-11.9) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Sicherer (2004) United States 2002 18-40 years Shellfish   
2.2 
(1.8-2.7) 
Sicherer (2004) United States 2002 41-60 years Shellfish   
3.1 
(2.5-3.7) 
Sicherer (2004) United States 2002 >61 Shellfish   
2.6 
(2.0-3.5) 
Gupta (2011) United States 2009-2010 <18 years Shellfish 
1.4 * 
(1.2-1.5) 
  
Sicherer (2004) United States 2002 All ages Shellfish 
2.7 
(2.5-3.0) 
 
2.0 
(1.8-2.3) 
South East Asia 
Santadusit 
(2005) 
Thailand N/R 6 months-6years 
Crustacean 
(shrimp) 
1.2 
(0.6-2.5) 
  
Lao-araya (2012) Thailand 2010 3-7years 
Crustacean  
(shrimp) 
3.1 
(1.8-5.3) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Lao-araya (2012) Thailand 2010 3-7years 
Crustacean  
(crab) 
0.7 
(0.2-2.1) 
  
Lao-araya (2012) Thailand 2010 3-7years Mollusc  (squid) 
0.2 
(0.0-1.4) 
  
Lao-araya (2012) Thailand 2010 3-7years Mollusc 
0.2 
(0.0-1.4) 
  
Santadusit 
(2005) 
Thailand N/R 6 months-6years 
Shellfish (crab. 
Mollusc, squid) 
0.5 
(0.1-1.5) 
  
Western Pacific 
Leung (2009) Hong Kong 2006-2007 2-7 years Crustacean 
1.3 
(1.0-1.7) 
 
0.9 
(0.6-1.3) 
Shek (2010) Philippines 2007-2008 14-16 years Shellfish 
8.7 
(8.2-9.2) 
5.1 
(4.3-6.1) 
 
Shek (2010) Singapore 2007-2008 4-6 years Shellfish 
7.2 
(6.5-8.1) 
1.2 
(0.9-1.6) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Shek (2010) Singapore 2007-2008 14-16 years Shellfish 
11.6 
(10.8-12.4) 
5.1 
(4.3-6.1) 
 
Wu (2012) Taiwan 2004 <3 years 
Crustacean  
(shrimp) 
  
0.6 
(0.2-1.5) 
Wu (2012) Taiwan 2004 4-18 years 
Crustacean  
(shrimp) 
  
4.0 
(3.7-4.4) 
Wu (2012) Taiwan 2004 >19 years 
Crustacean  
(shrimp) 
  
3.3 
(3.0-3.6) 
Wu (2012) Taiwan 2004 <3 years 
Crustacean  
(crab) 
  
0.4 
(0.1-1.2) 
Wu (2012) Taiwan 2004 4-18 years 
Crustacean  
(crab) 
  
2.6 
(2.3-2.8) 
Wu (2012) Taiwan 2004 >19 years 
Crustacean  
(crab) 
  
2.3 
(2.0-2.5) 
Wu (2012) Taiwan 2004 <3 years Mollusc   
0.1 
(0.0-0.8) 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
Self-report % 
prevalence 
Convincing 
Clinical history 
% prevalence 
Clinician-
diagnosed % 
prevalence 
     (95% CONFIDENCE INTERVAL) 
Wu (2012) Taiwan 2004 4-18 years Mollusc   
1.1 
(1.0-1.3) 
Wu (2012) Taiwan 2004 >19 years Mollusc   
1.5 
(1.3-1.7) 
Note: *= Study reported prevalence and confidence interval 
Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
SPT % 
prevalence 
History and 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Americas 
Liu (2010) United States 2005-2006 6-19 years 
Crustacean 
(shrimp) 
  
6.1 * 
(N/R) 
 
Branum (2009) United States 2005-2006 < 18 years 
Crustacean 
(shrimp) 
  
5.2 * 
(N/R) 
 
Burney (2010) United States 2000 20-44 years 
Crustacean  
(shrimp) 
  
0.0 
(0.0-5.3) 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
SPT % 
prevalence 
History and 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Liu (2010) United States 2005-2006 20-39 years 
Crustacean 
(shrimp) 
  
6.7 * 
(N/R) 
 
Liu (2010) United States 2005-2006 40-59 years 
Crustacean 
(shrimp) 
  
5.9 * 
(N/R) 
 
Liu (2010) United States 2005-2006 60+ years 
Crustacean 
(shrimp) 
  
4.6 * 
(N/R) 
 
Liu (2010) United States 2005-2006 All ages 
Crustacean 
(shrimp) 
  
5.9 * 
(N/R) 
 
South East Asia 
Santadusit 
(2005) 
Thailand N/R 
6 months-
6years 
Crustacean 
(shrimp) 
 
0.3 
(0.1-1.2) 
 
  
Santadusit 
(2005) 
Thailand N/R 
6 months-
6years 
Shellfish (crab, 
mollusc) 
 
0.3 
(0.1-1.2) 
 
  
Western Pacific 
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Study ID Country 
Year(s) in 
which study 
conducted 
Age group Allergen 
SPT % 
prevalence 
History and 
SPT % 
prevalence 
Serum SIgE 
% prevalence 
History & 
serum SIgE 
% prevalence 
     (95% CONFIDENCE INTERVAL) 
Osborne 
(2011) 
Australia 2007-2010 12-15 months Shellfish 
0.4 
(0.2-0.7) 
   
Burney (2010) Australia 2000 20-44 years 
Crustacean  
(shrimp) 
  
2.3 
(0.8-5.5) 
 
Chen (2011) China 2009 0-12 months 
Crustacean 
(shrimp) 
0.2 
(0.0-1.4) 
   
Hu (2010) China 1999 0-24 months 
Crustacean 
(shrimp) 
0.0 
(0.0-1.6) 
   
Hu (2010) China 2009 0-24 months 
Crustacean 
(shrimp) 
0.3 
(0.0-1.7) 
   
Note: *= Study reported prevalence and confidence interval 
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Study ID Country 
Year(s) in which 
study conducted 
Age group Allergen 
History and OFC 
% prevalence 
History and 
DBPCFC % 
prevalence 
 
     (95% CONFIDENCE INTERVAL) 
South East Asia 
Santadusit (2005) Thailand N/R 6 months- 6 years Crustacean (shrimp) 
0.3 
(0.1-1.2) 
 
 
Lao-araya (2012) Thailand 2010 3-7 years Crustacean (shrimp) 
0.9 
(0.3-2.4) 
 
Lao-araya (2012) Thailand 2010 3-7 years Crustacean (crab) 
0.2 
(0.0-1.4) 
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Appendix 5 Ethics approval 
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Appendix 6 R&D approval- Isle of Wight NHS Trust 
  
 
RM&G Office 
Planned Clinical Directorate 
St Mary’s Hospital 
Newport 
Isle of Wight 
PO30 5TG 
 
Direct Tel No (01983) 552354 
Direct Fax No (01983) 552521 
Email:  alexandra.punter@iow.nhs.uk 
 
7 October 2103 
 
Miss Harriet Moonesinghe 
PhD Research Student 
University of Portsmouth 
School of Health Sciences and Social Work 
James Watson West 
2 King Richard 1st Road 
Portsmouth, PO1 2FR 
 
 
Dear Harriet 
 
Fish and Shellfish Allergy: An in depth investigation 
 
I am writing formally to confirm that the R&D Committee granted provisional research 
governance approval to the above project on 27 September 2013.   
 
We note that NRES Committee London - Bloomsbury has now granted ethical approval, 
which applies to all NHS sites taking part in the study, and the University of Portsmouth 
has accepted the role of Sponsor.  Site-Specific Assessment at NHS sites is the 
responsibility of NHS R&D offices and, having reviewed the documentation submitted for 
this project, I confirm the R&D Committee has undertaken a favourable site specific 
assessment of the suitability of you as Principal Investigator and your facilities. 
 
Full research governance approval will be granted upon receipt of the following: 
 
 Written confirmation of a favourable ethical opinion – subsequently received from NRES 
Committee London – Bloomsbury on 4 October 2013 
 Written confirmation of sponsorship by academic institution, University of 
Portsmouth 
 
Recruitment must not commence at this site until you have received full research 
governance approval. 
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In accordance with our Trust Policy for R&D, I draw your particular attention to the 
following: 
 
 In the event of a serious adverse event, which is linked to your research study, you 
must report any occurrence using the Trust’s Incident Reporting Procedure. 
 
 You will be required to provide a periodic report of progress with your research to the 
R&D Committee.  Such progress reports should include details on any research 
outputs as well as current participant numbers, project start and end dates and 
account for all research income and expenditure. 
 
 
I wish you every success with your study and look forward to hearing from you. 
 
Yours sincerely 
 
Alexandra Punter 
Research Management and Governance Manager 
Isle of Wight NHS Trust 
 
cc: Carina Venter, NIHR Senior Research Fellow, University of Portsmouth/ 
Senior Allergy Research Dietitian, Isle of Wight NHS Trust 
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Appendix 7 R&D approval- Royal Brompton & Harefield NHS Foundation Trust 
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Appendix 8 R&D approval- University Hospital Southampton NHS Foundation 
Trust
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Appendix 9 Honorary contract- Isle of Wight NHS Trust 
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Appendix 10 Honorary contract- Royal Brompton & Harefield NHS Foundation 
Trust 
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Appendix 11 Anaphylaxis Campaign letter of introduction and participant 
Information sheet 
 
 
 
 
20 March 2014 
 
 
Dear Member  
 
You are receiving this research request on behalf of the University of 
Portsmouth because you are a member of the Anaphylaxis Campaign and 
we are assisting them with this project.  
 
Rest assured your contact information has remained with the Anaphylaxis 
Campaign and has not been shared with the University.  
 
 
 
Kind regards 
 
 
 
Carey Ledford 
Membership Manager  
Anaphylaxis Campaign  
Direct: 01252 893860 
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School of Health Sciences and Social Work 
University of Portsmouth 
James Watson West 
2 King Richard 1
st
 Road 
Portsmouth PO1 2FR 
 
Direct Tel: 02392844487 
Email: harriet.moonesinghe@port.ac.uk 
 
Dear Member 
Fish and Shellfish Allergy: An in-depth investigation 
 
Information Sheet 
 
My name is Harriet Moonesinghe and I am a PhD student at the University of Portsmouth. 
I am working with the Anaphylaxis Campaign.  
 
I would like to invite you to participate in a research study, which I am conducting as part 
of my PhD studies. Before you make any decision about your involvement in the study it is 
important for you to understand why the research is being done and what it will involve. 
Please read the following information carefully and discuss it with others if you wish. 
Please contact me if there is anything that is not clear, or if you would like more 
information. My email address and direct telephone number are: 
harriet.moonesinghe@port.ac.uk, 02392 844487. Please take time to decide whether or not 
you wish to take part.  
Thank you for reading this. 
 
What is the purpose of this study? 
The purpose of the study is to gain an in-depth understanding of the characteristics of fish 
and shellfish allergic adults. In particular I am interested in how your fish/shellfish allergy 
presents, any other allergies and or allergic conditions that you may have and the effect 
your allergy(s) have on your life. 
 
Why have I been chosen? 
You have been chosen because you are a member of the Anaphylaxis Campaign and have 
a fish and or shellfish allergy, which was identified on the membership database. 
 
Do I have to take part? 
No, it is up to you whether or not to take part. If you decide to take part I would like to 
suggest that you keep this information sheet for future reference. I will also ask you to 
complete and sign the enclosed consent form. If you decide to take part you are still free to 
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withdraw at any time without giving a reason. If you decide to stop taking part this will 
not affect the care your membership with the Anaphylaxis Campaign.  
 
What will happen if I decide to take part? 
If you decide to take part in this study I would ask you to complete the attached 
questionnaire and then send it back to myself in the enclosed stamped addressed envelope. 
Alternatively if you would prefer to complete the questionnaire online, please use the 
following link: 
https://www.survey.bris.ac.uk/portsmouth/seafoodallergy_anaphylaxisc
ampaign  
 
What are the benefits of taking part? 
There are no immediate benefits to you however I hope that this study will lead to a better 
understanding of fish and shellfish allergy, an allergy where currently there is little 
research information. This will hopefully allow us to give clearer advice to allergy 
sufferers on how to manage their allergies. 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to you in taking part of this study, although it will 
require giving up approximately 30 minutes of your time to complete the questionnaire. 
 
Will my taking part in the study be kept confidential? 
Yes. All the information collected during the course of research will be kept strictly 
confidential. You will be assigned an anonymous study number and not be identified by 
name in any reports or publications resulting from this study. If you take part in the study, 
it is possible that some of the data collected will be looked at by my supervisors from the 
University of Portsmouth. All completed questionnaires will be stored in a locked cabinet 
and any electronic files will be password protected. 
 
What will happen to the results of the research study? 
The results will be published in suitable clinical journals and presented at relevant 
scientific conferences, in the hope to share the results as widely as possible so that 
individuals like yourself can benefit from them. 
 
Who is organising and funding the research? 
The study is funded by a scholarship from the University of Portsmouth. A small donation 
is also provided towards this studentship from The Fishmongers’ Company. My 
supervisors at the University of Portsmouth will oversee this study, they are; Professor 
Tara Dean, Dr Heather Mackenzie and Dr Carina Venter. This study is supported by the 
Anaphylais Campaign, who have helped with the recruitment of study participants. 
 
Who has reviewed the study? 
This study has been reviewed and given a favourable opinion by Bloomsbury NHS 
Research Ethics Committee. 
 
Will I be contacted again? 
If there are parts of the questionnaire that haven’t been fully completed or if there are 
replies which are not clear, we would like to be able to contact you to clarify. However if 
you do not wish to be contacted you can indicate this on the questionnaire. 
 
APPENDICES 
286 
 
 
 
What should I do next? 
If you are interested in joining the study please sign the enclosed consent form and 
complete the enclosed questionnaire. Please then return these to me in the enclosed 
envelope. 
 
If you have any questions at all then please do not hesitate to contact me (Tel: 02392 
844487, Email: harriet.moonesinghe@port.ac.uk) and I will be happy to speak to you.  
 
Thank you for your time. 
 
 
 
 
 
Harriet Moonesinghe 
PhD Student. 
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Appendix 12 Royal Brompton & Harefield NHS Foundation Trust Letter of 
introduction and Allergy Outpatient Clinic participant information sheet 
 
 
 
 
                                                                                                               
Royal Brompton Hospital 
                                   Sydney Street   
                                         London 
SW3 6NP                                      
15 March, 2017 
 
Dear Sir or Madam 
 
A study is being carried out by Portsmouth University to find out more about 
seafood allergy. You have received this letter and questionnaire because you have 
had a positive test to seafood during your time as a patient at the Royal Brompton 
Hospital. Taking part involves completing the attached questionnaire. The 
enclosed letter from the researcher gives you more information about the study 
and how you can help. If you have any questions please contact the researcher 
direct (details are on the letter). 
 
The hospital is helping with this research by enabling this questionnaire to be sent 
to you. Your name and address were selected from a database of people who 
were eligible. No one else, including the researcher, has seen your confidential 
details or medical notes. Thus your legal rights in regard to confidentiality have 
not been compromised. 
 
Participation in the study is voluntary and will not affect any future care you 
receive at the Royal Brompton Hospital. If you complete the questionnaire, it will 
be received only by the researcher who will have your permission to see the 
results providing you complete, sign and return the consent form. No one at the 
Royal Brompton Hospital will know if you have responded, or be able to see the 
completed questionnaire. 
 
This study will help us deliver better care to future patients and so we would be 
very grateful if you would take the time to participate.  
 
Many thanks for your help. 
Isabel Skypala PhD RD 
Clinical Lead for Food Allergy  
i.skypala@rbht.nhs.uk 
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School of Health Sciences and Social Work 
University of Portsmouth 
James Watson West 
2 King Richard 1
st
 Road 
Portsmouth PO1 2FR 
 
Direct Tel: 02392844487 
Email: harriet.moonesinghe@port.ac.uk 
 
Dear (patient) 
Fish and Shellfish Allergy: An in-depth investigation 
 
Information Sheet 
 
My name is Harriet Moonesinghe and I am a PhD student at the University of Portsmouth. 
I am working with the doctors and nurses at the Asthma and Allergy clinics in 
(Southampton/ the Isle of Wight/ Royal Brompton). 
 
I would like to invite you to participate in a research study, which I am conducting as part 
of my PhD studies. Before you make any decision about your involvement in the study it is 
important for you to understand why the research is being done and what it will involve. 
Please read the following information carefully and discuss it with others if you wish. 
Please contact me if there is anything that is not clear, or if you would like more 
information. My email address and direct telephone number are: 
harriet.moonesinghe@port.ac.uk, 02392 844487. Please take time to decide whether or not 
you wish to take part.  
Thank you for reading this. 
 
What is the purpose of this study? 
The purpose of the study is to gain an in-depth understanding of the characteristics of fish 
and shellfish allergic adults. In particular I am interested in how your fish/shellfish allergy 
presents, any other allergies and or allergic conditions that you may have and the effect 
your allergy(s) have on your life. 
 
Why have I been chosen? 
You have been chosen because you have been diagnosed with a fish and or shellfish 
allergy, which was identified at the allergy clinic you attend. 
 
Do I have to take part? 
No, it is up to you whether or not to take part. If you decide to take part I would like to 
suggest that you keep this information sheet for future reference. I will also ask you to 
complete and sign the enclosed consent form. If you decide to take part you are still free to 
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withdraw at any time without giving a reason. If you decide to stop taking part this will 
not affect the care you receive from the Allergy Clinic.  
 
What will happen if I decide to take part? 
If you decide to take part in this study I would ask you to complete the attached 
questionnaire and then send it back to myself in the enclosed stamped addressed envelope. 
Alternatively if you would prefer to complete the questionnaire online, please use the 
following link: https://www.survey.bris.ac.uk/portsmouth/seafoodallergy/  
Once I have received this back, along with your consent, a member of the allergy clinic 
that you attend will extract any information relevant to your allergy from your medical 
notes (i.e. allergy test results). 
 
What are the benefits of taking part? 
There are no immediate benefits to you however I hope that this study will lead to a better 
understanding of fish and shellfish allergy, an allergy where currently there is little 
research information. This will hopefully allow us to give clearer advice to allergy 
sufferers on how to manage their allergies. 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to you in taking part of this study, although it will 
require giving up approximately 30 minutes of your time to complete the questionnaire. 
 
Will my taking part in the study be kept confidential? 
Yes. All the information collected during the course of research will be kept strictly 
confidential. You will be assigned an anonymous study number and not be identified by 
name in any reports or publications resulting from this study. If you take part in the study, 
it is possible that some of the data collected will be looked at by my supervisors from the 
University of Portsmouth. All completed questionnaires will be stored in a locked cabinet 
and any electronic files will be password protected. 
 
What will happen to the results of the research study? 
The results will be published in suitable clinical journals and presented at relevant 
scientific conferences, in the hope to share the results as widely as possible so that 
individuals like yourself can benefit from them. 
 
Who is organising and funding the research? 
The study is funded by a scholarship from the University of Portsmouth. A small donation 
is also provided towards this studentship from The Fishmongers’ Company. My 
supervisors at the University of Portsmouth will oversee this study, they are; Professor 
Tara Dean, Dr Heather Mackenzie and Dr Carina Venter. In addition the study involves 
individuals at University Hospital Southampton, the David Hide Asthma and Allergy 
Research Centre on the Isle of Wight and the Royal Brompton Hospital. 
 
Who has reviewed the study? 
This study has been reviewed and given a favourable opinion by ______________ NHS 
Research Ethics Committee. 
 
Will I be contacted again? 
If there are parts of the questionnaire that haven’t been fully completed or if there are 
replies which are not clear, we would like to be able to contact you to clarify. However if 
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you do not wish to be contacted you can indicate this on the questionnaire. 
 
What should I do next? 
If you are interested in joining the study please sign the enclosed consent form and 
complete the enclosed questionnaire. Please then return these to me in the enclosed 
envelope. 
 
If you have any questions at all then please do not hesitate to contact me (Tel: 02392 
844487, Email: harriet.moonesinghe@port.ac.uk) and I will be happy to speak to you.  
 
Thank you for your time. 
 
 
 
 
 
Harriet Moonesinghe 
PhD Student. 
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Appendix 13 Anaphylaxis Campaign consent form  
 
 
 
Fish and Shellfish Allergy: An in-depth investigation 
Anaphylaxis Campaign 
 
Instructions to Participants 
1. If you agree to participate in this study, please read and sign the consent 
below. 
2. Please proceed to answer the questionnaire over the page. 
3. Once completed, please return in the prepaid envelope provided. 
 
Consent Form 
 
Name of Researcher: Harriet Moonesinghe    Please initial box  
 
1. I confirm that I have read and understand the information sheet for the above study. 
I have had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily.        
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason.        
 
3. I understand that data collected during the study may be looked at by individuals 
from the University of Portsmouth or from regulatory authorities. I give permission 
for these individuals to have access to my data.      
         
 
x.  I agree to take part in the above study.       
 
 
Name of Participant:     
Date:    Signature:       
 
 
Name of Researcher:    
Date:    Signature:       
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Appendix 14 Allergy Outpatient Clinic consent form 
 
 
Fish and Shellfish Allergy: An in-depth investigation 
 
Instructions to Participants 
1. If you agree to participate in this study, please read and sign the consent 
below. 
2. Please proceed to answer the questionnaire over the page. 
3. Once completed, please return in the prepaid envelope provided. 
Consent Form 
Name of Researcher: Harriet Moonesinghe    Please initial box  
 
1. I confirm that I have read and understand the information sheet dated ** for 
the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.    
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason.     
 
3. I understand that data collected during the study may be looked at by 
individuals from the University of Portsmouth or from regulatory 
authorities. I give permission for these individuals to have access to my 
data.           
 
4. I give permission for authorised clinical staff to extract any relevant 
information with regards to my allergic status from my medical notes for 
the purpose of analysis.        
 
5. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from regulatory authorities 
or from the R&D Office at the hospital where I attend clinic, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.      
 
x.  I agree to take part in the above study.       
 
Name of Participant:     
Date:    Signature:       
 
 
Name of Researcher:    
Date:    Signature:       
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Appendix 15 Anaphylaxis Campaign reminder letter 
 
 
 
 
 
 
School of Health Sciences and Social 
Work 
University of Portsmouth 
James Watson West 
2 King Richard 1
st
 Road 
Portsmouth PO1 2FR 
 
Direct Tel: 02392844487 
Email: harriet.moonesinghe@port.ac.uk 
 
Dear Member 
Fish and Shellfish Allergy: An in-depth investigation 
 
We have recently sent you an information pack with regards to the above study that I am 
running. This is just a gentle reminder to you that if you would be interested in taking part 
please could you return the consent form and questionnaire by using the envelope 
previously provided. Alternatively, please use the following link to complete the 
questionnaire online: 
https://www.survey.bris.ac.uk/portsmouth/seafoodallergy_anaphylaxiscampaign  
 
If you have already done so, or would not like to take part please ignore this letter. 
 
Many thanks, 
 
 
 
 
 
Harriet Moonesinghe 
PhD Student. 
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Appendix 16 Allergy Outpatient Clinic reminder letter 
 
 
 
 
 
 
School of Health Sciences and Social 
Work 
University of Portsmouth 
James Watson West 
2 King Richard 1
st
 Road 
Portsmouth PO1 2FR 
 
Direct Tel: 02392844487 
Email: harriet.moonesinghe@port.ac.uk 
 
Dear (patient) 
Fish and Shellfish Allergy: An in-depth investigation 
 
We have recently sent you an information pack with regards to the above study that I am 
running. This is just a gentle reminder to you that if you would be interested in taking part 
please could you return the consent form and questionnaire by using the envelope 
provided. 
 
If you have already done so, or would not like to take part please ignore this letter. 
 
Many thanks, 
 
 
 
 
 
Harriet Moonesinghe 
PhD Student. 
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Appendix 17 Allergy Questionnaire 
 
ALLERGY QUESTIONNAIRE 
 
 
Name:         Date of Birth: 
 
Country of Birth: 
 
Ethnicity: White/British    Black/British Caribbean  Asian/British 
    
  White/European   Black/British African  Asian/British 
other   
   
White/Other    Black/British other  Chinese 
  
   
Mixed Background   Other, please state: 
 
Height:      Weight: 
 
 
Occupation (in particular, if your work involves contact with fish/shellfish please state): 
………………………………………………………………………………………………………
…............................ 
 
Contact telephone number/ email address (if you do not wish to be contacted further, please leave 
blank): 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………… 
 
1. For the following foods, please tick the appropriate box: 
 
 Eat regularly 
with no 
problems 
Avoid/ 
unrelated to 
allergy i.e. 
dislike 
Avoid/ proven 
allergy i.e. 
previous 
reaction + 
positive allergy 
tests 
Avoid/ 
suspected 
allergy i.e. 
positive tests + 
no previous 
reaction 
Fish, type if known: 
 
 
 
 
    
Crustacean- 
prawn/shrimp 
    
Crustacean- crab     
Crustacean- crayfish     
Crustacean- 
langoustines 
    
Crustacean- lobster     
Mollusc- mussels     
Mollusc- oyster     
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Mollusc- scallops     
Mollusc- clams     
Mollusc- squid     
Mollusc- octopus     
Celery     
Milk/ Dairy     
Egg     
Lupin     
Mustard     
Peanuts     
Tree Nuts i.e. brazil, 
cashew, hazelnut 
    
Sesame     
Soya     
Wheat     
Sulphite sensitivity     
Other food additives     
Other, please specify: 
 
 
 
    
 
2. Have you ever required hospitalisation following an allergic reaction? 
Yes    
No    
Don’t know   
 
3. Do you take any medications for your allergies? 
Yes    
No    
 
 If yes, which of the following medications do you take? 
   Antihistamines   
   Inhalers   
   Other, please specify: 
 
 
4. The next question asks you to provide further information for each of your CURRENT 
allergies. If you have more than 4 food allergies, please provide details for the 4 most 
SEVERE/RECENT allergies. In addition, if you are allergic to a number of fish species, 
group them together as ‘fish’, or if you are allergic to a number of shellfish species, group 
them together as ‘shellfish’. 
 
 Food 1 Food 2 Food 3 Food 4 
Allergen: 
 
    
Approx. age 
diagnosed: 
    
Symptoms: Itchy rash around 
the mouth  
Itchy rash all over 
the body  
Immediate 
vomiting  
Itchy rash around 
the mouth  
Itchy rash all over 
the body  
Immediate 
vomiting  
Itchy rash around 
the mouth  
Itchy rash all over 
the body  
Immediate 
vomiting  
Itchy rash around 
the mouth  
Itchy rash all over 
the body  
Immediate 
vomiting  
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Facial swelling 
i.e. 
lips/tongue/eyes 
 
Generalised 
swelling  
Wheeze, cough, 
hoarse voice  
Feeling 
faint/hypotension 
 
Other, please 
specify: 
 
 
 
 
 
 
 
Facial swelling 
i.e. 
lips/tongue/eyes 
 
Generalised 
swelling  
Wheeze, cough, 
hoarse voice  
Feeling 
faint/hypotension 
 
Other, please 
specify: 
 
Facial swelling 
i.e. 
lips/tongue/eyes 
 
Generalised 
swelling  
Wheeze, cough, 
hoarse voice  
Feeling 
faint/hypotension 
 
Other, please 
specify: 
 
Facial swelling 
i.e. 
lips/tongue/eyes 
 
Generalised 
swelling  
Wheeze, cough, 
hoarse voice  
Feeling 
faint/hypotension 
 
Other, please 
specify: 
 
How quickly 
did the 
symptoms 
occur after 
eating the 
food? 
Immediately  
<30 mins  
30 mins -2 hours
 
>2 hours  
Don’t know  
Immediately  
<30 mins  
30 mins -2 hours
 
>2 hours  
Don’t know  
Immediately  
<30 mins  
30 mins -2 hours
 
>2 hours  
Don’t know  
Immediately  
<30 mins  
30 mins -2 hours
 
>2 hours  
Don’t know  
How was this 
allergy 
diagnosed? 
Self-diagnosed 
 
Dr diagnosed  
Oral food 
challenge  
Skin prick test  
Blood test  
Don’t know  
Other, please 
specify:   
 
 
Self-diagnosed  
Dr diagnosed  
Oral food 
challenge  
Skin prick test  
Blood test  
Don’t know  
Other, please 
specify:   
 
 
Self-diagnosed 
 
Dr diagnosed  
Oral food 
challenge  
Skin prick test  
Blood test  
Don’t know  
Other, please 
specify:   
 
 
Self-diagnosed  
Dr diagnosed  
Oral food 
challenge  
Skin prick test  
Blood test  
Don’t know  
Other, please 
specify:   
 
 
 
With regard to the FIRST allergic reaction you had to fish/shellfish: 
 
5. What type of fish/shellfish did you react to? 
 
 
6. How was it prepared? 
Baked      BBQ    
Fried      Microwave     
Raw/Sushi    Steamed     
Smoked     Tinned      
Other, please specify: 
 
 
7. How old were you when this reaction first happened? 
 
8. Was this the first time you had eaten this food? 
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Yes    
No    
 
If no, how often had you eaten this food before? 
Once only   Occasionally (less than once a month) 
  
Regularly (2-3 times a month)  Frequently (once a week 
or more)  
 
9. What symptoms did you have at this first reaction to fish/shellfish? 
Itchy rash around the mouth    
Itchy rash all over the body    
Immediate vomiting     
Facial swelling i.e. lips/tongue/eyes   
Generalised swelling     
Wheeze, cough, hoarse voice    
Feeling faint/hypotension    
Other, please specify: 
 
 
10. Have you had any further reactions to other types of fish or shellfish? 
Yes   
No   
 
If yes, please provide the following details: 
 
Type of fish/shellfish How was it prepared? Age of first reaction to this 
food 
   
   
   
   
   
   
   
   
 
11. Have you ever reacted to the steam or vapours produced by cooking fish/shellfish? 
Yes   
No   
 
If yes, what sort of reaction: 
Itchy rash around the mouth    
Itchy rash all over the body    
Immediate vomiting     
Facial swelling i.e. lips/tongue/eyes   
Generalised swelling     
Wheeze, cough, hoarse voice    
Feeling faint/hypotension    
Other, please specify: 
 
 
12. Do you tolerate any tinned fish, that you cannot tolerate fresh i.e. fresh tuna vs. tinned 
tuna? 
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Yes   
No  
 
If yes, which ones: 
 
 
13. After visiting the allergy clinic with regards to your fish/shellfish allergy, were you given 
advice regarding avoidance of fish/shellfish? 
Yes    
No (go to Q.17)  
 
14. What advice were you given when the allergy to fish/shellfish was first diagnosed? 
Avoid all shellfish       
Avoid all fish        
Avoid all fish, but can eat tinned     
Avoid specific fish, please specify     
Avoid food where the label states ‘May contain traces of…’  
Avoid eating out in restaurants serving fish/shellfish   
Avoid food containing gelatin or fish oil supplements   
Other advice, please specify: 
 
 
15. What did you actually do with your diet? (For each row, tick one box which best suits your 
practice) 
 
 Not at all Sometimes Most of 
the time 
Always 
Avoid all shellfish 
 
    
Avoid all fish 
 
    
Avoid all fish, but can eat tinned 
 
    
Avoid specific fish 
 
    
Avoid food where the label states ‘May contain 
traces of…’ 
    
Avoid eating out in restaurants serving 
fish/shellfish 
 
    
Avoid food containing gelatin or fish oil 
supplements 
 
    
Other changes, please specify: 
 
 
16. Were you advised to avoid any non-food products that might contain fish/shellfish? 
Yes     
No    
 
If yes, please specify: 
 
 
17. Who gave you the advice discussed above? 
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Dietitian   
GP    
Allergy specialist  
Other, please specify: 
 
 
18. Have you EVER had wheezing or whistling in your chest at any time in the past? 
Yes     
No (go to Q. 20)  
 
19. Have you had wheezing or whistling in your chest in the past 12 months? 
Yes    
No    
 
20. Have you EVER had asthma? 
Yes    
No    
 
21. In the past 12 months, has your chest sounded wheezy during or after exercise? 
Yes    
No    
 
22. In the past 12 months, have you had a dry cough at night, apart from a cough associated 
with a cold or chest infection? 
Yes    
No    
 
23. Have you EVER had a problem with sneezing, or a runny, or blocked nose when you DID 
NOT have a cold or the flu? 
Yes    
No (go to Q.25)  
 
24. In the past 12 months, have you had a problem with sneezing, or a runny, or blocked nose 
when you DID NOT have a cold of the flu? 
Yes    
No    
 
25. Have you EVER had hayfever? 
Yes    
No    
 
26. Have you EVER had an itchy rash, which was coming and going for at least six months? 
Yes    
No (go to Q.28)  
 
 
27. Have you had this itchy rash at any time in the past 12 months? 
Yes    
No    
 
28. Have you ever had eczema? 
Yes    
No    
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Appendix 18 Allergy Outpatient Clinic proforma 
 
 
Fish and Shellfish Allergy: An in-depth investigation 
 
PROFORMA 
 
 
Patient Name:       Patient Date of Birth: 
 
Allergy clinic/ Consultant: 
 
Has the patient ever required hospitalisation following an allergic reaction? 
Yes    
No    
Not clear from notes  
 
Does the patient take any medications for their allergies? 
Yes    
No    
 
If yes, please state the name and dose: 
 
 
Skin Prick Tests (food) 
Food Size Date 
+   
-   
   
   
   
   
   
   
Serum-IgE (food) 
Food Date kuA/L RAST level (if 
applicable) 
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Food Challenges 
Food Type (ofc/dbpcfc) Date Symptoms 
    
    
    
    
    
    
    
    
 
Any other relevant blood tests 
Test Result Date 
   
   
   
   
   
   
   
   
 
Skin Prick Tests (Aeroallergens) 
Allergen Size Date 
+   
-   
   
   
   
   
   
   
 
Serum-IgE (Aeroallergens) 
Allergens Date kuA/L RAST level (if 
applicable) 
    
    
    
    
    
    
    
    
Has any advice been given regarding avoidance of fish/shellfish? 
Yes     
No     
Not clear from notes  
 
If yes, what? 
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Avoid all shellfish       
Avoid all fish        
Avoid all fish, but can eat tinned     
Avoid specific fish, please specify     
Avoid food where the label states ‘May contain traces of…’  
Avoid eating out in restaurants serving fish/shellfish   
Avoid food containing gelatin or fish oil supplements   
Other advice, please specify: 
 
Who gave the advice discussed above? 
Dietitian   
GP    
Allergy specialist  
Other, please specify: 
 
Has the patient ever had asthma? 
Yes     
No     
Not clear from notes   
 
Does the patient currently have asthma?  
Yes     
No     
Not clear from notes   
 
Has the patient ever had eczema? 
Yes     
No     
Not clear from notes   
 
Doe the patient currently have eczema? 
Yes     
No     
Not clear from notes   
 
Has the patient ever had allergic rhinitis? 
Yes     
No     
Not clear from notes   
 
Does the patient currently have allergic rhinitis? 
Yes     
No     
Not clear from notes   
 
Any other important information relating to the patient’s allergic status? 
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Appendix 19 FAQLQ-AF 
 
FOOD ALLERGY QUALITY OF LIFE QUESTIONNAIRE (ADULT FORM) 
 
Instructions 
The following questions concern the influence your food allergy has on your quality of life. Please answer 
every 
question by marking the appropriate box with an ‘x’. You may choose from one of the following answers: 
0 1 2 3 4 5 6 
Not Barely Slightly Moderately Quite Very Extremely 
 
How troublesome do you find it, because of your food allergy, that 
you … 
0 1  2  3  4  5 6  
         
1 must always be alert as to what you are eating?        
2 are able to eat fewer products?        
3 are limited as to the products you can buy?        
4 must read labels?        
5 have the feeling that you have less control of what you eat when 
eating out? 
       
6 must refuse many things during social activities?        
7 sometimes frustrate people when they are making an effort to 
accommodate your food allergy? 
       
8 are less able to spontaneously accept an invitation to stay for a 
meal? 
       
9 are less able to taste or try various products when eating out?        
10 can eat out less?        
11 must personally check whether you can eat something when eating 
out? 
       
12 hesitate eating a product when you have doubts about it?        
 
How troublesome is it, because of your food allergy, … 0 1  2  3  4  5 6  
         
13 that the ingredients of a product change?        
14 that labels are incomplete?        
15 that the lettering on labels is too small?        
16 that the label states: “May contain (traces of)….”?        
17 that ingredients are different in other countries (for example during 
vacation)? 
       
18 that people underestimate your problems caused by food allergy?        
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19 that it is unclear to which foods you are allergic?        
20 that you must explain to those around you that you have a food 
allergy? 
       
21 for your host or hostess should you have an allergic reaction?        
 
How worried are you because of your food allergy … 0 1  2  3  4  5 6  
         
22 about your health?        
23 that the allergic reactions to foods will become increasingly severe?        
 
 
How frightened are you because of your food allergy … 0 1  2  3  4  5 6  
         
24 of an allergic reaction?        
25 of accidentally eating the wrong food?        
26 of an allergic reaction when eating out despite the fact that your 
dietary restrictions have been discussed beforehand? 
       
 
Answer the following questions: 0 1  2  3  4  5 6  
         
27 To what degree do you feel you are being a nuisance because you 
have a food allergy when eating out? 
       
28 How discouraged do you feel during an allergic reaction?        
29 How apprehensive are you about eating something you have never 
eaten before?  
       
        
 
 
 
Thank you very much for your time in completing this questionnaire!
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Appendix 20 Published Article: Prevalence of fish and shellfish allergy: a systematic 
review 
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Appendix 21 UPR16 form 
 
 
